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Chapter 1
1.1. General functions of the p53 transcription factor
1.1.1. The p53-protein can function as a tumor suppressor
In almost half of all solid human tumors the p53-protein is mutated (Hollstein et al. 1991; 
Levine et al. 1991). While the wildtype protein can efficiently inhibit cell growth (Eliyahu 
et al. 1989; Finlay et al. 1989; Hinds et al. 1989), thereby displaying properties of a tumor 
suppressor, mutant p53 has certain gain-of-function activities, e.g. as first demonstrated 
by its cooperation with the onco-protein ras (Eliyahu et al. 1984; Jenkins et al. 1984; 
Parada et al. 1984). Mutations, responsible for the inactivation of p53, seem to cluster in 
six hotspot regions in the DNA-binding domain, in which three specific residues are highly 
overrepresented (Hollstein et al. 1991; Cho et al. 1994). They count up in total to around 
40% of the p53-mutations in humans. Furthermore, patients with Li-Fraumeni-syndrom, 
a rare inherited dominant disorder, suffer from multiple cancer types with early onset 
due to germ-line mutations of the p53-gene (Malkin et al. 1990; Srivastava et al. 1990). A 
similar phenotype was observed in mice without functional p53, in which tumors occur 
more often spontaneously, as well as after irradiation (Raycroft et al. 1990; Donehower et al. 
1992; Kemp et al. 1994). It was shown that wild-type p53 functions mainly as a transcription 
factor, recognizing a specific binding site, consisting of two copies of a ten base pair motif 
(Fields and Jang 1990; Bargonetti et al. 1991; el-Deiry et al. 1992), allowing wild type but 
not mutant p53 to transactivate corresponding genes (Raycroft et al. 1990).
1.1.2. Activation of the p53-pathway upon cellular stress
Under unstressed cellular conditions a high protein-turnover keeps p53 at a low basic level, 
mediated by ubiquitin-ligases like Mdm2 or ARF-BP1 (see 1.4.2.). The functional activity and 
protein levels of p53 increase upon stress-signals, like UV- or X-ray-irradiation, exposure to 
replication- or transcription-impairing chemicals or aberrant growth signals (Vogelstein et 
al. 2000; Kruse and Gu 2009). Multiple signal cascades trigger the activation of p53 upon 
DNA-damage during which several kinases like ATM/ATR or Chk2, phosphorylate p53 
and thereby enhance its stability and allow target gene activation (Canman et al. 1998; 
Hirao et al. 2000). ATM also phosphorylates Mdm2, the main antagonist of p53 after DNA- 
damage, leading to a conformational change resulting in disruption of the interaction of 
p53 and Mdm2 (Khosravi et al. 1999). This disruption is crucial for proper p53-activation 
and can be mediated as well by a gene product of the Ink4 tumor suppressor locus, p14Arf, 
which competes with the Mdm2-p53 protein interface (Pomerantz et al. 1998; Zhang et al. 
1998). Some ribosomal proteins also regulate Mdm2, e.g. L11, thereby stabilizing p53 and 
suggesting a response of p53 to translational perturbations (Lohrum et al. 2003). Milder 
forms of stress, like hypoxia, can trigger a p53 response that can be reversed after re­
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oxygenation (Graeber et al. 1994). Even the immunresponse to viral infections uses the 
p53-pathway, although p53 is rather induced on the transcriptional level by IFN-p than 
stabilized on protein-level (Vogelstein et al. 2000; Pestka 2003; Takaoka et al. 2003).
1.1.3. Growth arrest or apoptosis are results of p53-activation
Multiple different signal transduction pathways can sense damage within a cell and trigger 
a response of p53 (Vogelstein et al. 2000). In general, this response can induce two distinct 
cellular fates, cell survival or apoptosis. Having this choice allows the p53-pathway either 
to trigger DNA-repair during a temporary growth arrest, thereby maintaining genomic 
stability. Growth arrest is largely dependent on the kinase-inhibitor CDKN1A (p21), one 
of the earliest identified target genes of p53 (el-Deiry et al. 1993; Harper et al. 1993). The 
growth arrest is accompanied by the induction of genes involved in DNA-repair, like 
p53R2 (Tanaka et al. 2000), DDB2 (Hwang et al. 1999) or GADD45, the later also inhibits 
the progression through the G2/M phase of the cell cycle (Kastan et al. 1992; Smith et 
al. 2000). Alternatively, if the damage cannot be repaired, the p53-pathway allows the 
elimination of the cell from the proliferating pool by inducing senescence or apoptosis 
to prevent malignant transformation. Senescence, a stable growth arrest, can be caused 
by multiple events and occurs usually in cultures of primary cells after several passages 
(Lundberg et al. 2000). p53 induces this stable growth arrest upon several stimuli, like 
telomere shortening, oncogene activation or DNA double-strand breaks (Deng et al. 2008; 
Halazonetis et al. 2008) by inducing target genes like PAI-1, which is required and sufficient 
to establish this terminal growth arrest (Kortlever et al. 2006). The further proliferation of 
cells with genomic lesions can thereby be prevented, even in the absence of an apoptotic 
response (Van Nguyen et al. 2007). Senescence can be accompanied by a strong immune 
response leading to tumor clearance and to tumor regression (Xue et al. 2007). Another 
way of preventing malignant transformation is the induction of apoptosis, which is an early 
discovered function of p53 (Yonish-Rouach et al. 1991; Lowe et al. 1993). Two alternative 
signal pathways can trigger apoptosis, in the end both activate DNA-fragmenting 
caspases. During the intrinsic pathway signals like DNA-damage are sensed and lead to 
the release of cytochrome c from mitochondria (Cory and Adams 2002). This is mediated 
by a whole set of p53 target genes, like the Bcl-2 proteins Bax and Puma (Miyashita and 
Reed 1995; Nakano and Vousden 2001; Yu et al. 2001). Mitochondrial outer membrane 
permeabilization (MOMP) ultimately releases cytochrome c, leading to the cleavage of 
pro-caspases, which then exert the cell death program (Evan and Vousden 2001; Zornig et 
al. 2001). Fas and DR5 belong to another set of target genes inducing apoptosis through 
the extrinsic pathway in which extracellular signals are incorporated by death receptors, 
activating caspase 8 as an mediator, which in turn triggers the activation of executioner
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caspases (Owen-Schaub et al. 1995; Wu et al. 1997). Apoptosis can, to some extent, also 
be induced by some transcription-deficient p53-mutants (Haupt et al. 1995; Chipuk et al. 
2004; Moll et al. 2006). This occurs through a direct association of p53 with Bcl-2 proteins, 
which regulate the subsequent permeabilization of the outer mitochondrial membrane, 
characterizing cytoplasmic functions of p53 (Chipuk et al. 2004; Moll et al. 2006).
Several models describe the possible regulation of p53 during the decision-making 
process (Vousden 2000). Since most of the effects p53 exerts are mediated by its function 
as a transcription factor, it could either activate cell cycle arrest genes and apoptotic genes 
to the same extent, thereby leaving the decision of survival to additional signals (p53- 
dumb model). Alternatively, different stress signals could lead to distinct p53-responses 
during which genes of a certain pathway are preferentially induced, driving the cell into 
one or the other direction (p53-smart model). The fact that certain genes are induced only 
during the apoptotic response and upon certain kinds of genotoxic stress supports this 
model (Attardi et al. 2000; Relaix et al. 2000; Zhao et al. 2000). For this model argues also 
that for the regulation of certain target genes the amount of p53 seems to be important, 
thereby distinguishing low and high affinity sites, with higher p53-levels apparently 
inducing rather apoptosis than growth arrest (Chen et al. 1996; Szak et al. 2001). However, 
post-translational modifications of p53, the presence of co-factors and the duration of the 
stress signal also influence the choice between these responses (Murray-Zmijewski et al. 
2008).
1.1.4. Additional pathways influenced by p53
The activity of p53 is not restricted to the classical growth arrest and apoptosis pathways. 
Additional functions for p53 have been discovered, in the end all are related to cellular 
growth, too. The deletion or inhibition of p53 significantly increases the efficiency with 
which cells can be reprogrammed to generate induced pluripotent stem cells (iPS-cells) 
(Hong et al. 2009; Kawamura et al. 2009; Marion et al. 2009). Involved in this inhibition 
of iPS-cell-generation are additional components of the p53-pathway, like p21, which 
can rescue the inhibition after p53-deletion while the p53-antagonist Mdm2 as well as 
Mdmx both enhance the reprogramming efficiency. During reprogramming frequent 
DNA-damage occurs, which in turn activates the p53-pathway leading to apoptosis. This 
activity of p53 probably maintains genomic stability and integrity to allow only those cells 
to gain the capacity of renewal, which have a very low level of DNA-damage. p53 is also 
involved in the energy-metabolism of the cell. TIGAR, a direct target gene of p53, inhibits 
glycolysis and reduces the level of reactive oxygen species (ROS) (Bensaad et al. 2006). This 
is accompanied by a reduction of apoptosis, suggesting that TIGAR probably participates
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in the survival of cells exposed to short-term or mild stress. Glycolysis, the main source 
of ATP-generation under anaerobic conditions, like they are present in cancer cells, is 
also reduced by Sco2, a p53-dependent gene that shifts the energy-metabolism towards 
respiratory pathways (Matoba et al. 2006). By preventing glycolysis both genes might 
have an influence on cancer development. Autophagy is a third pathway in which p53 
participates. This process, also known as self-eating, allows the cell to degrade complete 
organelles. The p53-target DRAM is, upon activation of the p53-pathway, localized at the 
lysosomes, to which also LC3-II-complexes, known markers of autophagy, are recruited 
(Crighton et al. 2006). In this pathway the induction of autophagy, mediated by DRAM, 
causes apoptosis, although it is known that upon nutrient depletion autophagy may also 
allow cellular survival (Boya et al. 2005). Conversely, p53 can also inhibit autophagy under 
hypoxic conditions or starvation, which is an important mechanism to disrupt the energy- 
metabolism of cancer cells (Tasdemir et al. 2008). In these pathways p53 seems to have a 
crucial role with consequences for the whole organism. It might function as a regulator of 
live or death, depending on the cellular conditions.
1.2. Specific functions and interplay of p53-family members
1.2.1. p53 and its relatives p63 and p73 form the p53-family
Some years after the description of p53 as a tumor suppressor, it was discovered that two 
related proteins, p63 and p73, could also inhibit cellular growth and induce apoptosis 
(Kaghad et al. 1997; Marin et al. 1998; Yang et al. 1998). It became evident, that all three 
genes consist of multiple exons, which can be differentially spliced, especially in the 
C-terminus, probably giving rise to multiple splice-isoforms (Bourdon 2007). On top of 
this, alternative promoters can be used to generate N-terminal shortened proteins lacking 
the transactivation domain. So the whole family of the p53-related transcription factors 
consists of three different genes, from which a multitude of different isoforms can be 
transcribed. Although all family-members show a high similarity throughout their gene 
structure and a high degree of sequence similarity (Arrowsmith 1999), a first hint that they 
have distinct properties came from the observation that they interact differentially with 
some viral oncoproteins (Marin et al. 1998). With ongoing research more specific functions 
of the different family members became obvious (see 1.2.2), but still the extent and the 
consequences of their collaboration remain largely unknown. Especially the distinct roles 
of the respective splice-isoforms of single family-members are not well understood yet.
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1.2.2. Specific and synergistic functions of p73
Like p53, p73 emerged as a player in various cellular stress response pathways in cells. 
The activity of p73 to induce apoptosis mainly depends on functional c-Abl, which 
phosphorylates p73 in response to treatments like gamma-irradiation or Cisplatin (Agami 
et al. 1999; Gong et al. 1999; Yuan et al. 1999). Extended analysis identified additional 
stress stimuli, which induce p73-dependent apoptosis (Irwin et al. 2003). Nevertheless, 
no mutations of the p73 gene could be linked to cancer (Melino et al. 2002), although 
overexpression of some isoforms, lacking the N-terminal transactivation domain, could 
be observed in tumor patients (Zaika et al. 2002; Concin et al. 2004). Unlike p53 knockout 
mice, mice lacking the entire p73 gene do not develop tumors, but die rather early after 
birth due to severe developmental defects in the brain and to intraorganic bleedings as 
well as uncontrolled inflammation (Yang et al. 2000). Some of these defects are caused 
by the lack of ANp73-isoforms, which are derived from an internal promoter and can 
protect neurons during development from cell death (Pozniak et al. 2000). They are 
able to inhibit the function of full length p73 and of p53 by competing for binding sites 
and by repressing the same target genes (Moll and Slade 2004). Mice lacking only the 
transactivating full length p73 (TAp73) develop normally. Nevertheless, they are infertile 
and show a higher tumor incidence compared to wild-type mice thereby proving a tumor­
suppressor function for TAp73 (Tomasini et al. 2008). Further in vivo evidence comes from 
mouse models where heterozygous deletions of either p63 or p73 are associated with 
spontaneous tumors and shortened life span, co-occurring with loss of heterozygosity 
(Flores et al. 2005). Interestingly, mice with a combined heterozygous p53 plus p63 or 
p73 deletion show an even higher cancer incidence with more aggressive tumors. The 
suggestion of a functional interplay between p53 and p73 or p63 is further enhanced by 
the lack of p53-mediated apoptosis in fibroblasts with deleted p63- and p73-genes (Flores 
et al. 2002). Additionally, in the absence of p53, p73 is able to suppress polyploidy in MEFs, 
a phenotype that occurs rapidly after combined loss of p53 and p73 (Talos et al. 2007). 
Besides the obvious overlap in function and target gene choice, several target genes are 
selectively activated by single family-members or even by specific splice-variants, leading 
to clear differences in their apoptotic potential (Blint et al. 2002; Gonzalez et al. 2005). 
Furthermore, even the isoforms differ in their ability to induce the same target genes 
and to suppress cellular growth, which is most efficiently done by p73p (De Laurenzi et 
al. 1998; Davison et al. 1999; De Laurenzi et al. 2000). The different family members also 
display differences in their interaction with each other, e.g. p73Y interacts with most p73- 
isoforms, while p735 can interact only with p73a and p73p. While p63 and p73 do interact 
with each other, they do not form complexes with wildtype p53 (Davison et al. 1999). 
Nevertheless, mutated p53 has been reported to interact with and influence the functions 
of p63 and p73 (see 1.2.3.).
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1.2.3. Mutant p53 has antagonizing functions
Mutated p53 is not only unable to stop cancer development, but more and more evidence 
points out that mutations in p53 can even enhance cancer progression. Mutated p53 
renders cells resistant to chemotherapeutics (Blandino et al. 1999), probably at least 
partly due to an inhibiting interaction of mutated p53 with p73 that diminishes the DNA- 
binding capacity of p73, thereby abolishing p73-mediated transcription (Marin et al. 2000; 
Strano et al. 2000). The extent of this inhibition varies, depending on the conformational 
change of p53 introduced by a certain mutation (Gaiddon et al. 2001). In particular, a 
polymorphism at codon72 of p53 appears to be crucial. Mutant p53 with an arginine at 
position 72 shows stronger interaction with p73 and lower levels of apoptosis compared 
to p53-mutants with a proline at the same position (Marin et al. 2000; Bergamaschi et 
al. 2003). This naturally occurring polymorphism has an impact on the responsiveness of 
patients to chemotherapy, which have a better prognosis if the proline at position 72 is 
present (Marin et al. 2000; Bergamaschi et al. 2003). Recently, a role for mutant p53 in the 
progression of metastasis has been described (Muller et al. 2009). It appears that, through 
the inhibition of TAp63-mediated transcription, mutant p53 enhances the recycling of 
integrins and epidermal growth factor receptor, thereby promoting invasion of tumor 
cells. Nevertheless, the functions of mutated p53 are diverse and not every mutation 
in p53 renders it completely incapable of target gene activation. Certain in humans 
occurring p53-mutants impair only a subset of genes (Friedlander et al. 1996; Ludwig et 
al. 1996; Rowan et al. 1996) leading to a remaining activity to induce growth arrest but not 
apoptosis (Ryan and Vousden 1998). However, the overall consequences of mutant p53 on 
p73-growth regulating activities remain to be elucidated.
1.3. Genomic analysis of binding sites and transcriptional response
1.3.1. Global identification of target genes
Crucial for the appropriate cellular outcome under specific conditions is the selection 
of target genes and their proper regulation by the members of the p53-family. Different 
approaches have been exploited to identify new binding sites for p53 and the way of 
regulation of the respective target genes. For these studies several different cellular 
systems and varying p53-inducing treatments have been used, therefore a comparison 
between different studies might reveal system-specific effects. From a microarray-based 
chromatin-immunoprecipitation- (ChIP-) screen of the entire chromosomes 21 and 22 
a first extrapolation predicted roughly 1600 p53-binding sites in the human genome 
(Cawley et al. 2004), while a microarray experiment with spotted CpG-islands from
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promoter-sequences resulted in around 150 loci with enriched p53-binding (Krieg et al. 
2006). A first genome-wide identification of p53-binding sites using ChIP-PET identified 
a comparable number of sites as predicted by Cawley, however the overlap between 
these two data-sets for binding sites on chromosome 21 and 22 was surprisingly low 
(Wei et al. 2006). As described in chapter two, we used ChIP-enriched DNA hybridized 
to microarrays covering the whole human genome, to discover also ~1500 binding sites 
for endogenous p53 upon stress-treatment (Smeenk et al. 2008). It was shown that the 
earlier identified binding sites showed a reasonable to good overlap (50-70%) with this 
study. In this approach binding-sites for the other p53-family members p63 and p73 were 
also identified, based on a selection of all putative p53-binding sites. More recent studies 
showed that each family-member has its own set of target genes (Vigano et al. 2006; Yang 
et al. 2006), which although partly overlapping, still show significant differences, some of 
them will be described in detail in chapter three. Nevertheless, an exhausting comparison 
of the specific and the common target genes has not been done yet. It remains to be 
investigated how different cellular conditions influence the choice of target gene selection 
and activation, depending on the respective family-member and isoform.
1.3.2. Analysis of the transcriptional response
To induce changes in the expression of certain target genes, p53 interacts with components 
of the transcriptional machinery, like TAF250 or TBP in a stress-specific manner to change 
their occupancy at target promoters, and it also appears to recruit chromatin remodelling 
factors like the SWI/SNF complex (Lee et al. 2002; Espinosa et al. 2003). As a consequence 
of different kinds of stress-stimuli, varying sets of target genes change their expression 
inducing a certain cellular fate (Riley et al. 2008). A comparison of DNA-damaging and 
non-damaging treatments (Adriamycin versus hypoxia) resulted in a small cluster of 
genes changing upon both treatments, while bigger clusters of genes were found being 
differentially regulated (Hammond et al. 2006). Comparing the expression-data to binding 
studies, only a small subset of genes bound by p53 also changed their expression upon a 
certain stimuli (Krieg et al. 2006; Wei et al. 2006). Interestingly, not only different kinds of 
treatments induce different sets of target genes, but also different concentrations of p53- 
activators, like 5-Fluorouracil, induce distinguishable responses on the transcriptional and 
cellular level (Hernandez-Vargas et al. 2006). Besides transcriptional activation, p53 can 
also mediate transcriptional repression of genes, many of which are related to cellular 
growth. Several studies reported that p53 mediates transcriptional repression by either 
interacting with NF-Y or mSin3a at target promoters to recruit HDACs (Murphy et al. 1999; 
Imbriano et al. 2005). Other groups showed that p53 could mediate repression of target 
genes also by an indirect effect without detectable DNA-binding (Spurgers et al. 2006;
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Scian et al. 2008). The repression of these genes seems to require newly synthesized 
proteins and repression of reporter-constructs does occur even on a minimal sequence 
containing only an E2F and a myc-binding site, w ithout a motif for p53. Thus, p53 can 
directly and indirectly trigger transcriptional changes in response to stimuli of distinct 
kinds and duration leading to different cellular outcomes.
1.4. Regulation of the activity of p53
1.4.1. Post-translational modifications leading to p53-activation
Preceding the p53-driven decision between growth arrest and induced cell death is 
the p53-activation by various post-translational modifications (PTM) and co-factors, 
influencing the activity and the target gene choice of p53. As mentioned earlier, different 
stress-signals activate kinase-pathways leading to the phosphorylation of p53 at several 
N-terminal serine-residues (Appella and Anderson 2000). In particular serine 15- and 
serine 20-phosphorylation have been implicated in the disruption of the p53-Mdm2 
interaction and the subsequent stabilization and activation. During this response Pin1 
induces a conformational change of phosphorylated p53 leading to higher stability and 
transactivation capacity (Zacchi et al. 2002; Zheng et al. 2002). The phosphorylation of p53 
at serine 46 by HIPK2 subsequently induces acetylation of p53 by p300 and PCAF followed 
by enhanced function (Hofmann et al. 2002). The acetylation of the C-terminus of p53 
interferes with its ubiquitination, since the six lysine residues to which both modifications 
are linked are identical, leading to opposing consequences for the stability and activity of 
p53 (Kruse and Gu 2009). Furthermore, acetylation of lysine 320, one of these six residues, 
is an important target residue for PCAF-mediated acetylation associated with enhanced 
DNA-binding capacity of p53 after DNA-damage (Sakaguchi et al. 1998; Liu et al. 1999). 
Linked to preferential selection of pro-apoptotic target genes is the acetylation of lysine 
120 of p53 mediated by hMof or Tip60(Legube et al. 2004; Sykes et al. 2006; Tang et al. 
2006).
1.4.2. Regulation of p53-activity by ubiquitin-ligases
Since p53 is a potent inducer of growth arrest and apoptosis its activity has to be tightly 
controlled. The first identified antagonist regulating protein levels of p53 was the mouse 
double minute 2 protein (Mdm2) (Barak and Oren 1992; Momand et al. 1992; Chen et 
al. 1993). Mdm2 mediates the ubiquitination of p53 and thereby it contributes to the 
regulation of p53 by two means. First, it contributes to the nuclear export of p53, preventing 
its function as a transcription factor, mainly by performing mono-ubiqiuitination, as long 
as the level of Mdm2 itself is low (Lohrum et al. 2001; Li et al. 2003). Second, with increasing
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levels, Mdm2 strongly reduces the half-life of p53. By mediating its poly-ubiquitination 
Mdm2 is targeting p53 for proteasomal degradation (Honda et al. 1997; Kubbutat et al. 
1997). How essential this regulation is, becomes evident from the knockout of the mdm2- 
gene, which is embryonically lethal in mice unless the p53-gene is removed as well 
(Jones et al. 1995; Montes de Oca Luna et al. 1995). Interestingly, the mdm2-knockout 
mice are not viable beyond an early embryonic stage, suggesting that developmental 
stress at a certain point activates p53, which cannot be inactivated afterwards thus 
leading to unrestricted p53-activity and excessive cell death (Brooks and Gu 2006). This 
shows that Mdm2 is required to restrict the stress-response of p53. Since Mdm2 is a direct 
target gene of p53, being induced whenever p53 is activated, a negative feedback-loop 
between p53 and Mdm2 is established, allowing a fast regulation of the p53-response 
(Barak et al. 1993; Wu et al. 1993). Prerequisite for p53-ubiquitination by Mdm2 is the 
de-acetylation of lysine-residues in the C-terminus of p53, since these residues are the 
ones becoming ubiquitinated. De-acetylation of p53 can be mediated by a complex of 
Mdm2 and HDAC1 (Ito et al. 2002; Li et al. 2002). In an HDAC1-containing complex MTA2 
is present as well, interacting directly with p53 and lowering its acetylation levels, while 
SIRT1 also interacts directly with p53 leading to a similar effect (Luo et al. 2000; Vaziri et 
al. 2001). A protein related to Mdm2 and as well involved in p53-degradation is Mdmx. 
Its knockout is embryonically lethal as well, indicating that Mdmx has distinct functions 
from Mdm2 (Parant et al. 2001; Finch et al. 2002). This lethality can also be rescued by the 
simultaneous knockout of p53 suggesting an important role as a negative regulator of 
p53. Mdmx seems to interact with and enhance the ubiquitin-ligase activity of Mdm2, 
although the mode of action and the precise function remain unclear (Kawai et al. 2007). 
Various additional E3-ubiquitin-ligases for p53 have been identified, which also constitute 
negative feedback-loops, like Pirh2 or COP1 (Leng et al. 2003; Dornan et al. 2004). Not 
all o f the ubiquitin-ligases for p53 are direct transcriptional target genes, e.g. ARF-BP1, 
which is a p53-regulator independent of the p53-stress response pathway (Chen et al. 
2005; Brooks and Gu 2006). Recently JFK, a F-box protein was identified linking p53- 
degradation to multi-subunit ubiquitin ligases (SCF-complex), which have a prominent 
role in cell cycle regulation (Nakayama and Nakayama 2005; Sun et al. 2009). Although the 
physiological role of the different ubiquitin-pathways has not been elucidated it might 
be that they function in different tissues or during specific times in development, or that 
they can substitute each other as part of a safety net. Furthermore, ubiquitination of p53 
can be reversed, enzymes like HAUSP, an ubiquitin-specific protease, hydrolyses the p53- 
ubiquitin bond, thereby enhancing its stability (Li et al. 2002). Another ubiquitin-protease, 
USP2a, has a complete opposing effect, since USP2a specifically de-ubiquitinates Mdm2, 
leading to its stabilization and enhanced p53 degradation (Stevenson et al. 2007). Thus, 
depending on the ratio between these two enzymes p53 is either stabilized or degraded.
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So, while more regulators of p53 will be identified in the future, the challenge will remain 
to characterize their functions and interactions with p53 and with each other and to 
unravel their physiological significance.
1.4.3. Modulators of the p53 response
The regulation of p53 and its activity is held in a dynamic balance, mediated by numerous 
co-factors influencing all possible aspects of p53-activity. For instance, ubiquitin has 
not only been described as a signal for nuclear export or degradation, but it seems to 
be involved in the selection of p53-target genes as well. Linking differentially branched 
ubiquitin-chains other than the Mdm2-built chains to p53, E4F1 selectively enhances 
growth arrest mediated by p53, but not apoptosis (Le Cam et al. 2006). E4F1 might 
compete with PCAF for the same lysine-residues, thereby impeding on acetylation at 
residues required for activation of pro-apoptotic genes. Conversely, the co-activator 
Strap can enhance the acetylation of p53 by p300 or PCAF, leading to increased apoptosis 
(Demonacos et al. 2004).
Enhanced pro-apoptotic activity is also induced by JMY, a protein interacting with p300 
and p53 and specifically enhancing Bax- but not p21-transcription (Shikama et al. 1999). 
A similar increase in apoptosis by p53 is mediated by ASPP-proteins, which selectively 
lead to stronger p53-binding at promoters and transactivation of cell death inducing 
genes. Interestingly, a truncated dominant-negative form of ASPP also exists, having 
important physiological consequences as an inhibitor of apoptosis (Samuels-Lev et al. 
2001). Also hCAF, a factor involved in chromatin modification, can enhance p53-mediated 
transcription of target genes involved in programmed cell death but not growth arrest 
(Tanaka et al. 2007). On the other hand Hzf, a protein active during hematopoetic 
differentiation, favours a p53-response towards growth arrest by selectively enhancing 
the transcription of target genes in this pathway (Das et al. 2007). Also the repression 
of pro-apoptotic genes can have an influence on increasing the threshold for apoptosis, 
like it is mediated by transcriptional co-repressors like SLUG during hematopoesis or 
like IRF2BP2, a factor involved in the interferon response, its function will be discussed 
in chapter four of this thesis (Wu et al. 2005; Koeppel et al. 2009). Interestingly, both are 
transcriptional p53-target genes, showing certain feedback-regulation on p53-activity. 
Small ubiquitin-like molecules, like SUMO or Nedd8 are important regulators of cellular 
functions, besides protein turn-over. Several SCF-components use these molecules 
to regulate the function of p53 without inducing its degradation, like FBXO11 or Skp2. 
FBXO11 attaches Nedd8 to p53, thereby inhibiting the transcriptional activity of p53
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(Abida et al. 2007). Skp2 inhibits the interaction of p53 with p300, thereby p53-target 
gene induction is impaired (Kitagawa et al. 2008). This inhibition of p53 is required for the 
G2/M-progression through the cell cycle (Hu and Aplin 2008). The attachment of Nedd8 
to p53 mediated by Mdm2 can be inhibited by Tip60 and although the consequences 
of this interaction are not yet clear, it might influence the turnover rate of p53 (Legube 
et al. 2004; Dohmesen et al. 2008). Sumoylation mediated by PIAS was shown to repress 
p53-mediated transcription (Schmidt and Muller 2002), although the role of Sumo for the 
regulation of p53 seems to be more complex and probably influences many functions of 
p53 (Melchior and Hengst 2002).
1.5. Regulators of p73's function
1.5.1. Proteins regulating the activity of p73
Like p53, p73 is subject to various modifications and interacts with a variety of different 
co-factors. The histone acetyl transferase p300 can acetylate also p73, a modification 
occurring after DNA-damage, leading to a specific apoptotic response mediated by p73 
(Costanzo et al. 2002). Three residues in the region between the DNA-binding and the 
oligomerization domain are acetylated by p300. Although they are required to induce 
specifically pro-apoptotic target genes, they do not have an influence on growth arrest 
functions of p73. Pin1 can, like it does with p53, directly interact with p73 and increase 
its stability thereby enhancing p73's pro-apoptotic potential (Mantovani et al. 2004). This 
interaction depends on the phosphorylation of a motif present only in p73a and p73p, 
thereby mediating some p73-isoform specific effects. Interestingly, Tip60 seems to have 
an opposite effect on p73 than on p53, since it inhibits the transcriptional activity of p73p 
(Kim et al. 2008). A factor interacting specifically with p73a and p73p is the Yes-Associated- 
Protein (YAP) (Strano 2001). It plays an important role during the p73-response to 
genotoxic insults, like Cisplatin- or Doxorubicin-treatment, when it specifically enhances 
the recruitment of p73 and that of p300 to pro-apoptotic genes, a complex formation 
also requiring the Pro-Myelocitic-Leukemia-protein (PML) (Strano et al. 2005). Moreover, 
YAP1 is also a substrate for phosphorylation by c-Abl, which is prerequisite to enhanced 
protein stability of YAP1 and pro-apoptotic target gene activation (Levy et al. 2008). YAP1 
and p73 in turn induce the transcription of the PML-gene in a positive feedback-loop after 
chemotherapeutic treatment (Lapi et al. 2008). An opposite effect is mediated by the Akt­
kinase (Basu et al. 2003). Phosphorylation of YAP1 by Akt leads to a relocalization of YAP1, 
thereby inhibiting p73-mediated apoptosis. Another layer of regulation of p73-mediated 
apoptosis is added through the collaboration of p73 with c-Jun, which enhances p73- 
stability and its transactivation potential, although it does not interact directly with p73
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(Toh et al. 2004). Upon Cisplatin-treatment c-Jun is required to induce YAP, which in turn 
is involved in stabilization of p73 (Danovi et al. 2008). Interestingly, c-Jun seems to be 
involved in a bifunctional mode of action, since it also enhances growth together with 
p73 in the absence of genotoxic insults (Vikhanskaya et al. 2007). This is supposed to occur 
through an activating effect of p73 on AP1-site containing promoters, although it remains 
unclear which genes are bound by c-Jun and p73. Furthermore, c-Jun contributes to the 
degradation of anti-apoptotic ANp73 after Doxorubicin or UV-treatment (Dulloo et al. 
2010). Nevertheless, it has not been solved how extensive the collaboration between c-Jun 
and p73 is, whether other AP1-proteins show a similar collaboration or which C-terminal 
isoforms of p73 exert common functions with c-Jun. The work described in chapter three 
shows that the c-Jun p73 network is indeed p73 isoform dependent and can influence the 
apoptotic response.
1.5.2. Regulation of p73 through ubiquitination
Similar to p53, p73-protein levels are mainly regulated through proteasome-dependent 
pathways, as inhibition of the proteasome increases levels of p73 (Balint et al. 1999). 
However, Mdm2 cannot induce the degradation of p73a, but only inhibits its transcriptional 
activating function. Other E3-ubiquitin ligases are responsible for the proteasomal turnover 
of p73, like Itch, which interacts with a motif present in the C-terminus of only p73a and 
p73p, leading to their ubiquitination and subsequently to their degradation (Rossi et al. 
2005). The effect of Itch is reduced upon different chemotherapeutics or in the presence 
of YAP1, which prevents p73-ubiquitination (Levy et al. 2007). Both Itch and Mdm2 show 
some p73-isoform-specificity, introducing further complexity to the p73-isoform network 
(Janssen-Megens, unpublished). Another ubiquitin-ligase, UFD2a, reduces p73-protein 
levels and seems to function through an ubiquitin-independent pathway (Hosoda et 
al. 2005). A quite different effect is exerted by NEDL2, a HECT-domain containing ligase. 
Ubiquitination of p73 by NEDL2 stabilizes it and enhances its half-life and transcriptional 
activity (Miyazaki et al. 2003). Thus, several p73-supporting or -antagonizing factors exist, 
while their physiological significance still needs to be determined. So far it is unclear 
whether some of these factors have main regulatory functions for all p73-isoforms or just 
exert a similar regulation towards a subset of them. Also the extent of additional feedback­
loops awaits further elucidation.
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1.6. Research questions discussed in this thesis
During the last decades tremendous work has been done to reveal the exact mechanisms 
of p53-activaton and -regulation as well as the consequences thereof. Nevertheless, 
new and surprising functions of p53 are still being discovered. Although the role of p53 
as a stress dependent transcription factor has well been established and an increasing 
amount of p53-dependent effectors has been identified, characterization of most of them 
and the consequences of their regulation has not been done systematically. It remains 
to be analyzed what the functions of these newly identified target genes are during or 
immediately after the p53 response.
Although the knowledge about stress-response pathways leapt forward, several issues 
stay elusive. This thesis focuses on different aspects of the activity and regulation of p53 
and its family members. In the second chapter the elucidation of global binding pattern 
of endogenous p53 upon stress treatment will be described. Using an approach in which 
chromatin-immunoprecipitation- (ChIP-) derived DNA was hybridized on microarrays 
covering the whole human genome, high confidence DNA-binding sites of p53 were 
identified. The analysis of the bound DNA resulted in the adjustment of the so far known 
p53-binding motif present in over 80% of the binding sites. These sites were not restricted 
to promoter regions, but a subset of them was found to be active enhancers. Also a 
reasonable overlap of the identified sites with the binding sites of full length p63 and 
p73 was shown. The third chapter extents the elucidation of binding- and transactivation- 
events mediated by TAp73a, TAp73p and p53. Using isogenic cell lines and second 
generation sequence technologies we identified a possible cause for the very different 
cellular fate induced by these two p73-isoforms, which seems to be caused by the 
differential collaboration with the proto-oncogene c-Jun. Our findings support a model 
in which TAp73a can transactivate apoptosis-inhibiting target genes, together with c-Jun, 
while TAp73p reduces c-Jun levels, thereby enhancing programmed cell death. In chapters 
four and five the functions of two newly identified target genes of p53 are examined. 
IRF2BP2 can increase the apoptotic threshold, thereby leading to enhanced growth 
arrest, probably forming a negative feedback loop on the transcriptional activity of p53. 
The F-box protein Fbxo22 influences the stability of p53, likely through a modulation of 
Mdm2's activity. Independent of its function as a substrate receptor for SCF-complexes, it 
can directly interact with Mdm2 and lead to a reduction of p53-protein-levels. Finally, the 
last chapter will discuss the findings presented and put them into the context of decision­
making processes concerning cellular fate.
24
Chapter 1
25
26
Chapter 2
2. Characterization of genome- 
wide p53 binding sites upon 
stress-response
Leonie Smeenk, Simon J. van Heeringen, Max Koeppel, Marc A. van Driel, Stefanie J.J. 
Bartels, Robert C. Akkers, Sergei Denissov, Hendrik G. Stunnenberg, Marion Lohrum 
(2008). Nucleic Acids Research 36, 3639-3654
27
Chapter 2
2.1. Abstract
p53 is a sequence specific transcription factor which regulates the expression of target 
genes involved in different stress-responses. To understand p53's essential transcriptional 
functions, unbiased analysis of its DNA-binding repertoire is pivotal. In a genome-wide 
tiling ChIP-on-chip approach, we have identified and characterized 1546 binding sites of 
p53 upon Actinomycin D treatment. Among those binding sites were known as well as 
novel p53 target sites which included regulatory regions of potentially novel transcripts. 
Using this collection of genome-wide binding sites, a new high-confidence algorithm 
was developed, p53scan, to identify the p53 consensus binding-motif. Strikingly, this 
motif was present in the majority of all bound sequences with 83% of all binding sites 
containing the motif. In the surrounding sequences of the binding sites, several motifs 
for potential regulatory co-binders were identified. We finally show that the majority of 
the genome-wide p53 target sites can also be bound by overexpressed p63 and p73 
in vivo, suggesting that they can possibly play an important role at p53 binding sites. 
This emphasizes the possible interplay of p53 and its family members in the context of 
target gene binding. Our study greatly expands the known, experimentally validated p53 
binding site repertoire and serves as a valuable knowledgebase for future research.
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2.2. Introduction
The tumor suppressor gene p53 is the most frequently mutated gene in human cancers 
(Hollstein et al. 1991). It can be activated by a large number of stress signals. The p53 pro­
tein is able to function as a sequence specific transcription factor (Kern et al. 1991) and it 
regulates the expression of target genes involved in growth arrest, apoptosis, DNA repair, 
senescence, differentiation and other responses (Vogelstein et al. 2000). Substantial evi­
dence indicates that the transcriptional functions o f p53 are necessary for p53-mediated 
tumor suppression (Laptenko and Prives 2006), although it has also been reported that 
p53 can induce apoptosis without a functional transactivation domain (Erster and Moll
2005).
p53 has been shown to bind to DNA in a sequence-dependent manner to a so-called p53 
consensus binding motif. This motif is found in many identified binding sites of, mostly 
upregulated, p53 target genes and consists of two copies of the palindromic consensus 
half-site RRRCWWGYYY separated by a spacer o f 0-13bp, in which R = purine, W = A or T 
and Y = pyrimidine (el-Deiry et al. 1992). The p53 binding ability and its transcriptional 
activity might be influenced by the sequence of the two half-sites as well as their mutual 
orientation (Zhao et al. 2000; Inga et al. 2002). Up to now it was thought that this p53 
response element is mostly found within a few thousand base pairs of the transcriptional 
start site (Laptenko and Prives 2006). In addition, binding sites which differ from the classi­
cal p53 binding motif have been reported (Contente et al. 2002; Ho et al. 2005). It has been 
suggested that the deviations from the consensus sequence hint at the possibility that 
DNA topology also determines p53 binding (Gohler et al. 2002) and that even the DNA 
structure might totally replace the consensus sequence (Jett et al. 2000). However, these 
findings are largely based on single target genes; a genome-wide analysis of binding se­
quences for common motifs will be very informative.
The transcriptional activity of p53 can be regulated by post-translational modifications 
(Brooks and Gu 2003; Bode and Dong 2004) as well as transcriptional co-factors and p53- 
binding proteins (Laptenko and Prives 2006; Aylon and Oren 2007). p300 acts as a p53- 
dependent co-activator for p53 target genes by acetylating p53 (Avantaggiati et al. 1997; 
Gu and Roeder 1997) and it binds to various co-recruited factors that enhance the p53 
response (Coutts and La Thangue 2005). Two o f those have recently been identified, JMY 
and Strap, and both factors are required for p53 activity (Shikama et al. 1999; Demonacos 
et al. 2001). Recent studies have also provided evidence that the selection of p53 target 
genes can be modulated by p53 interacting proteins. The ASPP proteins have been shown 
to interact with p53 and to specifically modulate p53-induced apoptosis but not cell cycle
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arrest (Sullivan and Lu 2007). Interestingly, the hCAS protein has been reported to be part 
of a distinct macromolecular complex of p53 at specific subsets of p53 target genes, e.g. 
Pig3 and p53aip1 and its knockdown attenuates the p53 dependent apoptosis (Tanaka et 
al. 2007). Other transcription factors that might be involved in the target gene selection 
of p53 are the Brn3 family of POU domain transcription factors (Budhram-Mahadeo et al.
2006), the YB1 protein (Homer et al. 2005), NF-kB and IKKa (Schumm et al. 2006; Huang et 
al. 2007) as well as the Hematopoietic Zinc Finger Co-factor (HZF) protein (Das et al. 2007). 
In addition to transcriptional factors that influence the p53-target gene binding, there is 
also evidence that the p53-family members p63 and p73 can contribute to the p53-rec- 
ruitment at specific target genes. p63 and p73 were reported to be required for the p53- 
binding to the p53 response elements of the target genes Perp, Bax and Noxa, but not to 
those of p21 or Mdm2 (Flores et al. 2002). A 'priming model' was suggested, in which p63 
and p73 can bind to a specific chromatin-embedded response element not accessible for 
p53, and subsequently modify the context of the response element in such a way that 
it becomes available for p53 binding (Espinosa 2008). So far, a systematic analysis of the 
capability of p63 and p73 to play a role in vivo at p53-target sites has not been performed.
Many p53 target genes are currently known, e.g. identified with microarray expression 
profiling (el-Deiry 1998; Sbisa et al. 2007), and at the moment it is intensively studied 
how p53 determines which target genes to activate or repress in a certain stress response 
(Laptenko and Prives 2006; Horn and Vousden 2007). In addition to the experimentally 
identified p53 target genes there are also computationally predicted binding sites (Hoh 
et al. 2002; Veprintsev and Fersht 2008). These predictions do not necessarily reflect the 
actual target sites bound in vivo by p53. For the selection of functional binding sites the 
involvement of other cellular factors, chromatin accessibility, DNA sequences surrounding 
the potential binding site and DNA topology have to be taken into consideration, in 
addition to the consensus binding sequence itself. These factors cannot yet be accurately 
modeled. It is estimated that there are between 300 and 3000 binding sites for p53 in 
the human genome, based on studies from Hoh et al. (Hoh et al. 2002), ChIP-on-chip 
(chromatin immunoprecipitated DNA hybridized on DNA arrays) data extrapolated from 
chromosome 21-22 (Cawley et al. 2004) and ChIP-on-chip data derived from ENCODE 
regions (Kaneshiro et al. 2006). Since there are only about 180 experimentally confirmed 
target genes (Sbisa et al. 2007), and 542 high-probability binding sites (Wei et al. 2006), 
it is expected that there are still many unidentified binding sites and target genes, 
notwithstanding several studies that have reported binding sites for p53 (Cawley et al. 
2004; Hearnes et al. 2005; Jen and Cheung 2005; Ceribelli et al. 2006; Kaneshiro et al. 2006; 
Krieg et al. 2006; Wei et al. 2006; Zeng et al. 2008). Furthermore, it remains to be seen how 
a comprehensive set of p53-DNA binding sites in vivo can be used to give more insight
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into the different transcriptional functions o f p53.
Here, we report a genome-wide ChIP-on-chip study of p53 employing high resolution 
tiling arrays with an average probe spacing of 100 bp. We have identified 1546 high 
confidence sites and performed extensive analysis of the in vivo binding sites with respect 
to their sequence as well as surroundings and nearby genes. We report the development 
of a new publicly available algorithm, p53scan, to identify the p53 consensus binding 
motif with high specificity. The motif is present in 83% of all the p53-bound sequences 
and in almost all highly enriched binding sites. Potentially novel functions of p53 derived 
from the global binding sites were investigated and validated. To obtain a more complete 
picture of the in vivo bound target genes of p53, we have also performed ChIP-on-chip 
analyses with two of its family members, p63 and p73. We show that a large fraction of 
these newly identified binding sites for p53 could also be bound by p63 and p73 in vivo.
2.3. Results
2.3.1. Genome-wide identification of p53 binding sites using ChIP-on-chip
In order to detect in vivo binding sites for p53 on a genome-wide scale we applied the 
ChIP-on-chip approach to endogenous p53 expressing U2OS osteosarcoma cells. In un­
stressed cells, endogenous p53 is maintained at low levels. To activate p53, cells were 
treated with 5 nM Actinomycin D for 24 hours (Ashcroft et al. 2000). Upon Actinomycin 
D treatment, p53 is stabilized and growth arrest is induced (Figure 1A and B). ChIP was 
performed upon this treatment. To assess the specificity of our ChIP-results, p53 binding 
to exon 2 of the myoglobin-gene was determined as background signal and enrichment 
was calculated as fold binding over background signal (Figure 1C). For the p21-promoter, 
an enrichment of p53 binding of almost 600 fold was attained showing that the immuno- 
precipitation was highly specific. For the global binding site analysis, the enriched (ChIP) 
sample and the non-enriched (Total) DNA sample were amplified, differentially labeled 
and co-hybridized to 38 DNA arrays covering the whole human genome (repeat masked) 
with a probe spacing of 100 bp and a probe length of 50 bp (NimbleGen Systems, Inc.).
We called putative p53 binding sites combining three different peak extraction algorithms 
to maximize the number of potential peaks. The genomic loci of the combined peaks were 
combined to generate a so-called dedicated array (Kim et al. 2005), which was used to 
hybridize two further biological replicate experiments (Figure 1D). If a peak was identified 
in all three biological replicates it was considered as a high confidence p53 binding site. 
This way, we identified in total 1546 high confidence binding sites for p53. Verification of 
the identified binding sites was performed by quantitative PCR with three independent
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Fig. 1.: Genome-wide identification o f p53 binding sites using ChIP-on-chip
A. Representative cell cycle profile o f U2OS cells untreated or treated for 24 hours w ith 5 nM Actinomycin D.
B. Western b lo t showing p53 expression levels o f U2OS cells, untreated or treated for 24 hours w ith 5 nM Actin 
mycin
C. ChIP enrichment (fold over negative control, myoglobin) o f p53 a t the p21 prom oter and the intronic binding 
site o f  GADD45A.
D. ChIP-on-chip profile o f p53 b inding to  chromosome 6 visualized using Signalmap (NimbleGen Inc.). Shown are 
the log2 ra tio  o f  ChlP/Total signal derived from the genome-wide tiling data and a zoomed-in view o f binding 
to the p21 promoter for a ll three biological replicates. Genes are represented by thick horizonta l bars (plus­
strand positive, m inus-strand negative).
E. Overlap o f the ChIP-on-chip derived p53 binding sites w ith PET5+ data from Wei et al.
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Table 1. Overlap with published data sets
Published study: total number of binding sites
Overlap with p53 of 
this study 
(1546 total)
Yang et al. 5807 383
Wei et al. PET2+ 1773 301
PET2+ with p53PET motif 542 262
PET3+ 327 170
PET4+ 169 111
PET5+ 106 73
Krieg et al. Low 113 3
Mid 34 1
High 8 1
Cawley et al. 48 15
Kaneshiro et al. 37 16
Hearnes et al. 38 26
ChIP experiments. In total 50 potential binding sites were randomly selected and tested. 
This resulted in a confirmation of 48 out of 50 sites. We conclude that we identified 1546 
genome-wide p53 binding sites with a false positive rate of approximately 4%.
Since several studies, using different ChlP-based techniques, have identified binding sites 
for p53 in various cell systems (Cawley et al. 2004; Kaneshiro et al. 2006; Krieg et al. 2006; 
Wei et al. 2006; Yang et al. 2006), we compared these to the collection of our binding sites 
(Table 1). The overlap between our data set and the PET5 cluster in the ChlP-PET data set for 
p53 by Wei et al. (Wei et al. 2006) was 69%, even though different cell lines and treatments 
were used (Figure 1E). The extensive overlap with the highest ranked targets of the ChlP- 
PET data (69%) and lower overlap (17%) in the low ranked targets with ChlP-PET data is 
in concordance with the study of Euskirchen et al. (Euskirchen et al. 2007), where they 
compared ChlP-sequencing with ChlP-on-chip under the same conditions for STAT1 and also 
found the most overlap in the highest ranked regions. From the genes that were identified 
by a ChlP-based screen in yeast (Hearnes et al. 2005), 50% are found in our study. Thus, even 
when using different cellular systems and physiological conditions as well as various ChlP- 
based techniques, half or more of the p53 binding sites appear to be overlapping with our 
global ChlP-on-chip approach creating a high-confidence p53-binding set data.
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2.3.2. Characterization of identified p53 binding sites
To annotate the identified p53 binding sites, their locations were analyzed with respect 
to annotated Ensembl genes. We found that 21% of all p53 binding sites mapped to 
Transcriptional Start Site (TSS) flanking regions (5 kb upstream, first exon and intron), 28% 
were within a gene (excluding first exon and intron), 3% within 5 kb downstream, 16% 
within 5-25 kb upstream or downstream and 32% in intergenic regions (Figure 2A). We 
compared the frequency of p53-binding in specific genomic regions to the distribution 
of these genomic regions over the whole genome (using Ensembl gene annotations) and 
found that p53 binding sites are significantly enriched in TSS flanking regions and within 
5-25 kb upstream or downstream of a gene (p = 1.49E-009 and 0.0094, respectively) (Fi­
gure 2A).
To study if binding of p53 in TSS flanking regions can regulate the transcription of the 
corresponding gene products, we randomly selected 11 genes in this group to test their 
changes of expression upon p53 activation (Figure 2B). Four of these genes were indeed 
more than two fold upregulated, two were more than two fold downregulated, and five 
did not change more than two fold. Thus, upon p53 binding in TSS flanking regions, genes 
can get activated or repressed by p53, which is in accordance with the described function 
of p53 as transcriptional activator and repressor.
While the biological function of p53 binding to promoter regions is well established, we 
wanted to study the functional potential of intronic as well as intergenic p53 binding. 
We first tested nine of the intronic and intergenic binding sites (randomly chosen) in 
transactivation assays cloning them into a pGL3-promoter-luciferase vector, which can 
be used to test enhancer functions. U2OS cells were transiently transfected with these 
luciferase-constructs and treated with Actinomycin D to activate p53. For each of the 
selected binding sites the luciferase activity increased two to nine times compared to the 
pGL3prom control vector (Figure 2C). This indicates that p53 binding sites in introns and 
intergenic regions can play a role as transcriptional enhancers.
To test whether the p53 binding in intergenic regions could also regulate the transcription 
of novel gene products, we mapped the intergenic binding sites to human expressed 
sequence tags (ESTs). This revealed that 67% of intergenic p53 binding sites are located 
within 5 kb up- or downstream of an Expressed Sequence Tag (EST). This is a significant 
enrichment (p-value=1.50E-4) compared to the proportion of the complete genome that 
falls within this category. From these binding sites close to an EST, we chose four sites 
for further analysis (Figure 2D upper panel). We validated binding of p53 to these sites in 
targeted ChlP experiments (Figure 2D lower left panel) and tested changes of expression
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Fig. 2.: Characterization o f identified p53 binding sites
A. Distribution o f the p53 binding site location relative to Ensembl genes (left panel) compared to the genome 
wide distribution (right panel). Locations o f binding sites are divided in TSS flanking region (5 kb upstream 
o f TSS + first exon + first intron), intragenic region (all introns and exons except first), 5 kb downstream (5 kb 
o f last exon), 5-25 kb up- or downstream or intergenic regions (everything else). The asterisk represents 
significant enrichment.
Expression change o f genes, which have a p53 binding site in the TSS flanking region. The expression change is 
shown after 24 hours o f 5 nM Act.D treatment in fo ld  over untreated U2OS cells. Error bars represent standard  
deviation o f three independent experiments.
B.
C. Transactivation assay o f  intronic (yellow) and intergenic (blue) p53 binding sites. The relative luciferase activity  
is p lo tted in fo ld over empty vector. Error bars represent standard deviations o f three independent biological 
replicates.
D. Binding profile and expression change o f four expressed sequence tags (ESTs) bound by p53. In the upper panel 
the ChlP-on-chip data is visualized. In the lower le ft panel these binding sites are confirmed by targeted ChIP for 
p53. Shown is the enrichment in fo ld over negative control (myoglobin). In the lower righ t panel the expression 
change o f the EST is shown after 24 hours o f 5 nM Act.D treatm ent in fo ld over untreated U2OS cells. Error bars 
represent standard deviation o f  three independent experiments.
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of these novel transcripts upon p53 activation. The four chosen transcripts showed a 2- to 
15-fold induction (Figure 2D lower right panel) upon p53 activation. This indicates that 
many novel, currently unannotated transcripts may be regulated by p53.
2.2.3. Functional annotation of the p53 binding sites
Since we found well-known p53 target genes involved in pathways such as DNA repair 
(GADD45A, DDB2), cell cycle regulation (MDM2, p21) and apoptosis (BAX, DR5) (Table S1), 
we wanted to analyze the possible biological roles of all the p53 binding sites in our data 
set. When we grouped our p53 targets, which have a binding site within 5 kb, according 
to function in Gene Ontology (GO) using Ontologizer (Robinson et al. 2004; Grossmann et 
al. 2006), we found several new groups of target genes that have not been linked to p53 
function before or that expand p53's functions such as the phosphorus and biopolymer 
metabolism group (Figure 3A). Metabolic changes occur in many cancers and recently 
p53 has been linked to changes in metabolism (Bensaad et al. 2006). The fact that we find 
metabolism-related genes significantly enriched in our binding site list could well indi­
cate that p53 plays an even wider role in metabolic changes besides the so far described 
function of p53 in glucose metabolism and oxidative stress (Bensaad and Vousden 2007).
To study the involvement of our identified p53-target genes in entire biological pathways, 
we classified them according to the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
using FatiGO+ (Al-Shahrour et al. 2004). Axon guidance and calcium-signaling pathways 
(Figure 3B) are significantly overrepresented in our dataset, suggesting a hitherto 
undescribed role for p53 in these biological processes. To study the axon guidance target 
gene group further, we randomly chose three genes from this group for our analysis:
Fig. 3.: Functional annotation o f identified p53 binding sites
A. A ll Ensembl genes w ithin 5 kb o f an identified p53 binding site were annotated according to the Gene Ontology 
(GO) using Ontologizer. Significantly enriched groups (p-value <0.05) are indicated w ith an asterisk. Shown is a 
selection o f GO categories.
B. A ll Ensembl genes w ithin 5 kb o f  an identified p53 binding site were annotated according to Kyoto Encyclopedia 
o f Genes and Genomes (KEGG) using FatiGO+. Significantly enriched pathways (p-value <0.05) are indicated 
with an asterisk. Shown are the five pathways w ith the highest number o f p53-bound genes.
C. Binding profile o f p53 target genes involved in the axon guidance pathway. In the upper panel the ChIP-on-chip 
data is visualized. In the lower panel these binding sites are confirmed by targeted ChIP for p53. Shown is the 
enrichment in fo ld over negative control (myoglobin).
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SEMA3C, SEMA6A and SEMA3A (Figure 3C upper panel). We validated the ChlP-on-chip 
data (Figure 3C upper panel) by targeted ChIP and found a significant enrichment of 
p53 binding upon Actinomycin D treatment of U2OS cells to all tested sites (Figure 3C 
lower panel). Thus, it remains to be elucidated which role the target genes from the axon 
guidance group could play during the p53-mediated stress response.
2.2.4. Development of p53scan, a novel p53 motif finding algorithm
The p53 DNA binding site has been characterized and is consistently described as two co­
pies of the half-site RRRCWWGYYY separated by a spacer of 0-13 bp, where R = purine, W 
= A or T and Y = pyrimidine. Although this may be the most optimal sequence for p53 bin­
ding only 52 out of the 1546 binding targets in this study contain a perfect match to this 
sequence. Thus, the p53 motif shows a high degree of degeneracy, which could create the 
versatility of different p53-mediated stress responses in vivo. Different approaches for iden­
tifying the degenerate p53 consensus binding motif have been described. Most are based 
on a Positional Weight Matrix (PWM) scoring method although recently an algorithm based 
on experimentally measured binding affinity was shown to give interesting results (Veprint- 
sev and Fersht 2008).
An accurate PWM which correctly reflects the binding preference of a transcription-factor 
is a crucial parameter for identifying binding sites with PWM algorithms. The different 
PWMs that have been described for p53 until now were constructed based on only 17 
(TRANSFAC) to 39 (Wei et al. 2006) binding sequences. Consequently, these PWMs only 
reflect the information present in those few sequences. Therefore, not surprisingly, using 
p53MH (which uses a PWM based on 37 sequences) with a cutoff of 90 as suggested by the 
authors (Hoh et al. 2002), we find that only 33% of our high-confidence binding sequences 
contain a motif. Having identified a set of genome-wide binding sites we wondered if 
we could use the information encompassed in a wide variety of p53 binding sites to 
develop a more sensitive algorithm. We randomly selected 773 sequences (one half of 
our identified binding targets) and ordered these based on the ChlP/Total ratio of the 
highest probe in the peak. We used the de novo motif prediction program MDmodule (Liu 
et al. 2002) on the ordered sequences to predict the p53 motif (Figure 4A). The PWM was 
constructed from these results (matrix shown in Table S2) and combined with a scoring 
scheme adapted from the p53MH model. This approach enabled us to greatly increase the 
amount of binding sequences with an identified p53 motif up to 83% (FPR ~7%).
The performance of our algorithm, p53scan, was benchmarked on the binding sites 
identified in this study (the ones not used for training) and the human p53 binding sites 
identified previously by ChIP in combination with Paired End Tag sequencing (ChlP-PET 3+
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Table 2. The performance of p53scan
p53 ChIP-on-chip p53 ChIP-PET 3+
MNCP AUC F-measure MNCP AUC F-measure
p53scan 8.67 0.90 0.86 3.97 0.93 0.91
p53MH 5.62 0.83 0.76 3.37 0.86 0.81
Match 7.35 0.82 0.82 3.49 0.87 0.81
(Wei et al. 2006)). We compared the performance to p53MH and to the Match algorithm 
(Kel et al. 2003) with the p53 PWM from TRANSFAC, using three different metrics: Area 
under the Receiver Operator Curve (ROC AUC), Mean Normalized Conditional Probability 
(MNCP) (Clarke and Granek 2003) and the harmonic mean of precision and recall 
(F-measure). The training and benchmarking process was repeated in ten independent 
runs and the average results are shown in Table 2. We implemented the best performing 
PWM in p53scan, and compared the performance on all binding targets to p53MH and 
Match (Figure 4B). We also compared p53scan to the ChlP-PET algorithm described by Wei 
et al. using the ChlP-PET 3+ sequences. The authors identified 72% of these sequences 
as having a motif using p53PET with an estimated FPR of 0.68% (Wei et al. 2006). Using 
p53scan on their sequence set with the same estimated FPR we find a p53 binding motif 
in 83% of the binding sites. These results clearly show that p53scan can identify more p53 
motifs in the evaluated sequence sets than the currently described algorithms, without 
lowering specificity.
The possibility of a spacer within the p53 motif deserves special consideration. If all 
spacer lengths from 1 to 13 are considered without specifying additional constraints the 
false positive rate of a PWM algorithm like p53scan greatly increases, due to the greater 
number of possible motifs that is evaluated. As can be seen in Figure 4C most of our p53 
binding motifs actually do not have a spacer between the two half sites. Therefore by 
default p53scan employs a strict score threshold for all spacer lengths other than 0. The 
score threshold for each individual spacer length was selected by scanning a background 
sequence set (random non-bound sequences of equal length) for each spacer length and 
selecting the cutoff that resulted in no hits. Thus, we have developed a highly specific 
and inclusive algorithm to identify p53 binding motifs, which is freely available at: http:// 
www.ncmls.nl/bioinfo/p53scan.
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Fig. 4.: Development o f p53scan, a p53 m otif finding algorithm
A. p53 m o tif identified de novo w ith MD-module, visualized using WebLogo.
B. ROC curve comparing p53scan, p53MH and Match. The FPR used to characterize the p53 binding sites (~7%) is 
marked.
C. Distribution o f spacer length in the p53 consensus sites based on the p53scan algorithm.
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2.2.5. Characterization of the p53 binding motif
The p53scan cutoff resulting in the highest F-measure (FPR ~ 7%, as marked in Figure 
4B) represents a balance between retrieving false positives and missing false negati­
ves. We have used this setting to analyze and further characterize the bound target si­
tes identified in this study. We found the p53 motif in 1281 out of 1546 (83%) binding 
sites. We determined the location of the consensus motif with respect to the ChlP-on- 
chip data and found it to be located mainly in the centre of the peaks (Figure 5A). To 
study whether there is a correlation between the ChlP/Total binding ratio of p53 and 
the occurrence of the p53 binding motif, we ranked the identified p53 binding sites ac­
cording to their relative binding enrichment (log2 ChlP/Total) and divided them into 
three subgroups of low, medium and high ratios. The percentage of binding sites which 
contain the p53 binding motif increased slightly with the binding ratio of the peaks. 
ln the high enrichment subgroup (468 sites with a log2 ChlP/Total ratio of at least 3.17), 
almost 90% of the p53 binding sites contain a p53 binding motif (Figure 5B).
Next, we analyzed the binding enrichment as measured by ChlP/Total signal ratio in 
relation to the exact composition of the consensus site. We averaged the binding ratio as 
a function of the number of mismatches to the consensus motif (Figure 5C). This shows 
that there is a correlation between enrichment in vivo as measured by ChlP-on-chip and 
the nucleotide composition of the p53 binding motif.
Since 52 (~11%) of the sequences in the high subgroup, consisting of the most highly 
enriched targets (Figure 5B), do not contain a p53 binding motif as identified by p53scan, 
we tried to further characterize the motifs in these sequences. When we expand the peak 
area to 1.5kb, p53scan can find a binding motif in 43 out of the 52 sequences, using settings 
that result in only 15 motifs found in 1500 random coding sequences of equal length (FPR 
~1%). ln these cases the actual calling of the peak area could have been imprecise, most 
likely due to the binding site being located in repeat-masked areas. Remarkably, when 
we take these matches into account, in total 98% of the sequences in the high subgroup 
contain a p53 motif.
2.2.6. Transcription factor binding motifs in the vicinity 
of the identified p53 binding sites
Co-recruited DNA-binding factors (Coutts and La Thangue 2005) have been invoked to 
play a role in the flexible response of p53 to various stress signals. We therefore analyzed 
the vicinity of the p53 sites (500 bp centered on the peak of the p53 binding) for the po­
tential presence of other known transcription factor binding sites, using TAMO (Gordon et
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Figure 5
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Fig. 5.: Characterization o f the p53 binding m otif
A. Histogram o f the distance o f the p53 consensus site to the probe w ith the highest mean ra tio w ithin a binding 
site, based on the p53scan algorithm.
B. Percentage o f binding sites containing a m o tif relative to  binding ratio. The identified p53 binding sites were 
ranked according to their binding ratio (log2 ChIP/Total) and divided in to  three groups ranging from low  to 
high ratios. Shown for each group is the percentage o f sequences containing a motif, based on the p53scan 
algorithm.
C. Average binding ratio (log2 o f  ChIP/Total) relative to the number o f  mismatches to the p53 consensus site 
visualized in a boxplot. Data based on p53scan results.
44
Chapter 2
al. 2005) with the TRANSFAC database (Matys et al. 2003). Predicted binding sites of eight 
different motifs of transcription factors were found to be significantly overrepresented in 
the surrounding sequences of the p53 binding sites (Figure 6). Among those were poten­
tial binding sites for Kruppel-like factors (KLF), Sp1/Sp3, the group of basic Helix-Loop- 
Helix (bHLH) proteins, API, AP2, MZF1, CP2 and ETS2. Many of these factors that we have 
found to be statistically enriched in our genome-wide collection of p53 binding sites have 
been experimentally shown to influence p53-dependent transcriptional activity for single 
target genes. The most overrepresented motif in our dataset are the motifs for Kruppel- 
like factors; it has been suggested that Kruppel-like factor 4 is a mediator of p53 in control­
ling progression of the cell cycle following DNA damage (Yoon et al. 2003). Interestingly, 
p53 has been reported to require cooperation of Sp1 or a Sp1-like factor for the transcrip­
tional activation of the human BAX promoter (Thornborrow and Manfredi 2001) as well 
as for p21 (Koutsodontis et al. 2001). To find out if the potentially co-binding transcription 
factors might influence p53-transcriptional activity towards a specific direction of the re­
sponse pathway we looked at the different subsets of the p53 binding sites containing a 
specific motif. We analyzed the potential biological significance of the genes which are 
within 5 kb of these binding sites using GO annotations, as described above. Three sig­
nificantly enriched GO categories were found for the co-binding factors: developmental, 
metabolic and cell-cell signaling pathways (Table 3). In all three pathways p53 has been 
reported to play a role. Our data thus supports the notion that the response pathways of 
p53 might be influenced by the identified potential co-binding transcription factors.
2.2.7. p63 and p73 binding to p53 targets
The p53-family members p63 and p73 have been reported to contribute to the p53-stress 
response in certain tissues in vivo (Flores et al. 2002; Flores et al. 2005). They might play 
a role in the regulation of transcriptional activities of p53 as well as potential co-binding 
transcription factors as evidenced by their influence on p53's ability to bind to various 
apoptotic promoters in vivo (Flores et al. 2002; Flores et al. 2005). Furthermore, Yang et
Table 3. Enriched TRANSFAC motifs involved in a biological function
TRANSFAC GO Term GO Description p-value
MZF1 G0:0007275 multicellular organismal development 0.03
bHLH G0:0007275 multicellular organismal development 0.04
bHLH G0:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 0.04
CP2 G0:0007267 cell-cell signaling 0.04
API G0:0007275 multicellular organismal development 0.05
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Figure 6
Factor Number P-value Significance Motif 
of
sequences
KLF/PAX4/ 576 2.11e-21 19.77 
Sp1
Sp1 96 5.34e-20 18.37
bHLH 681 5.78e-09 7.34
AP2 14 2.31 e-06 4.73
MZF1 576 3.32e-05 3.58
CP2 72 1.09e-04 3.06
ETS2 33 2.38e-04 2.72
AP1 269 1.74e-02 0.86 *
Fig. 6.: Overrepresented transcription factor binding motifs in the vicinity o f  identified p53 binding sites 
Known transcription factors motifs identified in the 500 bp region centered around p53 binding sites based on 
TRANSFAC 6 database. Statistical significance (p-value <0.05) was calculated using TAMO.
Motifs were visualized using WebLogo.
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al. studied the genome wide binding of p63 and identified a p63-specific motif (Yang et 
al. 2006). Since this motif strongly resembles the motif to which p53 binds, we were in­
terested if and to what extend p63, and the other p53-family member p73, can bind to 
our identified p53 global binding sites. Because of possible cell-type specific differences 
in the transcriptional response pathways of the p53-family, a cellular system was needed 
that would allow a direct comparison between p53, p73 and p63. We generated Saos-2 
cell lines expressing TAp63a, TAp73a or p53 under a Tetracycline-inducible promoter. We 
performed ChlP-on-chip analysis for p63 and p73 as well as overexpressed p53 on the 
dedicated array. Comparing the binding sites identified for endogenous p53 in U2OS cells 
to those identified for exogenous p53 in the Saos-2 p53 cell line, we found that 1112 of the 
endogenous binding sites (72%) are bound by exogenous p53 as well. Very interestingly, 
if we compare these 1112 p53 exogenous binding sites which overlap with the binding 
sites occupied by endogenous p53 72% of those p53 binding sites could also be bound 
by p73 and/or p63 in vivo (Figure 7). With the majority of the p53 binding sites also being 
bound by p73 and p63, there seems to be good evidence that p63 and p73 could play an 
important role in the p53 transcriptional response pathways.
To investigate whether binding sites that can be bound only by p53 or also by p73 and 
p63 show sequence differences, we compared the p53 motif based on p53scan in shared 
binding sites (Figure 7B upper panel) and binding sites which are not bound by p63 and 
p73 (Figure 7B lower panel). These motifs very much resemble each other, independently 
of whether they are bound by p53 only or by all three family members. Accordingly, p63 
and p73 are actually able to bind sequences containing this p53 binding motif on a global 
scale. The p53 binding motif was identified in 86% of the shared binding sites and in 76% 
of the binding sites for p53 only. It remains to be elucidated which other parameters of 
a p53-binding site determine whether it can be bound by p53 only or also by the family 
members. It has been shown in vitro that 5 specific bases in the p53 consensus sequence 
are important for stable binding of p73 to DNA (Lokshin et al. 2007). These specific nucle­
otides are present in 9.6% of the motifs found by p53scan in the shared binding sites, and 
in 10.8% of the motifs in p53-only binding sites. Therefore, according to our observations 
this specific characteristic of the p53 consensus motif cannot explain the difference bet­
ween p53 only and shared binding site of our genome-wide in vivo binding data.
Besides differences in the p53 motif, we also analyzed the p53 only versus the shared 
binding sites in respect to their genomic location, GO annotation, and the potential pre­
sence of other known transcription factor binding sites, as described above, but could not 
observe significant differences (data not shown). Thus, we found that the DNA binding 
characteristics of the p53 binding sites which were bound by its family members closely 
resemble those which were bound by p53 only.
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2.3.1. Genome wide identification of p53 binding sites
To characterize the transcriptional mechanisms of the p53 mediated stress response, we 
analyzed p53 binding to chromatin on a genome-wide scale using the ChIP-on-chip ap­
proach and identified 1546 high confidence binding sites.
While these binding sites were significantly enriched inTSS flanking regions, encompassing 
possible promoters, a large fraction was located in intragenic or intergenic regions, as 
also observed in other studies (Hearnes et al. 2005; Wei et al. 2006). We and others have 
provided evidence for functionality of these intergenic binding sites. In our reporter 
assays, we could show that the intergenic and intragenic p53 binding sites can function 
as enhancers. Likely, the interaction between enhancer and target gene is mediated via 
loop formation, as shown for example for the Hoxd gene cluster and the beta-globin 
locus (Vlieghe et al. 2006). Furthermore, the intergenic binding sites could be involved
Figure 7
2.3. Discussion
B
§1-
shared
cm m in
p53 only
Fig. 7.: p63 and p73 binding to p53 targets
A. Overlap o f p53 binding sites also bound by p63 and p73 in Saos2 inducible cell lines as determined by 
ChIP-on-chip on the dedicatedp53 array.
B. p53 m o tif identified w ith p53scan, visualized using WebLogo for p53 binding sites also bound by p63 or p73 
(upper panel) and binding sites on ly bound by p53 (lower panel).
48
Chapter 2
in regulation of non-protein coding genes as well as other novel transcripts, as has been 
suggested by smaller scale ChIP-on-chip analyses (Cawley et al. 2004). In our study, we 
discovered that unannotated transcripts located near intergenic p53 binding sites can be 
upregulated upon p53 activation.
2.3.2. Motifs in the p53 binding site
We have developed a new algorithm, p53scan, which incorporates the motif derived de 
novo from the genome-wide binding sites identified in this study as shown in Figure 4A. 
Although this motif resembles the different versions of the p53 binding motif described 
up to now, it more accurately reflects the in vivo binding preference of p53, as this new 
motif is based on information from hundreds of binding sites. Indeed, comparisons of 
p53scan to other publicly available algorithms, including p53MH, which has been most 
widely used, show that it produces markedly better results in the metrics that were tested 
in this study. In addition, we compared p53scan to the algorithm developed by Wei et al. 
(Wei et al. 2006), called p53PET model, with the sequences identified in their study as in­
put. We found more sequences containing a motif with p53scan than with p53PET model 
(83% versus 72%) at the same specificity level. This confirms that the sensitivity of p53scan 
is not limited to the binding sites of our ChIP-on-chip data set, but that it can also be used 
for future analysis of other binding data. As a publicly accessible, intuitive and above all 
sensitive and specific algorithm, p53scan is a useful addition to the available tools that will 
help characterize the widely diverse binding preference of p53.
When analyzing our p53 binding sites with p53scan, 83% of the identified binding sites 
contained a motif that is reminiscent of the p53 binding motif. The predominant motif has 
no spacer in between the two half-sites although there is a small fraction with a spacer 
of one nucleotide. This is in agreement with the genome-wide spacer distribution found 
previously (Wei et al. 2006). In the most highly enriched group of target sites nearly all 
bound sequences contain our p53 consensus motif. This suggests that almost all highly 
enriched p53 binding sites are bound in a direct sequence-specific manner dependent 
on the consensus motif. Of all the identified binding sites, in 17% p53scan cannot detect 
the p53 consensus motif. Although previous studies have also found p53 binding sites 
without a detectable p53 consensus motif (Kaneshiro et al. 2006; Wei et al. 2006), we find 
less of those binding sites in our study using the more inclusive identification of the mo­
tif by p53scan. The fact that no p53 motif can be identified in a small subset of binding 
sites can have several reasons: either p53 is also able to bind purely on the basis of DNA 
topology independent of the sequence (Gohler et al. 2002), or it might bind to a different 
motif like microsatellites for the PIG3 target gene (Contente et al. 2002). The remaining
49
Chapter 2
sites without a common motif could of course also be bound due to indirect binding of 
p53 to chromatin.
By grouping the binding sites according to their ChIP/Total ratio, we found a positive cor­
relation with both the percentage of binding sites containing a p53 binding motif, as well 
as the degree of similarity of the identified motifs with the p53 consensus motif. Thus, 
the more the binding sequence resembled the p53 consensus motif, the higher the ChIP/ 
Total ratio. This is in accordance with the structural data of DNA-bound p53 that showed 
that protein-DNA interfaces vary as a function of the specific base sequence of the DNA 
(Kitayner et al. 2006). From this structural data it was also concluded that the differential 
binding affinity is correlated with sequence-specific variations which have a direct influ­
ence on the protein-DNA contact geometry.
The binding of p53 to DNA occurs in the context of other transcription factors and cofac­
tors. It has been shown for individual target genes that other transcriptional activators or 
repressors can act together with p53 and can have differential effects on the transcription 
of target genes. Therefore, we analyzed common cis-elements among the genome-wide 
set of p53 binding sites. We found potential SP1-binding sequences to be highly enriched 
in the vicinity of p53 binding sites in our global approach; p53 has been reported to requi­
re the cooperation of Sp1 or a Sp1-like factor for transcriptional activation of the human 
BAX and p21 promoter (Thornborrow and Manfredi 2001; Koutsodontis et al. 2005). For 
basic-helix-loop-helix (bHLH) motifs, which we found to be enriched in our set of target si­
tes, it is known that the p53 promoter itself contains a functional consensus sequence for 
bHLH proteins. In the murine p53 promoter, this element has been shown to be required 
for full promoter activity (Demonacos et al. 2001). The fact that we find bHLH motifs enri­
ched in the vicinity of p53 binding sites, shows that these factors might be involved in a 
positive feedforward regulation of p53 pathways. Thus, our findings extend the analysis of 
the transcriptional environment of single targets to a larger subset of target genes derived 
from a global screen. In the future, we will need to elucidate what biological consequen­
ces might result from certain combinatorial interplay between p53 and other co-binding 
factors. Therefore, an interesting challenge will lie in the elucidation of which transcription 
factor complexes can be found at which p53-target genes and whether certain biological 
responses appear to be dependent on the macromolecular transcription-factor comple­
xes at p53-binding sites. A first interesting approach to purify macromolecular complexes 
at different subsets of p53 target genes was done by Tanaka et al. by fractionating cross­
linked p53-associated chromatin and identifying the human cellular apoptosis suscepti­
bility protein (hCAS/CSE1L) in one fraction of a subset of p53 target promoters, including 
PIG3, in a p53-autonomous manner (Tanaka et al. 2007). Thus, it remains to be seen whe­
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ther also for other cellular response pathways specific combinations of co-binding factors 
can be isolated at p53 target genes.
2.3.3. Global binding of p73 and p63 to p53 binding sites
For the first time we investigated on a global scale to which extent p53 binding sites can 
be occupied by p73 and p63 upon a specific stress-signal in vivo. We found that 72% of 
the p53 binding sites can also be bound by p73 and/or p63. Some groups have postula­
ted differences in binding motif for the p53 family members, but this is mostly based on 
individual targets or in vitro derived data. Lokshin et al. showed the importance of 5 bases 
in the p53 consensus sequence for stable binding of in vitro p73 to DNA (Lokshin et al. 
2007). In our global binding site set, we cannot differentiate between the sets of shared 
and p53-only binding sites on the basis of this sequence difference. The fraction of motifs 
containing these 5 bases was comparable in both sets. We could also not identify a sig­
nificant difference between the motif for p53 in shared binding sides or sites exclusively 
bound by p53. The fact that we did not find specific motif variation, is in agreement with 
the genome wide screen for p63 binding sites by Yang et al. (Yang et al. 2006) and in vitro 
studies from Perez et al., which showed with a SELEX approach that p63 binds principally 
to the p53-consensus motif, preferentially to a slightly more degenerate form of it (Perez 
et al. 2007). Therefore, we conclude that p63 and p73 can bind to p53 binding sites on a 
large scale, which may imply that the stress response is mediated in part by either com­
petitive or cooperative binding of p53 family members to target genes. Alternatively this 
could hint at the possibility that p63 and p73 are capable of taking over part of the func­
tion of p53 if needed.
This study provides a global set of high-confidence p53 binding sites, which greatly ex­
pands the known, experimentally validated p53 binding repertoire and gives a global 
insight into their characteristics. These data can serve as a valuable knowledgebase for 
further research, in which new functional studies will help to further clarify the complex 
role of p53 and its family members.
2.4. Materials and methods
2.4.1. Cell culture and drug treatment
The human osteosarcoma cell lines U2OS expressing endogenous wild-type p53, and 
Saos-2, which are p53 null (Kubbutat et al. 1998), were maintained in Dulbecco modi­
fied Eagle medium supplemented with 10% fetal calf serum at 37°C. The Tet-on inducible 
expression system (BD Biosciences) was used in Saos-2 cells to generate cell lines that
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conditionally express FLp53, TAp63a or TAp73a. cDNA of the gene of interest was cloned 
into the pTRE vector and co-transfected with the pZoneXN, which has a puromycin selec­
tion marker, into Saos-2 cells. Transfections were performed by the calcium phosphate 
precipitation method (BES). Stable clones were selected with 1 ^g/ml puromycin (Sigma). 
To induce the expression of FLp53, TAp63a or TAp73a, 2 ^g/ml doxycyclin (Sigma), a Tet­
racyclin homologue, was added to the medium. The inducible Saos-2 cell lines were first 
induced with doxycyclin for 24 hours and then treated with 5nM Actinomycin D (Sigma) 
for another 24 hours. The U2OS cells were treated with 5 nM Actinomycin D for 24 hours.
2.4.2. Cell cycle analysis
Cells were induced and treated as described above. The cells were fixed with 96% ethanol 
and stained with propidium iodide (Sigma). DNA content was analyzed by flow cytometry 
(Becton Dickinson FACScan) and analyzed using CellQuest Pro software.
2.4.3. Immunoblotting
To assess protein levels, proteins from whole-cell extracts were harvested, lysed and sepa­
rated by SDS-PAGE and analyzed by Western blotting with a-p53 (DO1, BD PharMingen).
2.4.4. Transactivation assays
The selected binding sites were amplified from genomic U2OS DNA and cloned into the 
pGL3-promoter vector (Invitrogen), which contains a luciferase reporter gene behind a 
SV40 promoter. U2OS cells were transiently transfected with pGL3 constructs and a pRL- 
TK reporter (Promega), constitutively expressing Renilla as a normalization control, by Cal­
cium Phosphate transfection. Cells were lysed and luciferase activity was measured using 
the Dual-Luciferase Reporter Assay System (Promega).
2.4.5. RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini kit according to protocol (Qiagen). For 
cDNA synthesis, reverse transcription was performed with 1 ^g of the total RNA, oligodT 
anchor primers, dNTPS, DTT, buffer and Superscript Retrotranscriptase (Invitrogen). cDNA 
was analyzed by qPCR using a MyIQ machine (Biorad). Primers used for real-time PCR are 
available upon request.
52
Chapter 2
2.4.6. ChIP and ChIP-on-chip
Chromatin immunoprecipitation (ChIP) was essentially performed as described by De- 
nissov et al. (Denissov et al. 2007). The cells were sonicated using a Bioruptor sonicator 
(Diagenode) for 15 minutes at high power, 30 seconds ON, 30 seconds OFF. Antibody in­
cubation with chromatin from U2OS treated with Actinomycin D was performed over­
night at 4°C with 2 ^g of DO1 antibody (BD PharMingen). For ChIP experiments in Saos-2 
inducible cell lines DO1 (BD PharMingen), 4A4 (Abcam) and BL906 (Abcam) were used 
for p53, p63 and p73 respectively. Real-time PCR was performed using the SYBR Green 
mix (Biorad) with the MyIQ machine (Biorad). Primers used for real-time PCR are available 
upon request. To produce more material for a ChIP-on-chip, the total DNA and ChIP DNA 
needed to be amplified. For genome-wide hybridization the material was amplified using 
LM-PCR amplification (Ren et al. 2000). The T7 based amplification procedure (Liu et al. 
2003) was used for the hybridizations on the dedicated arrays. The total DNA and ChIP 
DNA were hybridized to whole genome tiling arrays (HG17Tiling Set) or custom designed 
microarrays manufactured by NimbleGen Systems, Inc. Raw data for all microarray hybri­
dizations is available at ArrayExpress (http://www.ebi.ac.uk/arrayexpress) under accession 
E-TABM-442.
2.4.7. Custom microarray design
Peak detection (see below) was performed on the genome-wide dataset and all probes 
within the positive regions recognized by the peak detection procedure, extended equally 
up- and downstream to a total of 2 kb, were spotted on a custom design array (Nimble­
Gen Systems), hereafter referred to as dedicated design. All the probes from a continuous 
region of chromosome 21 (from 28692406 to 41270931) on the hg17 array were included 
in the dedicated design to provide a baseline for normalization purposes. This region is 
hereafter referred to as tilepath.
2.4.8. Data normalization
The probe sequences from both the whole genome and the dedicated design were com­
pared to the human genomic sequence with BLAT (Kent 2002). Probes with 10 or more 
matches were discarded for use in the subsequent analysis. The raw probe ratios were 
normalized within arrays using Tukey's biweight. For all hybridizations performed on the 
dedicated array, the ratios were normalized against the tilepath region.
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2.4.9. Peak detection
The microarray data was analyzed using three different peak detection programs to iden­
tify putative targets with a high degree of confidence. Default parameters where used 
except where noted. The proprietary program provided by NimbleGen was run with a 
1% false positive rate. For Tilemap (Ji and Wong 2005) hybridization length was set to 50, 
maximal gap size to 100. All probes with posterior probability of at least 0.9 were defined 
as peaks. For Mpeak (Zheng et al. 2005) the maximum gap was set to 300, and a minimum 
log2 ChIP/Total ratio of at least 2.5 standard deviation was used as a threshold. All positive 
regions or peaks less than 1 kb in length were extended equally up- and downstream to 
cover 1kb. Per biological replicate all regions determined to be positive by one of the pro­
grams were combined. Finally, a peak was defined as a binding target if positive regions 
shared any overlap in each biological replicate.
2.4.10. Mapping binding sites to genes
Target locations were mapped to NCBI 36 coordinates using the Batch Coordinate Conver­
sion (liftOver) utility provided by the UCSC Genome Bioinformatics group. Gene locations 
of all genes were downloaded from Ensembl (release 43, Feb 2007 (Hubbard et al. 2007)). 
To map a target to a gene, the distance from the middle of the target to the Ensembl gene 
start was used.
2.4.11. Annotation of genes
For annotation of genes, only target genes with a binding site within 5 kb of the gene were 
used. Overrepresented Gene Ontology (GO) (Ashburner et al. 2000) categories within an­
notation of the target genes were determined with Ontologizer using the parent-child 
method, which takes into account the parent-child relationships of the GO hierarchy 
(Grossmann et al. 2006). The p-values were adjusted using Westfall-Young Single-Step 
multiple testing correction and a corrected p-value threshold of 0.05 was used as a cut-off 
for reporting significant matches. Genes were annotated with KEGG pathways (Kanehisa 
et al. 2006) using Fatigo+ (Al-Shahrour et al. 2004). Overrepresented pathways were de­
termined according to the hypergeometric distribution with a p-value threshold of 0.05.
2.4.12. The p53scan algorithm and motif analysis
Sequences of equal length were selected for all targets by determining the probe with 
the highest mean ratio value within each peak and selecting a 500 bp region centered 
on this probe. All probes within regions on the slide of at least 10 consecutive probes,
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or 1 kb, with a maximum mean log2 ChIP/Total ratio of 0.5 were selected as background 
sequences. These sequences were divided in 500 bp regions to create sequences of the 
same length as the target sequences.
To determine the optimal positional weight matrix (PWM) for p53scan, the de novo motif 
discovery program MDmodule (Liu et al. 2002) was applied to half of the 500 bp target 
sequences, 773 in total. Sequences were ordered based on the ChIP/Total ratio of the 
highest probe in the peak. MDmodule was run with a width of 20 and the number of top 
sequences to look for motifs was set to 200. Default parameters were used for all other 
options. The MDmodule output was subsequently converted to a PWM.
In p53scan the score of a subsequence x of length L is calculated as follows:
L
J  ln(f  ■ >> 1 g  + z)
i =1
where fi,b is the fraction of each nucleotide at position i, g is 0.25 and z is 0.01.
To incorporate a variable spacer length, the two half-sites are scanned separately and the 
scores for each half-site are combined. Cutoffs for spacer lengths greater than 0 were de­
termined by scanning ten times as many random non-bound sequences and choosing 
the threshold that resulted in no hits. This enables p53scan to take high-scoring motifs 
with spacer lengths other than 0 into account without drastically changing the FPR.
To test the performance of the algorithm and to compare it to other available algorithms, 
the 773 sequences not used for training were compared to a background set of five times 
as many random non-bound sequences. Three different metrics were used for compari­
son:
1) The area under the Receiver Operator Curve (ROC AUC), which reflects the ba 
lance between the false positive rate and the true positive rate.
2) The mean normalized conditional probability (MNCP) as described by 
Clarke and Granek (Clarke and Granek 2003).
3) The maximum F-measure, or weighted harmonic mean of precision and recall.
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„  True Positives
Recall =----------------------------
True Positives + False Negatives
True PositivesPrecision =----------------------------
True Positives + False Positives
_ 2 • Precision • Recall
F -  measure =------------------
Precision + Recall
The process of randomly selecting training, test and background sequences and subse­
quent performance comparison was repeated in 10 independent runs. In all cases the 
performance was comparable. The best scoring PWM was kept and implemented. All 1546 
targets were compared to five times as many randomly selected non-coding sequences of 
equal length to produce Figure 4B. p53scan was subsequently used to analyze the com­
plete set of target sequences with a score cutoff of 4.393 for spacer length 0 resulting in 
the highest F-measure, corresponding to an estimated FPR of ~7%.
For de novo motif prediction of possible co-factor motifs the motif discovery program 
MDmodule was applied to the 500 bp target sequences. The same procedure as described 
for the p53scan PWM was followed. The number of top sequences to look for motifs was 
set to 100, all widths from 6 to 16 were considered, and the number of motifs to report was 
set to 10. To calculate the significance of the discovered motifs the number of sequences 
with at least one motif instance with 0.8 * maximum possible score was determined in 
both the sample and the background sequences using TAMO (Gordon et al. 2005). For 
each motif a p-value was calculated using the hypergeometric distribution. The corres­
ponding significance value was calculated as .
Significance (S) = - log10(p  -  value)
As selection criteria we used a significance cut-off of 1.3 corresponding to a p-value of 0.5 
with a minimum of occurrence of at least ten times. All significantly enriched motifs were 
clustered using a k-medoids clustering algorithm as described by Harbison (Harbison et 
al. 2004). Clustered and aligned motifs were averaged to produce consensus motifs. The 
significance of the resulting motifs was determined as described in the previous para­
graph.
To analyze target sequences for known motifs, the sequences were scanned with all the 
position weight matrices from the TRANSFAC database (public release version 6.0) (Matys 
et al. 2003) and further analyzed as described in the previous de novo motif prediction 
section. Similar motifs were grouped and averaged.
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3. Crosstalk between c-Jun and 
TAp73a/ß contributes to the 
apoptosis-survival balance
Max Koeppel, Simon J. van Heeringen, Daniela Kramer, Leonie Smeenk, Eva Janssen-Me- 
gens, Marianne Hartmann, Hendrik G. Stunnenberg and Marion Lohrum (2011). In Press
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The p53-family member p73 plays a role in various cellular signaling pathways during de­
velopment and growth control and it can have tumor suppressor properties. Several iso­
forms of p73 exist with considerable differences in their function. Whereas the functions 
of the N-terminal isoforms (TA and DNp73) and their opposing pro- and anti-apoptotic ro­
les have become evident, the functional differences of the distinct C-terminal spliceforms 
of TAp73 have remained unclear. Here, we characterized the global genomic binding sites 
for TAp73a and TAp73p by ChIP-sequencing as well as the transcriptional responses by 
performing RNA-sequencing. We identified a specific p73 consensus binding-motif and 
found a strong enrichment of AP1 motifs in close proximity to binding sites for TAp73a. 
These AP1 motif-containing target genes are selectively upregulated by TAp73a, while 
their mRNA expression is repressed upon TAp73p induction. We show that their expressi­
on is dependent on endogenous c-Jun and that recruitment of c-Jun to the respective AP1 
sites was impaired upon TAp73p expression, in part due to downregulation of c-Jun. Seve­
ral of these AP1-site containing TAp73a-induced genes impinge on apoptosis-induction 
suggesting an underlying molecular mechanism for the observed functional differences 
between TAp73a and TAp73p.
3.1. Abstract
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The transcription factors of the p53-family, p53, p63 and p73, maintain the balance bet­
ween cell survival and induction of apoptosis during development, growth, differentiati­
on and cellular stress. The members of the p53-family thereby display common as well as 
specific functions. They determine the cellular fate dependent on the family member and 
isoform expressed in a specific tissue (Deyoung and Ellisen 2007). The p73 protein exists 
in multiple isoforms due to different promoter usage at the N-terminus and to C-terminal 
splice events. The ANp73-isoforms that are derived from an internal promoter antagoni­
ze the growth suppressing, pro-apoptotic functions of p53 and of the full length TAp73- 
isoforms in a dominant negative way by competing for the respective binding sites (Moll 
and Slade 2004). Overexpression of ANp73-isoforms is found in several tumors (Zaika et 
al. 2002; Concin et al. 2004) whereas mutations in the p73 gene are rarely found in human 
cancers (Melino et al. 2002).
Under certain conditions, p53 is unable to induce apoptosis in the absence of p73 or p63 
(Flores et al. 2002). Furthermore, mice heterozygous for p53/p73 show a higher tumor bur­
den compared to p53 heterozygous mice (Flores et al. 2005). Although complete knock­
out of the p73 gene in mice mainly leads to developmental defects (Yang et al. 2000), 
the knockdown of only the TA-isoforms induces genomic instability, thus showing tumor 
suppressor activities of TAp73 (Tomasini et al. 2008). TAp73 isoforms have been reported 
to play a role in DNA damage pathways, since p73 is activated by ionizing irradiation and 
cisplatin through c-Abl, thereby inducing apoptosis (Agami et al. 1999; Gong et al. 1999; 
Yuan et al. 1999). Furthermore, TAp73-isoforms are upregulated by different mechanisms 
through chemotherapeutic drug induced DNA damage (Irwin et al. 2003; Pediconi et al. 
2003).
The transcriptional function of p73 is complex because of the plethora of p73-isoforms, 
which have varying transcriptional activity towards target genes. In addition to shared 
target sites, the p53-family members differ in their ability to transactivate common target 
genes like p21 (De Laurenzi et al. 1998) or Bax (Melino et al. 2004; Flinterman et al. 2005). 
Some genes are only induced by specific isoforms, like p57/kip2 by p73p but not by p73a 
or by p53 (Blint et al. 2002).
Besides its function as a pro-apoptotic protein, several reports have also described an inhibition 
of apoptosis or a support of growth by TAp73 in certain cell lines under specific conditions (Ny­
man et al. 2005; Toh et al. 2008). It has been shown, that a cross-talk between the transcription 
factor c-Jun and p73 regulates growth and that c-Jun enhances the function of p73 (Toh et al.
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2004; Vikhanskaya et al. 2007). However, the exact molecular mechanism of this crosstalk remains 
unknown.
C-Jun is a member of the AP1 family of heterodimeric transcription factors, regulating 
growth and apoptosis depending on the cellular environment and on the composition of 
the respective dimer (Shaulian and Karin 2002). Dimers containing c-Jun mainly promote 
growth via G1-progression through the transactivation of Cyclin D1 (Wisdom et al. 1999). 
The fact that a c-Jun null mutation is embryonic lethal and causes retarded growth of cul­
tured cells underscores the importance of c-Jun for cellular growth (Johnson et al. 1993). 
AP1 dimers can also protect cells from UV-mediated apoptosis by negatively regulating 
p53 (Schreiber et al. 1999) and c-Jun is also required for re-entry of cells into cell cycle after 
UV-induced p53 mediated growth arrest (Shaulian et al. 2000). Due to the complexity of 
the many p73-isoforms and the varying composition of the Jun/Fos dimers several dif­
ferent interactions between p73 and Jun/Fos might be possible, probably with different 
consequences for the cellular fate.
To gain insight into the molecular basis for the different physiological function of TAp73a 
and TAp73p, we identified their binding sites by chromatin-immunoprecipitations (ChIPs) 
coupled with deep-sequencing (ChIP-seq) and global expression analysis using RNA- 
sequencing (RNA-seq). This revealed that the two TAp73-isoforms bind to both shared 
and isoform-specific target sites and distinctly transactivate target genes. We uncovered 
a p73-consensus motif that is present in a large fraction of the p73 binding sites. The bin­
ding sites of TAp73a but not those of TAp73p showed an overrepresentation of AP1 bin­
ding sites to which c-Jun can bind simultaneously with TAp73a. The binding of c-Jun to 
DNA is reduced upon TAp73p expression, which reduces the mRNA and protein levels of 
c-Jun. The expression of distinct target genes with an AP1 site close to TAp73a binding si­
tes depends on c-Jun and influences apoptosis induction by TAp73a, possibly explaining 
the different physiological responses mediated by the respective TAp73-isoforms.
3.3. Results
3.3.1. Physiological and molecular differences in the cellular responses 
to TAp73a and TAp73P
The domain organization of the predominant TAp73a- and TAp73p-isoforms shows some 
similarity with the related tumor suppressor p53, but the three proteins differ complete­
ly in their C-terminus (Figure 1A). To characterize their common and distinct functions, 
we used isogenic Saos cell lines (Smeenk et al., 2008) to express TAp73a and TAp73p at 
comparable protein-levels as detected in whole cell lysates as well as in the chromatin
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bound fraction (Figure 1B). To quantify the degree of cell death after induction of TAp73a, 
TAp73p or p53, FACS analysis was performed and apoptosis was measured as the sub-G1 
cell population (Figure 1C). As a comparison the effect of p53 on apoptosis induction was 
included. Whereas in the parental Saos2 cells only a small proportion of cells undergo pro­
grammed cell death, the induction of TAp73a, TAp73p or p53 leads to an increase in the 
apoptotic population. The levels of apoptosis after TAp73a induction are rather modest. 
Upon TAp73p induction on the other hand apoptosis levels are three to eight times higher 
than in parental Saos2 cells, thus comparable to p53 induced cell death. Since the diffe­
rent p53-family members displayed distinct effects on the level of apoptosis induction, we 
examined possible molecular causes for these differences. To analyze the DNA-binding ca­
pacities of the two p73-isoforms and p53 we used chromatin-immunoprecipitation follo­
wed by qPCR (ChIP-qPCR). As shown in Figure 1D binding of p53 and both TAp73-isoforms 
is observed to the p21 and Mdm2 genes. It is higher for TAp73p at the p21 and Mdm2 bin­
ding sites than for TAp73a. Examining the transactivating potential of these p73-isoforms 
and p53 shows that both isoforms increase the level of p21 mRNA, with a much stronger 
increase mediated by TAp73p (Figure 1E). The mRNA level of Mdm2 is increased upon 
TAp73p and p53 expression, but not upon TAp73a expression in this cell system (Figure 
1E). Thus, induction of TAp73a and TAp73p had different effects on the transcriptional 
activation of target genes as well as on the cellular apoptotic response.
3.3.2. Global binding profiles reveal common as well as distinct binding sites for 
TAp73a and TAp73P
To shed light on the molecular mechanisms for the differential cellular responses induced 
by the two TAp73-isoforms we compared their DNA-binding site repertoire at a genome 
wide scale, performing ChIP-seq of the TAp73-isoforms as well as of p53 (two biological 
replicates each). To validate the reproducibility of the data-sets we compared the number 
of reads per peak between two biological replicates and found a high correlation between 
them (Supplemental Figure 1). Identifying binding sites by peak calling on the combined 
data using MACS (Zhang et al. 2008), with an input DNA sample as background control, 
resulted in 15,293 peaks for TAp73a, 23,505 peaks for TAp73p and 9,878 peaks for p53 
(Table I). We identified genome-wide binding sites that are shared by both p73 isoforms 
(10,319 sites) or are preferential for either TAp73a (4,196 sites) or TAp73p (11,849 sites) 
exemplified by the Mdm2, IL1RAP and APOD gene, respectively (Figure 2A-C).
Comparing the binding sites of TAp73a, TAp73p and p53, we found that a large portion 
of binding sites is bound by all three proteins, but also that a considerable number is 
preferably bound by only one of the three proteins (Figure 2D). We found that 44% of the
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Fig. 1: Differential physiological and molecular effects o f TAp73a and TAp73@
A. Domain structure o f  the p53-fam ily members TAp73a, TAp73fi and p53. TA: transactivation domain; DBD: DNA 
binding domain; OD: oligomerization domain; SAM: sterile alpha m otif; ID: inh ib itory domain
B. Expression o f  TAp73a, TAp73@ and p53 in Saos inducible cell lines. Whole cell extracts or chromatin was harves 
ted after 24 h r o f induction and protein levels were analyzed by western blot.
C. Induction o f apoptosis. Saos cells expressing the indicated member o f the p53-family were induced for 24 hr or 48 
hr, before the am ount o f  cells in sub-G1 phase was counted using FACS. Error bars indicate standard deviation 
(SD) derived from three independent experiments, asterisks indicate statistical significance as shown by Student's 
T-test (p< 0.05).
D. D ifferential binding o f  TAp73a, TAp73@ or p53 to target genes. Saos TAp73 or p53 inducible cells were induced 
fo r 24 hr before chromatin was isolated. Complexes o f TAp73 or p53 and chromatin were precipitated and 
qPCR analysis was performed w ith primers for the putative binding sites and enrichment is shown in fold  
over an unspecific control (myoglobin). SD results from three independent experiments.
E. Expression changes upon induction o f p53-family isoforms. RNA from Saos cells was harvested 24 hr after 
induction o f the respective family-member. After cDNA synthesis qPCR was performed with the indicated primers 
and results were normalized against GAPDH expression. The induction was calculated as fo ld over the normalized 
expression values from Saos2 parental cells. SD was calculated from three independent experiments.
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Fig. 2: Global binding site analysis o f p53-family members
A. Common binding site for TAp73a and TAp73@. The lower track displays the location o f the Mdm 2 proto-oncoge  
ne in the UCSC genome browser. The upper track shows the binding site for TAp73a and the m iddle one the site 
fo r TAp73@ as determined by ChlP-seq using the Genome analyzer (Illumina) and visualized w ith the UCSC 
genome browser.
B. Preferential binding site for TAp73a. The lower track displays the location o f the IL1RAP gene, the other tracks as 
in A).
C. Preferential binding site for TAp73p. The lower track displays the location o f the APOD gene, the other tracks as in 
A).
D. Overlap o f  target genes tha t were determined by ChIP-seq between TAp73a, TAp73@ and p53.
E. The genomic distribution o f binding sites for TAp73a, TAp73p and p53 after ChIP-seq is compared to the respective 
categories within the human genome. Locations o f binding sites are divided in transcriptional start site (TSS) 
flanking region (5 kb upstream o f TSS + first exon + first intron), intragenic region (all exons and introns except 
first), < 25 kb (peaks within 25 kb o f the next annotated gene) and intergenic region (peaks > 25 kb away from 
any annotated gene).
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Table 1: ChIP-seq results
Uniquely 
mapped reads 
(million)
Reads 
after normalization 
(million)
Number of 
peaks
Genes with a 
peak within 25kb
Saos
control 1 14.82 14.82
Saos
TAp73a 1 12.52 7.41 15,293 5,405Saos
TAp73a 2 13.77 7.41
Saos
TAp730 1 12.10 7.41 23,505 6,932Saos
TAp73B 2 13.08 7.41
Saos p53 1 5.53 3.00
9,878 5,665
Saos p53 2 14.71 3.00
TAp73p binding sites and 46% of the p53 binding sites, respectively, overlap with TAp73a 
(Figure 2D). Thus, while there are many target genes common between TAp73a, TAp73p 
and p53, there are also isoform and family-member specific binding sites, possibly media­
ting the differential functions of TAp73a, TAp73p and p53. To gain further insight into the 
characteristics of the DNA-binding sites we analyzed their genomic distribution (Figure 
2E). Both TAp73-isoforms show almost the same genomic binding distribution, they are 
both significantly enriched in promoter regions, compared to genomic background, but 
not as pronounced as the p53-binding sites from which almost one third are found close 
to transcriptional start sites.
Since we have identified global binding profiles for TAp73a, TAp73p and p53 expressed in 
isogenic Saos cell lines we wanted to verify that these binding sites could be physiologi­
cal target sites of endogenous p73 and p53. Therefore, we have analyzed MDA-MB231-, 
HEK293, and HCT116- cell lines, which express p53 and p73 (Figure 3A, left), for p73- and 
p53-DNA binding and compared it to the binding-events in the different Saos cells used 
before. Binding to the positive control p21 occurred in all cases (Figure 3A, right), while 
some binding sites can be bound by p73 as well as p53 in several different cell lines, e.g. 
binding sites close to the FAS, DCP1B and GDF15 gene (Figure 3B). Furthermore we also 
identified target sites that are selectively bound by p73 only in specific cell lines, such as 
the METT10D, NDUFS2 and DEDD gene (Figure 3C). Thus, binding sites originally identi­
fied in Saos cell lines can also be found in cell lines expressing endogenously p73 or p53. 
The isoform-specific occupancy appears to be cell-type dependent.
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Figure 3: Validation o f binding sites in other cell lines
A. Expression o f  endogens p73 and p53 in several human cell lines. Protein samples were harvested from the 
different cell lines and stained against p73 or p53 as indicated.
B. Binding o f  p73 and p53 to target genes in several cell lines. ChIP-qPCR with a p73-antibody was performed in 
MDA-MB231, HEK293 and HCT116 cells or against p53 in HCT116 and HEK293 cells. As a comparison, b inding  
to  the sites in the different Saos cells is shown. The indicated primers were used to calculate enrichment. SD was 
derived from tw o independent experiments.
C. Cell line specific binding to  target genes. ChIP-qPCR was performed as in A).
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3.3.3. Isoform-specific transcriptional responses
Having identified genome-wide binding sites for TAp73a and TAp73p, we were interested 
in the transcriptional consequences of the induction of TAp73a and TAp73p and to which 
extent the DNA-binding and transcriptional changes could be correlated. Therefore, we 
performed global transcriptome analysis of TAp73a, TAp73p and p53 expressing Saos cells 
using RNA-seq. Two biological replicates were sequenced per cell-line and the fold change 
relative to the Saos2 parental control was calculated using DEGseq (Wang et al.). The two 
p73 isoforms show distinct expression signatures, with genes specifically regulated after 
induction of TAp73a (485 genes) or TAp73p (575 genes), as well as genes regulated in both 
cases (338 genes) (Figure 4A and B). The previously reported, TAp73p-specific target gene 
p57/Kip2/CDKN1C is also in our genome-wide RNA-seq data clearly induced only upon 
TAp73p expression (Supplemental Figure 2A). Two examples of isoform-specific regulati­
on are shown in Figure 4C and D: the SFN gene, specifically activated by TAp73a and the 
BGN gene, specifically activated by TAp73p. Both genes are also differentially bound by 
one of the p73-isoforms as seen in the ChlP-seq data, which is in good agreement with 
the RNA-seq data. The GHRL3 gene on the other hand showed binding and activation by 
both isoforms (Figure 4E). The differential transcriptional response observed in the RNA- 
seq data was further validated by RT-qPCR (Figure 4C-E, right).
The overlap between regulated genes and p73 binding sites is highly significant. Of the 
TAp73a upregulated genes 49% have a TAp73a binding site within 25 kb (p = 3.08E-19), 
and 50% of the TAp73p upregulated genes have a TAp73p binding site (p = 3.56E-7) (Table 
II and Supplemental Table SI). The relation between binding and expression is visualized 
in Figure 4F, which illustrates that differentially regulated genes have a significantly high­
er association strength (Ouyang et al. 2009) than unregulated genes (TAp73a p<2.2e-16, 
TAp73p p<2.2e-16).
Analyzing the functional annotation of bound and regulated TAp73a and TAp73p target 
genes by GO analysis using DAVID (Dennis et al. 2003; Huang da et al. 2009) we uncovered 
a plethora of different physiological aspects that appear to be regulated by TAp73a and 
TAp73p (Supplemental Table SI). Most strikingly both isoforms regulate the expression 
of genes involved in different developmental processes such as tissue development, cell 
differentiation and development of specific anatomical structures. Interestingly, in a KEGG 
pathway analysis (Kanehisa et al. 2006) of regulated target genes, the two p73 isoforms 
appear to regulate different functional subgroups of genes highlighting that the function 
of TAp73a and TAp73p are not merely overlapping, but also distinct (Supplemental Table 
SII). The most prominent functional link of this KEGG pathway analysis can be seen for 
TAp73a for metastasis involved processes: TAp73a seems to induce target genes that fall
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Table 2: Expression changes upon TAp73 induction
Total 
number of 
genes
Genes with a 
binding site within 
25 kb
p-value of overlap between binding 
and expression-change
Induced by TAp73a 344 170 3,08E-019
Repressed by 
TAp73a 477 100 9,99E-001
Induced by TAp73P 260 129 3,56E-007
Repressed by 
TAp733 653 193 9,97E-001
Induced by p53 350 152 6,53E-010
Repressed by p53 305 66 9,97E-001
into several functional categories linked to metastasis, such as focal adhesion, ECM-recep- 
tor interaction, cell communication and regulation of actin cytoskeleton. For TAp73p on 
the other hand the p53-signalling pathway is the first functional category that appears in 
the KEGG pathway analysis. Thus, the functional annotation analysis hints at common as 
well as distinct functions of TAp73a and TAp73p during cellular growth and development.
3.3.4. Characteristics of TAp73a and TAp73p binding sites
The distinct binding patterns of TAp73a and TAp73p as well as their different transacti- 
vating potential led us to analyze the binding sites with respect to their sequence con­
tents and properties. We used a comprehensive discovery approach to predict motifs for 
the TAp73a as well as the TAp73p binding sites. Three different motif prediction tools (MD- 
module, MotifSampler and Weeder) were applied to the binding sites and resulting motifs 
were tested for their significance compared to a set of background sequences (see Mate­
rials & Methods for details). After inspection of the significant motifs using STAMP (Ma- 
hony and Benos 2007) we found the prevalent motif in both TAp73 sets to be a p53-like 
motif, hereafter referred to as the p73 consensus-binding motif (Figure 5A; Supplemental 
Table SIII). We tested the performance of the discovered motifs by comparing the Area 
Under Curve (AUC) of the Receiver Operator Curve (ROC), which summarizes the tradeoff 
between sensitivity and specificity when varying the motif score threshold. There was no 
clear difference in the Positional Weight Matrices (PWM) of the best performing TAp73a 
and TAp73p motif, but slight differences when comparing it to the PWM we published 
earlier for p53 (Supplemental Table SIV) (Smeenk et al. 2008). The best performing p73
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A. D ifferential transcriptional responses upon induction o f TAp73a or TAp73@. Upon 24 hr induction o f  TAp73a or 
TAp73@ global expression profiles were obtained in duplicates using RNA-seq. The fo ld  change relative to Saos2 
parental control was calculated using DEGseq (Wang et al.) and differential gene expression o f  the tw o p73-iso 
forms was plotted.
B. Overlap o f  expression-changing genes after induction o f TAp73a, TAp73@ or p53 as analyzed by RNA-seq.
C. Preferential b inding o f TAp73a results in specific transcriptional induction o f the SFN gene by TAp73a. The two 
upper tracks display the ChlP-seq-data from TAp73a or TAp73@, respectively. The three lower tracks show the 
signals from RNA-seq for Saos2 parental cells or upon induction o f either TAp73a or TAp73@. Below the tracks 
the respective gene is displayed. On the righ t the expression change o f the respective gene upon TAp73a
or TAp73@ induction is validated by RT-qPCR. SD was derived from three independent experiments.
D. Preferential b inding o f TAp73@ results in specific transcriptional induction o f BGN by TAp73@.
E. The GRHL3-gene was bound by TAp73a and TAp73@ and changes its expression upon induction o f both iso 
forms.
F. Correlation between association strength o f  TAp73a and TAp73@ and expression changes. Non-regulated genes 
and genes regulated with an absolute log2 > 1 are shown.
Fig. 4: Analysis o f expression changes induced by TAp73 by RNA-Seq
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consensus motif based on the ROC AUC, is more degenerate than the previously iden­
tified p53 motif and clearly shows a better performance for the p73 sequences (Supple­
mental Figure 3). We used the algorithm p53scan (Smeenk et al. 2008) with this PWM to 
scan all identified binding sites for the new p73 consensus motif. For this purpose, we 
grouped all binding sites into seven different groups, according to which combinations of 
p53-family proteins were recruited (Table III). Subsequently, we determined the fraction 
of sequences containing a p73 motif for each group (Figure 5B). In the p73 groups we 
find that at least 70% of the sequences contain the p73 consensus motif. In contrast, the 
group of sequences bound only by p53 has a low number of p73 consensus motifs (20%). 
The score of the p73scan algorithm depends on the conformity of the identified motif in
Table 3: Groups of p53-family specific genes
Genes bound by different family members Number of binding sites
TAp73a only 4,196
TAp73p only 11,849
p53 only 4,009
p53+ TAp73a 4,532
p53+ TAp73p 5,091
TAp73a+ TAp73p 10,319
p53+TAp73a + TAp73p 3,754
a specific sequence to the ideal consensus motif, the p73 motif in this case. Interestingly, 
the median motif score for TAp73a and p53 groups of binding sites is lower compared to 
groups containing TAp73p binding sites (Figure 5C). The group with the highest score, i.e. 
with the highest similarity to the ideal consensus p73 motif, is the group of target sites 
bound by both p53 and TAp73p. We conclude that the p53-family members have distinct 
requirements towards their binding sites resulting in specific motifs and that a p73 speci­
fic binding motif can be extracted from our global analysis.
Besides the p73 motif itself, the API motif (Figure 5D) which can be bound by hetero­
dimers of the Jun/Fos family (Nakabeppu et al. 1988) is significantly overrepresented 
in the sequences occupied by TAp73a (8.2 times, p<1e-10) and in the TAp73a and p53 
group (11.8 times, p<1e-10) compared to a random set of background sequences (Figure 
5E). Strikingly, whereas this motif is found in 24-35% of the sequences in sites bound by
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TAp73a or TAp73a and p53, it is not enriched in the TAp73p or the p53 and TAp73p sites. 
The location of the AP1 motif is plotted relative to the TAp73a peak summit in Figure 
5F. The distinct centered distribution indicates that the AP1 motif is located in very close 
proximity to the actual TAp73a binding site. A similar distribution is also seen for the 
distance between TAp73p or p53 peak summits and occurring AP1-motifs, although the 
frequencies of AP1 motif occurrences are lower (Supplemental Figure 4A). While the AP1 
and p73 motifs occur close together, there does not seem to be a specific fixed distance 
(Supplemental Figure 4B).
The relationship between TAp73a and c-Jun was further strengthened when we assessed 
presumed AP1 target genes. Recently, a group of genes predicted to be controlled by 
c-Jun/NF-KB was identified (Barenco et al. 2009). Of those genes, 20% overlap with the 
genes differentially regulated by TAp73a and TAp73p (p < 0.0001). Strikingly the median 
log2 fold expression change for these genes in TAp73a cells is 0.36, while these genes 
have a median log2 fold change of -0.41 (p < 0.001) in TAp73p cells (Figure 5G). In TAp73a 
expressing cells genes with an AP1 motif are more often upregulated compared to genes 
lacking this motif (Supplemental Figure 5). This correlation is not observed for TAp73p.
Thus, the sequences of the identified p73 binding sites show clear isoform-specific charac­
teristics. In particular, the overrepresentation of the AP1 motif distinguishes the TAp73a 
from the TAp73p binding sites.
3.3.5. TAp73a activates genes containing an API motif close to a p73 binding site
The transcription factors of the AP1 family regulate many growth related functions, there­
fore we wondered whether genes assigned to p73 binding sites co-occurring with AP1 
motifs could contribute to the physiological differences we observed between TAp73a 
and TAp73p. We chose five genes in which an AP1 motif is also present and detected 
strong enrichment of TAp73a at all tested binding sites, while the binding of TAp73p is not 
enriched significantly (Figure 6A). Next, we assessed whether c-Jun is differentially recrui­
ted in the presence or absence of TAp73a or TAp73p. ChIP-qPCR of c-Jun revealed clear 
binding of c-Jun to target sites in parental Saos2 and in TAp73a expressing cells (Figure 
6B). In the cases of NEDD4L and RNF43 the expression of TAp73a increases the binding of 
c-Jun, compared to parental Saos2 cells. We also analyzed whether p53 was bound to the­
se AP1-motif containing sites and whether it could change the recruitment of c-Jun. While 
strong binding of p53 was not observed, the binding of c-Jun to these sites appears to 
remain unchanged in p53- expressing cells compared to parental Saos2 cells (Supplemen­
tal Figure 6). To validate that TAp73a and c-Jun are actually bound simultaneously to the
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Fig. 5: Characteristics o f TAp73a and TAp73@ binding sites
A. The newly identified TAp73 binding m o tif visualized by WebLogo (Crooks et al. 2004).
B. The percentage o f  binding sites containing the p73 m o tif as determined by p73scan. Binding sites are divided in 
seven different groups based on detected binding o f  TAp73a, TAp73@ and/or p53:1)-3) bound by on ly one fam ily  
member, 4) and 5) by p53 and either TAp73-isoform, 6) by both TAp73-isoforms and 7) by both TAp73-isoforms and 
p53.
C. Boxplot o f  the TAp73 m o tif scores, as determined by p73scan, o f the groups described in B).
D. The API sequence m o tif identified in the TAp73a binding sites visualized by WebLogo.
E. The percentage o f  binding sites containing the API m o tif o f  the groups described in B).
F. The location o f  the API m o tif in TAp73a binding sites, relative to the peak summit.
G. Boxplot o f  the log2 fo ld expression change (Saos cells expressing TAp73alpha or TAp73beta versus Saos2 paretal 
control) o f the genes identified in Barenco et al. (Barenco et al. 2009) as c-Jun/NF-kB dependent. Expression o f  
TAp73a cells is shown in green, TAp73@ is shown in blue. The difference in the median fo ld  change between 
TAp73a and TAp73p is significant (p<0.001, Wilcoxon Rank Sum test).
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Fig. 6: Opposite effects o f TAp73a and TAp73@ on target genes close to an A PI m otif
A. TAp73a bu t no t TAp73@ binds to API m o tif containing binding sites. ChlP-qPCR was performed in Saos cells 
expressing TAp73a or TAp73@ for 24 hr, w ith primers covering putative API binding sites. SD was derived from  
three independent experiments.
B. Binding o f  c-Jun to putative target genes is reduced in TAp73p expressing cells. ChlP-qPCR o f c-Jun was performed 
in Saos2 cells, either the parental cell line, or cells expressing TAp73a or TAp73@ for 24 hr. Same primers as in A) 
were used and SD was derived from three independent experiments.
C. ChlP-re-ChIP shows binding o f TAp73a and c-Jun to the same sites on DNA. After induction o f TAp73a chromatin- 
complexes were precipitated first w ith a p73-antibody. A fter elution a second round o f  immunoprecipitation was 
performed w ith a c-Jun- or again w ith a p73-antibody. The second ChIP included a unspecific antibody-control 
to  calculate enrichment. SD was derived from three independent experiments.
D. Opposite regulation o f API m o tif containing target genes by TAp73a and TAp73@. Changes in expression o f  
mRNA o f the target genes from A), upon induction o f  TAp73a or TAp73@ for 24 hr. SD was calculated from three 
independent experiments.
E. Expression o f  AP1-m otif containing target genes is reduced after knockdown o f  p73. A fter knockdown o f p73 in 
HCT116 cells, protein levels o f  p73 (left) or transcriptional levels o f the respective target genes (right) were 
analyzed. SD was derived from tw o independent experiments.
F. Knockdown o f c-Jun reduces the expression o f AP1-m otif containing target genes. A fter knockdown o f  c-Jun in 
MDA-MB231 cells, protein levels o f c-Jun (left) or transcriptional levels o f  the respective target genes (right) were 
analyzed. SD was derived from tw o independent experiments.
G. The levels o f c-Jun are downregulated by TAp73@. Expression o f  c-Jun mRNA upon induction o f TAp73a, TAp73fi 
or p53 for 24 hr (left). SD was calculated from three independent experiments. Protein-levels o f c-Jun were ana 
lyzed in Saos cells after induction o f TAp73a, TAp73@ or p53 for 24 hr before whole cell extract was isolated and 
the indicated proteins were stained by western b lo t (right).
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same binding regions, we performed ChIP-re-ChIP analysis. For all tested target genes we 
could re-ChIP c-Jun at the TAp73a-bound target sites and vice versa, showing that TAp73a 
and c-Jun can indeed be found on the same binding regions at the same time (Figure 6C, 
Supplemental Figure 7).
In concordance with the binding data, TAp73a induces the mRNA expression of all five 
genes (Figure 6D). Surprisingly, we found a repression of the level of mRNA of the same 
genes upon TAp73p induction, in the case of RNF43 or IL1RAP a substantial decrease to 
5-10% of the level of expression in the parental Saos2 cells. To show the dependence of 
these target genes from endogenous p73 and c-Jun we silenced the expression of p73 
and c-Jun in HCT116 and MDA-MB231 cells, respectively and analyzed the expression 
NEDD4L, IL1RAP and CDK6 (Figure 6E,F). The reduction of p73-levels leads to a small de­
crease of NEDD4L- and CDK6-mRNA and a strong reduction of the IL1RAP-expression (Fi­
gure 6E). After the reduction of c-Jun expression, the mRNA levels of all three tested genes 
were reduced more than 30% (Figure 6F).
To further explore the relationship between c-Jun and p73, we analyzed the levels of c- 
Jun mRNA in TAp73p expressing cells (Figure 6G, left). Strikingly, upon TAp73p induction 
the c-Jun mRNA level is strongly reduced, an effect also seen in our RNA-seq data (Sup­
plemental Figure 2C). The protein level of c-Jun is also reduced specifically upon TAp73p 
induction, while neither TAp73a nor p53 exert a similar effect (Figure 6G, right).
Thus, we have identified a specific set of TAp73a target sites that contain also an AP1 site 
and that are bound by c-Jun. Very interestingly, these AP1 motif containing target sites 
are not bound by TAp73p. Furthermore, while the endogenous expression of these genes 
seems to depend on p73 and c-Jun, a repression of the associated genes specifically upon 
TAp73p induction is observed, probably due a negative regulation of c-Jun by TAp73p. 
Thus, the interplay between c-Jun and TAp73 is isoform dependent, leading to differential 
binding of c-Jun to its target genes and to a differential transcriptional outcome.
3.3.6. The TAp73a target genes IL1RAP and NEDD4L can influence apoptosis
Several of the genes that are in close proximity to combined TAp73a/AP1 binding sites are 
linked to tumorigenesis or malignant growth (Table IV). Because TAp73a can induce these 
genes, we assessed whether these target genes impede on the induction of program­
med cell death. To this end we overexpressed two of these gene products, NEDD4L and 
IL1RAP, in Saos cells inducible for TAp73a. The effect of the overexpressed proteins on the 
TAp73a induced apoptosis was monitored by staining for active Caspase3. TAp73a indu-
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Figure 7
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Fig. 7: Target genes o f TAp73a and c-Jun impede on apoptosis induction
A. Overexpression o f IL1RAP, NEDD4L or an em pty vector in Saos cells expressing TAp73a. A fter induction for 24 hr 
or 48 hr whole cell extracts were analyzed by western blot.
B. Knockdown o f IL1RAP and NEDD4L. TAp73a expressing Saos cells were transfected twice w ith a pool o f four 
different siRNAs against each gene or a non-targeting siRNA-pool. A fter induction for 24 hr mRNA was harves 
ted and the efficiency o f  knockdown was m onitored setting the non-targeting sample to  100%. Error bars result 
from tw o biological replicas.
C. Knockdown o f IL1RAP and NEDD4L increases apoptosis. TAp73a expressing Saos cells were transfected as in B), 
prio r to isolation o f whole cell extract and western b lo t analysis (left panel) o r preparation for FACS-analysis to 
determine the am ount o f cells in sub-G 1 phase as a measure for apoptotic induction (right). * indicates p  < 0.05. 
SD was derived from three independent experiments.
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ces the cleavage of Caspase3 mainly after 48 hr (Figure 7A). Upon transfection of IL1RAP, 
the amount of activated Caspase3 is markedly decreased, especially after 48 hr of TAp73a 
induction. NEDD4L impedes on the accumulation of active Caspase3 in a similar way , es­
pecially after 48 hr of TAp73a induction. To examine the physiological role of IL1RAP and 
NEDD4L in the TAp73a signaling pathway, we transfected siRNAs directed against IL1RAP 
and NEDD4L into TAp73a expressing cells. Analysis of the mRNA after transfection of the 
respective siRNA and induction of TAp73a for 24 hr shows that the knockdown of IL1RAP 
and NEDD4L has an efficiency of at least 80% (Figure 7B). Strikingly, the knockdown of IL- 
1RAP and NEDD4L increases the induction of active Caspase3 after 24 and 48 hr of TAp73a 
induction (Figure 7C, left). Analyzing the population of cells in sub-G1, we found that the 
knockdowns lead to a statistically significant increase of TAp73a induced apoptosis (Figu­
re 7C, right). Thus, we have identified two target genes of TAp73a that seem to impede on 
the apoptosis induction capability of TAp73a, most likely via a c-Jun involving pathway.
Table 4: Known function of TAp73a target genes with an API motif
Gene name Known Function Reference
RNF43 upregulated in colorectal cancers; growth promoting if exogenously expressed
(Yagyu et al. 2004; Sugiura et al. 
2008)
NEDD4L
Na+ channel regulation/ tumor associated via Wnt- 
signaling in liver cancer/ neuronal survival via Trk 
neurotrophin receptors
(Arevalo et al. 2006; Lee et al. 2007)
CDK6
catalytic subunit for G1/S transition/ stimulates 
growth in prostate cancer/ overexpressed in 
medullablastoma; poor prognosis marker
(Lim et al. 2005; Mendrzyk et al. 
2005)
IL1RAP involved in IL1 action during inflammation/ activation of NFkB-pathway
(Cullinan et al. 1998; Towne et al. 
2004)
PAI-1 promoter of tumor progression/ poor prognosis marker
(Nekarda et al. 1994; Bajou et 
al. 1998; Gutierrez et al. 2000; 
Kortlever and Bernards 2006)
RIPK4 can activate NFkappaB/ processed during apoptosis/ involved in differentiation
(Meylan et al. 2002; Adams et al. 
2007)
GAP43
growth associated protein 43/ highly expressed 
during neuronal development and axonal 
regeneration/neurite outgrowth/ AP1& TrkA 
associated
(Diolaiti et al. 2007)
SDC1
participates in cell proliferation, cell migration 
and cell-matrix interactions/ Altered (higher) 
syndecan-1 expression has been detected in several 
different tumor types
(Maeda et al. 2006; Choi et al. 2007)
NGFR
tumor suppressor in retinoblastoma/ necessary 
for cell survival in ESCC/ Inducer of apoptosis in 
absence of ligand/ Interaction with TrkA/ critical 
regulator of glioma invasion
(Khwaja et al. 2006; Okumura et al. 
2006; Johnston et al. 2007; Dimaras 
and Gallie 2008)
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We propose that the difference in apoptosis induction by TAp73a and TAp73p is mediated 
by the differential collaboration with c-Jun: in the case of TAp73a API binding sites are 
bound by c-Jun and the respective proliferation related target genes are induced leading 
to a weaker apoptotic response of TAp73a. On the other hand the TAp73p binding sites 
are not only devoid of API sites, but TAp73p also negatively regulates the c-Jun levels, 
resulting in much higher levels of apoptosis.
3.4. Discussion
A marked physiological difference between the two most commonly expressed TAp73- 
isoforms, TAp73a and TAp73p has been reported (Melino et al. 2004; Klanrit et al. 2008), 
but the molecular mechanism for the observed different cellular responses upon TAp73a 
and TAp73p activation has remained elusive. Here, we analyze the differences of TAp73a 
and TAp73p target gene-binding and -regulation and propose that the balance between 
survival and apoptosis induction by TAp73a and TAp73p is mediated at least partly by the 
differential interplay with c-Jun. In our global binding site analysis we identified a consen­
sus binding motif for TAp73a and TAp73p. Although this motif resembles the previously 
described p53 consensus motif (Smeenk et al. 2008), it has several distinct features, e.g. 
the bases outside the four nucleotide core are less preserved and it is thereby closer rela­
ted to the binding motif described for p63 (Ortt and Sinha 2006).
Assessing the molecular differences between TAp73a and TAp73p, we found that an API 
motif is strongly enriched in the region surrounding many binding sites of TAp73a, but 
not in TAp73p binding sites. We observed a striking difference in the expression of the 
target genes with an API motif in the TAp73a- versus TAp73p-expressing cells. While the­
se target genes are selectively bound by TAp73a together with c-Jun and subsequent­
ly upregulated, TAp73p represses their mRNA expression. In line with these findings, we 
observed that the recruitment of c-Jun to the API sites of these genes is impaired upon 
TAp73p induction probably caused by a downregulation of c-Jun mRNA and protein by 
TAp73p. Several of the assigned target genes are related to malignant growth, like CDK6 
and RNF43 (Lim et al. 2005; Sugiura et al. 2008). We show that two genes specifically upre­
gulated in TAp73a expressing cells, NEDD4L and IL1RAP, are able to influence the induc­
tion of apoptosis upon their overexpression or siRNA-mediated downregulation, thereby 
showing that TAp73a indeed induces anti-apoptotic factors.
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3.4.1. Analysis of TAp73a and TAp73p transcriptional activities
It has been reported previously, that TAp73p can induce the expression of p53-target ge­
nes like p21 or Mdm2 to a higher extent than TAp73a (De Laurenzi et al. 1998; Lee and La 
Thangue 1999; Ueda et al. 1999), while also TAp73a-specific target genes have been re­
ported (Fontemaggi et al. 2002). TAp73p has been described to be a much stronger indu­
cer of apoptosis (Gonzalez et al. 2005; Oshima et al. 2007). In line with this, our data shows 
that known target genes like Mdm2 and p21 are bound with higher affinity and induced 
to higher levels through TAp73p and that the induction of apoptosis by TAp73p is much 
stronger. Nevertheless, our study now extends previous analysis by combining ChIP-seq 
and RNA-seq to compare these two most prevalent TAp73 isoforms with each other as 
well as with p53 with respect to global target gene binding and expression. Strikingly, be­
sides common target genes bound and regulated by TAp73a, TAp73p and p53 we found 
target genes that were regulated in an isoform-specific manner. In summary, our data 
provide genome-wide analysis of TAp73a, TAp73p and p53 chromatin occupancy and the 
correlation thereof with transcriptional changes upon TAp73a, TAp73p and p53 induction. 
This enables a careful examination of the isoform-specific as well as overlapping target 
genes and provides a basis for further functional characterization.
3.4.2. Isoform-specific functional interplay of TAp73 with c-Jun
Our data shows that the cellular outcome of the interplay between c-Jun and p73 de­
pends on the presence of the respective TAp73-isoform. Firstly, our motif analysis of ge­
nome wide data showed a striking co-occurrence of c-Jun binding motifs with TAp73a- 
binding sites, to which both proteins bind simultaneously. Secondly, induction of TAp73p 
resulted in a reduction of c-Jun mRNA and protein levels and hence lack of recruitment 
of c-Jun. Third, there is a positive correlation between TAp73a-induced genes and c-Jun 
target genes, while this correlation is inversed for TAp73p-regulated genes. Thus, the poor 
induction of cell death by TAp73a could be due to activation of anti-apoptotic target ge­
nes along with c-Jun, while the stronger apoptosis induced by TAp73p is caused at least in 
part by a reduction of cellular c-Jun levels and subsequent reduced recruitment of c-Jun 
to DNA resulting in repression of these target genes. Several of these target genes are 
linked to malignant growth and their mRNA levels were induced by TAp73a but repressed 
by TAp73p. The negative regulation of genes related to proliferation by TAp73p and p53 
that was reported earlier (Scian et al. 2008) might therefore also be extended to these AP1 
motif containing genes. This AP1 motif can be bound by c-Jun, which has been reported 
to stabilize p73 and thereby to enhance its function, although no direct interaction was 
observed (Toh et al. 2004). More recently it was reported, that c-Jun plays an important 
role in apoptosis induced by chemotherapeutic treatments mediated by YAP1, a critical
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regulator of p73 (Strano et al. 2005; Danovi et al. 2008). On the other hand, c-Jun and 
p73 have also been shown to co-operate during growth promotion and to synergistically 
induce transcription from c-Jun response element containing promoter constructs in the 
absence of additional apoptosis-inducing treatments (Vikhanskaya et al. 2007). Based on 
our findings, we speculate that the differences in cellular outcome are due to the pre­
sence of the particular TAp73 isoform and its respective interplay with c-Jun. The weaker 
induction of cell death by TAp73a that we observed might be mediated by the activation 
of anti-apoptotic target genes together with c-Jun, while the stronger apoptosis induced 
by TAp73p might be due to the repression of these target genes and a reduction of c-Jun 
levels. The treatment- and isoform-specific differences influencing the cellular fate hint to­
wards several layers of regulation between p73 and c-Jun and might be a very important 
molecular explanation for the differential observed phenotypes induced by the TAp73 
isoforms.
3.5. Material and Methods:
3.5.1. Cell culture conditions
The human MDA-MB231, HCT116, HEK293 cell lines and the osteosarcoma cell line Saos2 
(parental cells or cell lines with inducible p53, TAp73a or TAp73p) (Smeenk et al. 2008) 
were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal calf 
serum at 37°C. Expression of p53, TAp73a or TAp73p in stably transfected cells was in­
duced with 0.5 mg doxycyclin (for TAp73a) or 2.0 mg doxycyclin (for TAp73p and p53). 
Transfections were performed using the calcium phosphate precipitation method (BES). 
Transient knockdown of IL1RAP and NEDD4L was achieved by using Dharmacon ON-TAR- 
GETplus siRNAs, according to manufacturers manual. Lentiviral transduction was used to 
deliver pLKO-siRNA constructs for the knockdown of c-Jun (a kind gift from F. Galvagni) 
and p73 (Sigma), while pLKO-siRNA targeting Luciferase served as a control.
3.5.2. Cell cycle analysis
Saos2 parental cells and Saos cell lines inducible for TAp73a, TAp73p or p53 were induced 
for 24 hr or 48 hr, prior to harvest. All cells were collected, resuspended in PBS containing 
1% FCS and fixed in ethanol overnight at 4°C. DNA content was stained with propidium 
iodide (Sigma) for 30 min at room temperature and analyzed by flow cytometry (Becton 
Dickinson FACScan). The data was analyzed using CellQuest Pro software.
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3.5.3. Western Blot analysis
Whole cell extract was harvested in 2x SDS-sample buffer, 4x sample buffer was added 
to aliquots of chromatin samples (see below for preparation of chromatin), both types 
of samples were boiled and proteins were separated by SDS-page. After blotting the fol­
lowing antibodies were used to detect proteins: BL609 (anti-p73; Abcam), DO1 (anti-p53; 
BD PharMingen), ab13487 (anti-active Caspase3; Abcam), SC45-X (anti-cJun; SantaCruz 
Biotechnology), SL30 (anti-TATA-box Binding Protein; anti-TBP), M2 (anti-FLAG; Sigma). 
Secondary antibodies used were either rabbit-anti-mouse or swine-anti-rabbit conjuga­
ted to HRP (Dako).
3.5.4. Chromatin immunoprecipitation (ChIP)
The chromatin immunoprecipitation (ChIP) was basically done as described by Denissov 
et al. (Denissov et al. 2007). To immunoprecipitate p53, DO1 antibody (BD PharMingen) 
was used and BL906 (Abcam) was used for p73. Immunoprecipitation of c-Jun was done 
with an anti-c-Jun antibody (Upstate). Real-time qPCR was performed using the SYBR 
Green mix (Biorad) with the MyIQ machine (Biorad). Primers are listed in Supplemental 
Table SV.
Prior to the Re-ChIP, p73-antibody (BL609) or c-Jun-antibody (Upstate) was cross-linked 
to protein-A/G-beads (SantaCruz) using 20 mM dimethylpimelimidate (pH: 8,5). The chro- 
matin-complexes from the first ChIP were eluted in 50 ^L of elution-buffer and the SDS- 
concentration was adjusted with 5x incubation buffer without SDS to 0.15% in the second 
ChIP-reaction. The Re-ChIP included an unspecific or a beads only control, respectively, to 
allow an estimation of leakage and antibody-carryover from the first ChIP.
3.5.5. RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini Kit according to protocol (Qiagen). For cDNA 
synthesis retrotranscription was performed using 1 ng of RNA with random hexamer pri­
mers, dNTPS, DTT, buffer and Superscript Retrotranscriptase (Invitrogen). The cDNA was 
analyzed by real-time qPCR using a MyIQ machine (Biorad). Primers are listed in Supple­
mental Table SV.
3.5.6. RNA-sequencing
To prepare samples for RNA-seq 100 ^g of total RNA were subjected to polyA-selection 
with Oligotex Kit according to protocol (Qiagen). Fragmentation of 100 ng polyA-selected
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mRNA was done for 105 seconds at 94°C in 1x fragmentation buffer (40 mM Tris acetate, 
pH 8.2; 100 mM potassium acetate; 30 mM magnesium acetate). After purification with 
RNeasy mini Kit, according to protocol (Qiagen) first strand cDNA synthesis was perfor­
med with random hexamer primers, dNTPS, DTT, buffer and Superscript Retrotranscripta- 
se (Invitrogen). Second strand synthesis was done with E.coli DNA polymerase, E.coli DNA 
ligase, dNTPs buffer and RNAseH. After purification with Minelute Reaction Cleanup Kit 
(Qiagen) the obtained material was used to prepare sequencing samples according to the 
manufacturers protocol (Illumina).
3.5.7. Illumina high throughput sequencing (ChIP-seq)
Sequencing samples were prepared according to the manufacturers protocol (Illumina). 
Shortly, adapted sequences were linked to the generated ChIP, the library was size selected 
(200-250 bp) and amplified by PCR. Clustering and 36-cycle sequencing were performed 
using an Illumina Cluster station and Genome Analyzer according to the manufacturer's 
instructions. Images acquired from the Genome Analyzer were processed through the 
bundled image extraction pipeline (Illumina). All 35 bp sequence reads were uniquely 
mapped to the human genome NCBI build 36.1 (hg18) with zero or one mismatch allowed 
using ELAND software (Illumina). For visualization purposes, all reads were directionally 
extended to 200 bp, and the number of overlapping sequence reads was determined for 
each position in the genome, averaged over a 10 bp window and visualized in the UCSC 
genome browser (http://genome.ucsc.edu).
3.5.8. ChlP-seq data analysis
Two biological replicates were sequenced for all ChIP samples. To incorporate the diffe­
rent signal/background ratios of the different biological replicates and generate high- 
confidence peaks we called peaks on a set of combined reads randomly sampled from 
each combination of two replicates. We randomly selected ~7 million reads from each 
TAp73a and each Tap73p replicate and 3 million from each p53 replicate. We combined 
these randomly selected reads (~14 million for both TAp73a and TAp73p, 6 million for 
p53) and used this set as input for MACS (Zhang et al. 2008). Peaks were called using de­
fault parameters (p-value threshold 1e-5), using a Saos2 input DNA sample as control 
(~14 million reads). This random sampling procedure was repeated 10 times, and only 
the peaks determined in every single analysis were kept. Peaks were mapped to RefSeq 
genes, downloaded from the UCSC Genome Browser, to determine genomic location.
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3.5.9. RNA-seq data analysis
Two biological replicates were sequenced for each sample. Reads were mapped to the 
genome, and all reads mapping within RefSeq genes (downloaded from the UCSC Geno­
me Browser) were counted. The read counts per gene per replicate were used as input for 
DEGseq (Wang et al.). This R package was used to call differentially regulated genes using 
the MARS method, with default parameters. All genes with a significant change (FDR < 
0.001) and an absolute log2 fold change of 1 were called as regulated.
3.5.10. Association strength
The continuous association strength per gene was calculated as described in Ouyang et 
al. (Ouyang et al. 2009). The association strength of gene i is calculated as the a weighted 
sum of intensities of all of the peaks within 2Mb of the gene, according to the following 
formula:
ai =2gke-dk,d° 
k
where gk is the total normalized number of reads aligned of the kth binding site, dk is the 
distance (number of nucleotides) between the TSS of gene i and the kth binding site and 
d0 is 5000. The association strength values are log2-transformed and quantile-normalized.
3.5.11. Motif analysis
The location and score of the p53 motif within the 200 bp peaks was determined using 
p53scan with default settings (www.ncmls.nl/bioinfo/p53scan/) (Smeenk et al. 2008).
To determine the p73 motif three motif prediction tools were run on the 200 bp peaks: 
MotifSampler (Thijs et al. 2001), Weeder (Pavesi et al. 2004) and MDmodule (Liu et al. 2002). 
A set of 1000 sequences, randomly selected from the highest 5000 peak sequences was 
used as input to predict motifs. We used the 'large' analysis setting for Weeder, and MD­
module and MotifSampler were used to predict 10 motifs for each of the even widths bet­
ween 6 and 20. The significance of the predicted motifs was determined by scanning the 
remaining 80% of the 5000 highest peak sequences (4000 sequences) and two different 
backgrounds: a set of random genomic sequences with a similar genomic distribution as 
the peak sequences and a set of random sequences generated according to a 1st order 
Markov model (similar dinucleotide distribution as the peak sequences). P-values were
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calculated using the hypergeometric distribution with the Benjamin-Hochberg multiple 
testing correction. All motifs with a p-value < 0.001 and at least an absolute enrichment > 
1.5 compared to both backgrounds were determined as significant. The closest matching 
motif in the JASPAR database (Vlieghe et al. 2006) was determined using STAMP (Mahony 
and Benos 2007).
The p53scan algorithm was modified to use the best p73 motif matrix found in the motif 
analysis, hereafter referred to as p73scan. The PWM is included as Supplemental Table SIII. 
All p73scan analyses reported in this study were carried out with a spacer length of 0.
The AP1 motif analyses were carried out with the pwmscan.py program included with 
p53scan, using the best performing AP1 matrix identified in this study as PWM. This matrix 
is provided as Supplemental Table SIII. As a threshold for the AP1 pwmscan.py 0.98 was 
used, to select for stringent matches.
3.5.12. Data availability
The data has been deposited in NCBI's Gene Expression Omnibus (Edgar et al. 2002) and 
are accessible through GEO Series accession number GSE15780 (http://www.ncbi.nlm.nih. 
gov/geo/query/acc.cgi?acc=GSE15780).
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3.8. Supplemental Material
Supplemental Figure 1
Chapter 3
Correlation between replicates 
TAp73a TAp73p
replicate 1 (log2 number of reads) replicate 1 (log2 number of reads)
Correlation between ChlP-seq replicates.
The number of reads for each peak is plotted per replicate.
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Supplemental Figure 2
TAp73p-specific regulation
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Preferential expression changes induced by TAp73f3.
The three tracks show the signals from RNA-seq for Saos2 parental cells or upon Induction of either p53, TAp73a or 
TAp73p. Below the tracks the respective gene is displayed.
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Supplemental Figure 3
TAp73a  TAp73p
1 -  Specificity 1 -  Specificity
p53
1 -  Specificity
Receiver Operator Curve (ROC) comparing the p73scan performance to p53scan on TAp73a, TAp73(3 ad p53 
binding sites.
The curves summarize the tradeoff between sensitivity and specificity, when varying the motif score threshold. The 
binding sites as well as genomic background sequences were scanned with all motifs using different thresholds. For 
each individual threshold the fraction of binding sites with a motif (sensitivity) as well as the fraction of background 
sequences with a motif (1 -  specificity) were calculated.
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Supplemental Figure 4
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Distribution of AP1 motifs and p73 binding sites.
A. Plotted ist the frequency of AP1 motif occurence relative to the peak summit of TAp73<x, TAp730 or p53 binding sites.
B. The distance between the AP1 motif and the p73 motif in TAp73cx, TAp73p or p53 binding sites is plotted, together with the 
frequency of its occurrence.
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Supplemental Figure 5
TAp73a-regulated genes TAp73p-regulated genes
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Presence of the AP1 motif in genes differentially regulated by T A p73a  or TAp73p.
Target genes of T A p73a  or TAp73p were grouped according to the presence or absence of an A P I motif 
and the expression change for the respective group is shown.
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Supplemental Figure 6
c-Jun-ChIP of AP1-s ites
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p53-induced expression changes
A. Binding of p53 to AP I motif containing binding sites. C h lP -qPCR  was performed in Saos cells expressing p53 for 24 hr. 
with primers covering putative AP I binding sites. SD  was derived from three independent experiments.
B. Binding of c-Jun to putative target genes in p53 expressing cells. Ch lP -qPCR  of c-Jun was performed in parental Saos2 
cells or in Saos cells expressing p53 for 24 hr. Same primers as in A) were used and SD  was derived from three independent 
experiments.
C. Expression changes of A P I motif containing target genes induced by p53. Changes in expression of mRNA of the target 
genes from A), upon induction of p53. SD  was calculated from at least two independent experiments.
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Supplemental Figure 7
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0
ChlP-re-ChIP shows binding of c-Jun and TAp73a to the same sites on DNA. After induction of TAp73a, 
chromatin-complexes were precipitated first with a c-Jun-antibody. After elution a second round of immuno- 
precipitation was performed with a p73- or again with a c-Jun-antibody. The second ChIP included a 
beads-only control to calculate enrichment. Error bars were derived from one technical replicate.
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4. The novel p53 target gene 
IRF2BP2 participates in cell 
survival during the p53 stress- 
response
Max Koeppel, Simon J. van Heeringen, Leonie Smeenk, Anna C. Navis, Eva M. Janssen- 
Megens and Marion Lohrum (2009). Nucleic Acids Research 37, 322-335.
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The tumor suppressor p53 contributes to the cellular fate after genotoxic insults, mainly 
through the regulation of target genes, thereby allowing e.g. repair mechanisms resulting 
in cell survival or inducing apoptosis. Unresolved so far is the issue, which exact mechanisms 
lead to one or the other cellular outcome. Here, we describe the Interferon Regulatory 
Factor-2 Binding Protein-2 (IRF2BP2) as a new direct target gene of p53, influencing the 
p53-mediated cellular decision. We show that upregulation of IRF2BP2 after treatment 
with Actinomycin D (Act.D) is dependent on functional p53 in different cell lines. This 
occurs in parallel with the downregulation of the interacting partner of IRF2BP2, the 
Interferon Regulatory Factor-2 (IRF2), which is known to positively influence cell growth. 
Analyzing the molecular functions of IRF2BP2, it appears to be able to impede on the p53- 
mediated transactivation of the p21- and the Bax-gene. We show here that overexpressed 
IRF2BP2 has an impact on the cellular stress-response after Act.D treatment and that it 
diminishes the induction of apoptosis after Doxorubicin treatment. Furthermore, the 
knockdown of IRF2BP2 leads to an upregulation of p21 and faster induction of apoptosis 
after Doxorubicin as well as Act.D treatment.
4.1. Abstract
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The loss of the tumor suppressor p53 appears to be a crucial event in the development of 
cancer, since p53 plays an essential role in the cellular stress response program. Germline 
mutations of p53 lead to a strong cancer predisposition in mice and in humans (Lozano 
and Zambetti 2005). Various forms of stress such as DNA damage, oncogene activation, 
hypoxia, viral infection or nutrient deprivation all induce activation of p53 (Vogelstein et 
al. 2000). Besides the regulation of transcription-independent apoptotic pathways (Moll 
et al. 2005), p53 mediates many of its key functions by transactivation or transrepression 
of its target genes. It can recognize and bind to specific DNA sequences, thereby recrui­
ting general and specialized transcriptional coregulators (Laptenko and Prives 2006). In­
terestingly, p53 can regulate target genes that promote growth arrest and DNA repair, 
ultimately leading to cellular survival, as well as target genes that eventually trigger cell 
death (Vousden 2006). Thus, one of the most important current research questions is how 
the decision between the different p53-mediated response pathways is being made.
In general, the outcome of the p53-activation appears to depend on the respective cell 
type, the nature of the stress-signal itself or the kind and extent of DNA-damage, the pre­
sence of survival factors in the cell and, if present, inappropriate activity of oncogenes 
(Vousden and Lu 2002). The activity of p53 itself seems to be influenced by the overall le­
vels of p53, post-translational modifications of p53, the presence or absence of transcrip­
tional cofactors and possible differences in the p53 binding sequences of the potential 
target genes (Laptenko and Prives 2006; Vousden 2006).
For the induction of certain subsets of p53-target genes distinct transcriptional factors are 
required, such as CARM1, PRMT and JMY, that cooperate with the CBP/p300 family of ace­
tyl transferases to activate specific p53-target promoters (Coutts and La Thangue 2005) as 
well as the long-range chromatin modifier hCAS/CSE1L, which affects different classes of 
p53 target genes (Tanaka et al. 2007).
For the induction of apoptosis, p53 alone appears not to be sufficient, but it seems to 
require other factors binding to cis-elements in promoters of crucial genes (Qian et al.
2002) like proteins of the ASPP-family (Samuels-Lev et al. 2001) or the NF-kB transcription 
factor that has been shown to influence the outcome of p53-activity under certain cellular 
conditions (Ryan et al. 2000). Also, post-translational modifications appear to influence 
the p53 response. Phosphorylation of serine 46, which was reported to be crucial for p53- 
induced apoptosis, can be regulated through the antagonizing actions of p53DIP1, a kina­
se cofactor and WIP1, a phosphatase (Takekawa et al. 2000; Okamura et al. 2001). The fact
Chapter 4
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that both proteins are induced by p53 shows how tight the activity of p53 is regulated. 
While the binding of p53 to its binding sites requires acetylation of its C-terminus (Gu and 
Roeder 1997; Liu et al. 1999), the activation of certain apoptotic target genes, like Bax and 
Puma, is associated with acetylation of lysine 120 within the DNA-binding domain (Sykes 
et al. 2006).
For the induction of growth arrest other cofactors are responsible, e.g. proteins which me­
diate inhibition of cell cycle progression or those that impede on the induction of apopto- 
sis, like Miz (Herold et al. 2002), Hzf (Das et al. 2007) or SLUG (Wu et al. 2005). Some of these 
factors are target genes of p53 and although they do not necessarily interact directly with 
p53, they can form regulatory loops, delaying or inhibiting p53-mediated apoptosis.
Within the Interferon Regulatory Factor (IRF) family of transcription factors that play im­
portant roles in antiviral defense, immune response and cell growth regulation, IRF1 and 2 
are generally described as a tumor suppressor and an oncoprotein, respectively (Nguyen 
et al. 1997). IRF1 was identified as the first member of the IRF-family being induced upon 
IFN-y and activating the transcription of IFN-y responsive genes. IRF2 is also induced by 
IFN-y- While IRF2 can bind to the same target gene sequences as IRF1, it can act as an an­
tagonist of the latter (Tanaka 2000; Taniguchi et al. 2001). In addition to the repression of 
IRF1 induced target genes, IRF2 has also been shown to promote cell proliferation through 
the transcriptional activation of the histone H4 gene (Vaughan et al. 1995; Vaughan et al.
1998). Both IRFs are able to recruit the histone acetyl transferases PCAF and CBP/p300 
to target promoters resulting in enhanced transcriptional activity (Masumi et al. 1999). 
Experiments in nude mice and expression pattern analysis in several different kinds of tu­
mors support the hypothesis that IRF1 can function as a tumor suppressor and IRF2 as an 
oncoprotein (Harada et al. 1993; Lowney et al. 1999; Connett et al. 2005; Wang et al. 2007).
Interestingly, IRF1 can induce the growth arrest mediating p21 gene together with p53 
(Tanaka et al. 1996). Although a binding site for IRF1 was identified in the p21 promoter 
(Coccia et al. 1999), Dornan et al. showed that this transactivation depends on the interac­
tion between IRF1 and p300 (Dornan et al. 2004). On the other hand, knockdown of IRF2 
or mutation of its repressive C-terminus was shown to upregulate p21 transcription (Ru­
binstein et al. 2000; Wang et al. 2007), suggesting that this part of the protein, at least in 
part, is responsible for its oncogenic potential. Recently, a new nuclear factor, IRF2BP2, has 
been identified that interacts with the C-terminal repression domain of IRF2 and that has 
the potential of an IRF2-dependent transcriptional corepressor (Childs and Goodbourn
2003).
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Here, we describe IRF2BP2 as a direct target gene of p53. We show that p53 can bind 
in vivo and in vitro to a p53 consensus-binding site upstream of the transcriptional start 
site of the IRF2BP2 gene and that p53 can transactivate its transcription. Functioning as 
a transcriptional cofactor IRF2BP2 was able to influence the p53-mediated transactivati­
on of target genes as shown by luciferase assays. Upon induction, IRF2BP2 promotes cell 
cycle arrest and seems to interfere with p53-mediated apoptosis after chemotherapeu­
tic treatment. When IRF2BP2 is knocked down with small interfering RNA, stress-induced 
p53-mediated apoptosis increases. We propose a function of the new p53 target gene 
IRF2BP2 in a feedback-loop, influencing the outcome of p53-activation in the direction of 
growth arrest instead of apoptosis.
4.3. Results
4.3.1. Identification of IRF2BP2 as a direct target gene of p53
To obtain more insight into the molecular mechanisms how the activation of p53 upon 
genotoxic stress can lead to growth arrest and DNA repair or apoptosis, we have previ­
ously performed a systematic analysis to identify new binding sites for p53 in the human 
genome applying the ChIP-on-chip technique on Act.D treated U2OS cells (Smeenk et 
al. 2008). One of the interesting newly identified target genes was IRF2BP2, an interac­
ting partner of IRF2 (Childs and Goodbourn 2003). As shown in Fig. 1A, a p53 binding site 
was found 9 kb upstream of the promoter of the IRF2BP2 gene. Within this binding site 
we could identify the p53 consensus binding motif, consisting of two halfsites with the 
sequence RRRCWWGYYY (el-Deiry et al. 1992). Scanning the surrounding sequences of 
the IRF2BP2 gene for more potential p53 consensus binding motifs with the p53MH algo­
rithm (Hoh et al. 2002), we found four different motifs, each of them with more than 80% 
of similarity to the ideal p53 binding motif (Fig. 1A and Table 1). These included a motif 
(motif 4) upstream of the transcriptional start site, corresponding to the site which was 
found by ChIP-on-chip. Since we had found only this last motif bound by p53 in the ChIP- 
on-chip analysis we wanted to know if the other predicted sites were really not bound in 
vivo by endogenous p53. To this end, we performed targeted ChIPs using an anti-p53 anti­
body to precipitate p53-chromatin complexes from U2OS cells treated for 24 hr with 5 nM 
Act.D and PCR-primers for all potential binding sites. We verified that only the sequence 
for motif 4 is bound by p53 with a significant enrichment (Fig. 1B). The binding strength of 
p53 towards the motif 4 is comparable to its binding strength to the known target gene 
Mdm2 (Fig. 1B). In addition, we found that p53 is also bound to motif 4 in untreated U2OS 
cells, although to a much lesser extent (Fig. 1B). To obtain a complete analysis of the 5 kb 
region upstream of the IRF2BP2 transcriptional start site we designed primers every 500
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bp and tested for further p53-binding in this region. In the whole region no p53 binding 
was observed (Supplemental Fig. 1). To analyze if IRF2BP2 is a common target gene of the 
p53-family, we compared the binding properties of p53 with those of the closely related 
protein p73a. For this purpose, we used a Saos osteosarcoma cell line stably expressing 
p73a under the control of an inducible promoter (Smeenk et al. 2008). After the induced 
expression of p73a, the cells were treated with 5 nM Act.D for 24 hr prior to chromatin 
isolation. DNA bound by p73a was precipitated using anti-p73 antibody and real-time PCR 
was performed with the indicated primers. We verified that the p53-binding site upstream 
of the IRF2BP2 gene is bound by p73a in this Saos cell line upon Act.D treatment to the 
same extent as the known binding site of Mdm2 (Fig. 1C). To test whether binding of p53 
to the binding site upstream of IRF2BP2 is restricted to Act.D treatment or a more general 
response, we also performed targeted ChIP from U2OS cells treated for 24 hr with 1 nM 
Doxorubicin (Fig. 1D). We found that the IRF2BP2 binding site was also strongly bound by 
p53 upon Doxorubicin treatment. Next we tested if one or more of the identified motifs 
were directly bound by p53. Therefore we performed electrophoretic mobility shift assays 
(EMSA) on radioactive labeled nucleotides spanning each of the predicted p53-binding 
sites, motifs 1-4, (Fig. 1E). The p21-binding motif was used as a positive control. After incu­
bation of the different nucleotides together with p53 and an anti-p53 antibody, a super­
shift could be observed after incubation of p53 with motif 4, but not with the motifs 1-3. To 
show the specificity of the binding an excess of unlabeled p21-binding motif was added, 
either the wild-type or a mutant sequence (as indicated). To analyse whether the identified 
p53-binding site upstream of the IRF2BP2 gene also has a potential transactivating proper­
ty, we cloned a 500 bp fragment containing the sequence around motif 4 into a luciferase 
vector. This vector contains a basic promoter and therefore can be used for testing poten­
tial enhancer activity. Upon cotransfection of this pGL3-IRF2BP2-luc vector together with 
p53 into Saos cells, luciferase activity increased 3-4 fold, compared to the luciferase vector 
transfected alone (Fig 1F). A mutation in the central binding motif for p53 from CATG to 
TATA abolished the transactivation, thus proving a specific and functional p53-binding site.
Table 1: p53-motifs close to the IRF2BP2-gene
Sequence Location relative to IRF2BP2-gene
Identity
score
Motif 1 TGGCATGCCC <6bp> CAACATGCCC 0.4 kb downstream 96.57%
Motif 2 GGACTAGCCT <8bp> CACCAAGTGC 1.4 kb upstream 83.60%
Motif 3 AAACATGCCT <9bp> ACACATGTGA 7.3 kb upstream 81.49%
Motif 4 AAACATGTCA <0bp> GGACATGCCT 9.0 kb upstream 95.27%
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Thus, we verified an in vivo binding site for p53 upstream of the IRF2BP2 gene, which had 
originally been identified by our ChIP-on-chip approach. Although more binding motifs 
were predicted by the p53MH algorithm, we found that they were not bound by p53 in 
U2OS cells after Act.D as well as Doxorubicin treatment. Furthermore, this newly identified 
p53-binding site could also be bound by p73a. In addition, we found that this sequence 
is also bound in vitro by p53 and it can potentially function as a p53-dependent enhancer 
sequence as shown by luciferase assays.
4.3.2. Activated p53 increases the expression of IRF2BP2
Next we examined whether p53 binding also leads to a change in IRF2BP2 expression. To 
test to which extent the regulation of IRF2BP2 expression is dependent on p53, we compa­
red its expression change in wild-type U2OS cells with the expression change in U2OS-p53 
knockdown cells upon stress treatment. Although the knockdown of p53 is not complete 
in these cells, the p53 protein levels are markedly decreased (Fig. 2A). The respective cells 
were either treated with 5 nM Act.D for 24 hr or left untreated. In treated cells the expressi­
on of IRF2BP2 increases two-fold compared to untreated cells, which is comparable to the 
p53-induced activation of the known p53-target gene Bax under the same physiological 
conditions (Fig. 2B). However, the cells containing the p53 knockdown do not show incre­
ased mRNA levels of IRF2BP2 nor Bax upon treatment, thus suggesting a p53-dependent 
induction of IRF2BP2. A similar induction of IRF2BP2 mRNA could be observed after treat­
ment with Etoposide (data not shown). To further validate that the observed induction of 
IRF2BP2 indeed is mediated directly through p53, we studied the kinetics of its expressional 
change (Fig. 2C). The level of IRF2BP2 mRNA increases 6 hr after stabilization of p53 and 
reaches its highest level after 24 hr of treatment, showing kinetics which could reflect a di­
rect response to p53 and which are comparable to the kinetics of Bax mRNA induction upon 
the same treatment (data not shown). In our previous study (Smeenk et al. 2008) we also 
found a binding site for p53 close to the IRF2 gene. Because IRF2 is a protein directly inter­
acting with IRF2BP2 (Childs and Goodbourn 2003), we were interested to analyze whether 
the expression of IRF2 also changed over time upon treatment with Act.D. We observed a 
decrease of IRF2 expression to 50% during the first 12 hr of treatment. However, after 24 hr 
the levels of IRF2 mRNA were restored to the same relative mRNA levels as of unstressed cells 
(Fig. 2C). Since p73a could bind to the upstream sequence of IRF2BP2 as well, we wanted to 
know whether p73a was also able to induce the expression of the IRF2BP2 gene. Therefore 
we analyzed RNA isolated from the p73a-expressing Saos cells, which had been treated with 
Act.D. Although p73a can bind the same site as p53, induction of p73a does not lead to an 
elevated expression of IRF2BP2 mRNA (Fig. 2D), while known target genes like GADD45 or 
Mdm2 are upregulated after p73a-induction (data not shown).
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A. ChlP-on-chip profile from U2OS cells expressing p53. A region on chromosome 1 including the IRF2BP2 gene is 
visualized using Signalmap (Nimblegen Systems Inc.). Cells were treated with 5 nM Act.D for 24 hr prio r to chroma 
tin isolation and ChIP w ith anti-p53 antibody. In the upper track the log2 ra tio o f  p53 ChIP material over input 
signal is shown. Every bar represents one probe on the array. The lower track displays the location o f the IRF 
2BP2 gene including a schematic representation o f p53-motifs identified by the p53MH algorithm  in
the vicinity o f  the IRF2BP2 gene. Also shown are their locations relative to the IRF2BP2 gene. M o tif 4 corresponds 
to  the p53 binding site previously identified by ChIP-on-chip.
B. Binding o f endogenous p53 in U2OS cells to the putative p53-binding motifs. Cells were treated w ith 5 nM Act.D 
fo r 24 hr or le ft untreated prio r to chromatin isolation. Targeted ChIP was performed with primers for M dm2 and 
fo r sequences spanning the predicted motifs. Shown is the enrichment in fo ld over the negative control (myoglo 
bin). Error bars represent the standard deviation o f three independent experiments.
C. Saos cells expressing p73a were induced w ith Doxycyclin for 24 hr prio r to treatment w ith 5 nM Act.D for 
another 24 hr before chromatin was isolated. Targeted ChIP was performed using an anti-p73 antibody. Extent 
o f binding o f p73a was determined by real-time PCR w ith primers used in Fig. 1B. Error bars
represent the standard deviation o f  three independent experiments.
D. U2OS cells were treated w ith 1 nM Doxorubicin for 24 hr, before chromatin was isolated. Targeted ChIP was done 
as in Fig.IB.
E. EMSA shows specific binding o f  p53 to the DNA-sequence containing m o tif 4. Labeled oligonucleotides span 
ning either the p53-binding site in the p21-promoter or DNA-sequences o f the IRF2BP2 surrounding regions con 
ta in ing the motifs 1-4 were incubated w ith in vitro translated p53. In a ll lanes except lane 1 p53-antibody
was added to  induce a supershift o f  the protein-DNA complexes. An unlabeled oligo containing the wild-type or 
a m utan t p53-binding site o f the p21-promoter was used as a com petitor to show specificity o f  binding.
F. The m o tif 4 containing p53-binding site can function as an enhancer. Saos cells were transfected with a luciferase- 
construct containing either the wildtype or a m utan t DNA sequence derived from m o tif 4, alone or together with 
p53. Shown is the fo ld  activation o f  the IRF2BP2 luciferase construct over the vector alone. Error bars represent 
the standard deviation o f three independent experiments.
Fig. 1. Identification o f a p53-binding site upstream of the IRF2BP2 gene
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Because expression levels of a certain mRNA species may vary between several cell types 
we analyzed more cell lines for their expression of IRF2BP2 upon stress treatment: synovial 
sarcoma cell line Syo-1 and NCI-H460 cells derived from a lung adeno-carcinoma, both 
containing wild-type p53 and a breast carcinoma cell line, MDA-MB231 without functio­
nal p53. The expression of IRF2BP2 was analyzed under the same conditions as used be­
fore (Fig. 2E). The induction of IRF2BP2 mRNA in the Syo-1 and NCI-H460 cell lines was 
comparable to the one observed in U2OS cells. Strikingly, in MDA-MB231 cells the level 
of IRF2BP2 mRNA did not increase upon Act.D treatment and those cells do not contain 
functional p53. Thus, it appears that the expression change of IRF2BP2 mRNA upon Act.D 
treatment seems to depend on the activation of functional p53 in several different tumor 
cell lines.
4.3.3. IRF2BP2 can influence the transactivation function of p53
Recently the IRF2BP2 related protein IRF2BP1 was identified as an ubiquitin ligase (Kimura 
2008). Since IRF2BP2 shares the C3H4 RING finger with IRF2BP1, which mediates the trans­
fer of ubiquitin molecules and since p53 is regulated through ubiquitination (Horn and 
Vousden 2007), we decided to test whether IRF2BP2 could influence the protein stability 
of p53 by transfecting U2OS cells with p53 and increasing amounts of IRF2BP2 or vice
Fig. 2.: Upregulation of IRF2BP2 after p53 induction
A. Induction o f p53 in U2OS wild-type or p53 knockdown cells. Cells were treated w ith 5 nM Act.D for 24 hr, before 
whole cell extracts were prepared and protein levels o f  p53 and tubulin as loading control were determined.
B. Expression changes in U2OS wild-type and p53 knockdown cells after treatment w ith 5 nM Act.D for 24 hr, 
compared to  untreated cells. Whole RNA was extracted and quantita tive RT-PCR was performed, w ith primers 
fo r IRF2BP2 and Bax. Upregulation is shown after normalization against GAPDH and calculated over the untrea 
ted control. Error bars represent the standard deviation o f  three independent experiments.
C. Kinetics o f expression changes o f IRF2BP2 and IRF2 upon Act.D treatment. U2OS cells were treated for the 
indicated time points w ith 5 nM Act.D before whole RNA was isolated, followed by quantitative RT-PCR for 
IRF2BP2 and IRF2 expression. Error bars result from tw o independent experiments.
D. Induction o f target genes by p73a in Saos t.o. cells induced for 24 h r and treated with 5 nM Act.D for another 24 
hr prio r to RNA isolation. Error bars represent the standard deviation o f  three independent experiments.
E. Human cell lines containing wild-type p53 (Syo1, NCI-H460) or no functiona lp53 (MDA-MB231) were treated 
with 5 nM Act.D for 24 hr. Changes in the levels o f  IRF2BP2 mRNA are shown after normalization to  GAPDH and  
calculated against untreated controls. Error bars result from tw o independent experiments.
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versa (Fig. 3A). We could not detect that IRF2BP2 renders the levels of cotransfected p53 
nor that p53 could change the protein levels of transfected IRF2BP2. To unravel the func­
tional consequence of the IRF2BP2 upregulation, we investigated whether IRF2BP2 could 
have an influence on the transactivation of p53-dependent promoters, which would be 
comparable to its described function as a transcriptional corepressor of IRF2 (Childs and 
Goodbourn 2003). Therefore we transfected U2OS or Saos cells with p53 and IRF2BP2 
expression constructs together with different luciferase reporter constructs containing 
known target gene sequences. Neither p53 nor IRF2BP2 have an effect on the basic pGL3- 
luciferase construct (pGL3-luc), which does not contain a p53-response element (data not 
shown). The cotransfection of p53 together with a Bax-luciferase construct (Bax-luc) leads 
to a 150 times higher luciferase activity of the Bax-luc construct than the transfection of 
the reporter construct alone (Fig. 3B). Very interestingly, the IRF2BP2 overexpression alone 
has no effect on the transactivation of the Bax-luc construct, but upon cotransfection of 
p53 and IRF2BP2, we could observe an inhibition of the p53-mediated activity of Bax-luc 
up to 75% (Fig. 3B). To test whether this effect was dose-dependent we increased the 
amounts of transfected p53 from 200 ng to 2000 ng, while holding the IRF2BP2 levels 
equal. At the highest amount of cotransfected p53, the luciferase level is restored to the 
level reached with p53 alone (Fig. 3C). To test whether the inhibition mediated by IRF2BP2
Fig. 3.: IRF2BP2 is able to influence the transactivation of p53-responsive promoters
A. Neitherp53 nor IRF2BP2 have an influence on each other's protein stability. U2OS cells were transfected either 
with p53 and increasing amounts o f IRF2BP2 or vice versa and 24 hr later the indicated proteins were detected 
by Western Blot. GFP staining was used to ensure equal transfection efficiency.
B. IRF2BP2 can impede on the p53-transactivation o f  Bax-luc. A luciferase reporter construct containing the Bax- 
prom oter was transfected in to  U2OS cells together w ith p53, IRF2BP2 or an em pty vector, as indicated. Luciferse 
activity was normalized to Renilla. Error bars represent the standard deviation o f  three independent exper 
ments.
C. Higher p53 levels can reverse the effect o f IRF2BP2 on Bax-luc. Increasing amounts o f  p53-plasmid were trans 
fected, ranging from 200 ng to 2000 ng, together w ith Bax-luc and 2000 ng o f  IRF2BP2 where indicated.
D. IRF2BP2 can impede on the p53-transactivation o f  p21-luc. Saos cells were transfected with a luciferase-const 
ruct containing the p21-promoter together w ith p53, IRF2BP2 or em pty vector where indicated.
E. The high-affin ity site o f p53 is no t required for IRF2BP2 function. Saos cells were transfected w ith p53, IRF2BP2 or 
em pty vector where indicated together w ith a luciferase-construct containing the p21-promoter lacking
the high a ffin ity  binding site for p53.
F. Overexpressed IRF2BP2 can influence the expression o f p21. U2OS cells were either tranfected with empty vector 
or IRF2BP2. Cells were treated w ith 5 nM Act.D for 24 h r before RNA was isolated and mRNA o f p21 was ana 
lysed by PCR. Error bars represent the standard deviation o f  three independent experiments. The asterisk 
indicates statistical significance shown by Student's T-Test (p < 0,05) compared to control transfection.
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was specific for the Bax-luc construct, we also tested a p21-luciferase construct (p21-luc) in 
cotransfections with p53 and IRF2BP2. Also with the p21-luc construct we observed that 
the p53-mediated transactivation was impeded by the cotransfection of IRF2BP2 (Fig. 3D). 
We also tested a p21-luciferase construct in which the distal, high affinity binding site of 
p53 in the p21 promoter was deleted, p21-luc delta p53 (Tu et al. 2007). As expected, the 
p53-transactivation of this deletion construct was reduced to less than 50% of the activity 
of the wild-type construct, although a certain luciferase activity was still seen probably 
due to the low-affinity binding site of p53 present in the p21-promoter (Fig. 3E). Interes­
tingly, IRF2BP2 coexpression was able to reduce also the p53-mediated transactivation of 
this deletion luciferase construct. Thus, the effect of IRF2BP2 on the transactivation acti­
vity of p53 does not seem to be dependent exclusively on the high-affinity binding site 
of the p21 promoter. To analyze the effect of IRF2BP2 on the expression of endogenous 
genes regulated by p53, we transfected cells with IRF2BP2 and subsequently treated them 
with Act.D before changes in the mRNA-levels were analyzed. We found a slight, but signi­
ficant downregulation of p21-mRNA in IRF2BP2 transfected cells compared to the control 
cells. Thus, IRF2BP2 seems to have a repressing effect on the transactivation function of 
p53 towards its target genes and this repression can be overcome by increasing the pro­
tein levels of p53, without rendering the protein stability of p53.
4.3.4. Overexpression of IRF2BP2 influences the induction of apoptosis after 
genotoxic stress
Since IRF2BP2 was described as a binding partner of IRF2, which is involved in the positive 
regulation of the cell cycle, we wanted to examine a possible role of IRF2BP2 during cell 
cycle regulation, especially upon chemotherapeutic treatment, since we had found IRF- 
2BP2 to be upregulated during the p53-response to Act.D. Two major response pathways 
mediated by p53 after genotoxic insults are growth arrest and apoptosis. To stimulate the­
se responses we treated U2OS cells transfected with IRF2BP2 either with 2.5 nM Act.D or 1 
nM Doxorubicin, for 12 to 24 hr to induce growth arrest or apoptosis, respectively. The ef­
ficiency of tranfection was monitored by GFP, to ensure that at least 60% of the cells were 
transfected. To discriminate between the different phases of the cell cycle BrdU staining 
was performed. In untreated IRF2BP2 transfected cells, a slight but significant increase in 
the S-phase population (48% in IRF2BP2 transfected cells versus 41% in the control cells) 
and a decrease of cells in the population in G2-phase (26% in IRF2BP2 transfected cells 
versus 31% in the control cells) can be observed compared to the control cells transfected 
with empty vector DNA only (Fig. 4A). Upon Act.D treatment we observed a slight increase 
of S-phase in the control cells (from 41% to 47%), whereas IRF2BP2 transfected cells show 
a statistical significant decrease in S-phase (from 47% to 39%) (Fig. 4B). Furthermore, the
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G1-population of the control cells was reduced from 23% to 16%, which was not seen in 
the IRF2BP2 transfected cells. On the other hand we observed an increase in the G2-phase 
of Act.D treated, IRF2BP2 transfected cells (from 26% to 35%). The treatment of cells with 
Doxorubicin for 18 hr or 24 hr induces several changes in the cell cycle distribution, wit­
hout significant differences between the IRF2BP2- and the control transfected cells (Fig. 
4C,D). However, Doxorubicin leads after 18 hr to a strong increase in the G2-phase in both 
transfected cell populations, up to 50%, whereas the populations of G1- and S-phase cells 
decrease. This is reversed after 24 hr of treatment with Doxorubicin, the amounts of cells 
in each phase of the cell cycle vary now between 20-30%.
Finally, we examined the induction of apoptosis after treatment in cells transfected with 
IRF2BP2 compared to cells transfected with empty vector only. After transfection and 
treatment PI-staining was performed and the Sub-G1 population was determined (Fig 
4E). Upon treatment with Act.D the levels of apoptosis do not increase compared to un­
treated cells, although the Sub-G1 population in the IRF2BP2 transfected cells is signifi­
cantly smaller compared to the control transfection (4% in IRF2BP2 transfection; 7% in 
the control cells). The treatment with Doxorubicin induces apoptosis already after 18 hr, 
which increases even more after 24 hr. This occurs mainly in the cells transfected with 
empty vector to a total of 14% after 24 hr of treatment. In IRF2BP2 transfected cells the 
population of apoptotic cells is significantly smaller, even after 24 hr less than 9% of the 
cells undergo programmed cell death.
From this we concluded, that IRF2BP2 can induce some changes in the cell cycle of li­
ving cells, mainly it changes the S-phase population, which increases in untreated and 
decreases in Act.D treated cells, compared to control transfections. Interestingly, IRF2BP2 
appears to impede or diminish the induction of cell death after apoptotic stimulation.
4.3.5. More rapid apoptosis after chemotherapeutic treatment in IRF2BP2 
knockdown cells
To investigate the function of IRF2BP2 during cell cycle under more physiological condi­
tions, we downregulated the endogenous levels of IRF2BP2 by introducing siRNAs against 
three different regions of the IRF2BP2 mRNA. We monitored the efficiency of the knock­
down by analyzing the transcript levels of IRF2BP2 in U2OS cells 24 hr after treatment 
with 5 nM Act.D and observed a significant reduction of IRF2BP2 expression, especially 
after Act.D treatment compared to the cells transfected with non-targeting siRNAs (Fig. 
5A). Furthermore we analyzed the knockdown efficiency by Western blotting. Due to the 
lack of a specific IRF2BP2 antibody we transfected FLAG-IRF2BP2 into the knockdown and
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A. Cell cycle analysis o f  U2OS cells transfected either w ith an em pty vector or w ith an IRF2BP2-expression const 
ruct. Transfection efficiency was m onitored by GFP and BrdU-staining was performed for analysis.
The transfected cells were left untreated prio r to harvest.
B. A fter transfection the cells were treated w ith 2.5 nM Act.D for 12 hr prio r to  cell cycle analysis.
C. Treatment o f the transfected cells w ith 1 nM o f Doxorubicin for 18 hr.
D. Treatment o f the transfected cells w ith 1 nM o f Doxorubicin for 24 hr.
E. Determ ination o f  levels o f  apoptosis after transfection o f cells w ith IRF2BP2 or em pty vector. Sub-G1 population  
was measured after treatment o f cells by propidium iodide staining. A ll standard deviations result from
three biolo-gical replicas, each performed in duplicate. Statistical significance was determined by Student's 
T-Test (*: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.0005).
Fig. 4.: Cell cycle changes after overexpression of IRF2BP2
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the control cells. Fig. 5A shows that the knockdown of the transfected protein is under 
these circumstances almost complete. Equal levels of transfection were monitored by GFP 
cotransfection.
First, we analyzed whether the p21 and Mdm2 expression levels were influenced by the 
knockdown of IRF2BP2. We observed a small, but reproducible and significant increase of 
p21 expression levels upon Act.D treatment in the IRF2BP2 knockdown cells in compari­
son to the control cells. The Mdm2 expression level, on the other hand, stays the same in 
IRF2BP2 knockdown as well as the control cells (Fig. 5B). To test the possibility that IRF- 
2BP2 influences protein stability of p53 itself in a feedback-loop comparable to the one of 
Mdm2, we analyzed whether the protein levels of p53 and p21 were affected in the IRF- 
2BP2 knockdown cells (Fig. 5B). In untreated cells very low levels of p53 and p21 are pre­
sent, without any difference between the IRF2BP2 knockdown and the control cells. After
Fig. 5.: Knockdown of IRF2BP2 renders cells sensitive to chemotherapeutic stress
A. Knockdown o f IRF2BP2 in U2OS cells using lentiviral vectors or ON-TARGETplus oligo siRNAs. Efficiency o f  the 
knockdown was monitored by analyzing the transcript-levels o f IRF2BP2 relative to GAPDH and by transient 
retransfection o f500 ng FLAG-IRF2BP2 followed by Western b lo tting w ith anti-FLAG antibody. GFP-staining 
was used to m onitor transfection efficiency. Standard deviation was derived from three biological replicas. 
Asterisk indicates statistical significance shown by Student's T-Test (p < 0,05) compared to non-targeting siRNA.
B. Expression analysis showing the induction o f  p21 andM dm 2 mRNA in the control and the IRF2BP2 knockdown 
cells after treatment w ith 5 nM Act.D for 24 hr. Standard deviation was derived from three independent experi 
ments. Asterisk indicates statistical significance shown by Student's T-Test (p < 0,05) compared to non­
targeting siRNA. Western Blot showing the levels o f  p53 and p21 in the IRF2BP2 knockdown and the control 
siRNA cells. TBP was used as a loading control. Whole cell extracts o f the IRF2BP2 knockdown and the control 
cell line were prepared after treatm ent w ith either Act.D and 15 ^ g  o f protein from each sample were used for 
Western b lo t and stained against the indicated proteins.
C. Activation o f Caspase 3 after chemotherapeutic treatment. IRF2BP2 knockdown or control cells were treated for 
the indicated times with 5 nM Act.D (left panel) or w ith 1 nM Doxorubicin (right panel) before Caspase 3 levels 
were analysed. Tubulin was used as loading control.
D. Quantification o f  apoptosis determined by FACS analysis o f  the control (left) and the IRF2BP2 knockdown (right) 
cells. Cells were treated for the indicated times w ith 5 nM Act.D prio r to harvest and propidium iodide staining 
fo r FACS. Apoptotic Sub-G1 population is shown as percentage o f a ll cells. Standard deviation was derived from  
three independent experiments. Asterisks indicate statistical significance shown by Student's T-Test (p < 0,05) 
compared to  the non-targeting siRNA.
E. Quantification o f  apoptosis after treatment w ith 1 nM Doxorubicin. A fter the indicated time points IRF2BP2 
knockdown and control cells were harvested and propidium iodide staining was performed. Apoptotic  
Sub-G1 population is shown as percentage o f a ll cells. Standard deviation was derived from three independent 
experiments. Asterisks indicate statistical significance shown by Student's T-Test (p < 0,05) compared to the non­
targeting siRNA.
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treatment with Act.D, p53 and also p21 accumulates. While p53 levels seem to be very 
similar in the knockdown and the control cells, we observed slightly higher p21 protein 
levels in the IRF2BP2 knockdown cells upon Act.D treatment. Thus, IRF2BP2 knockdown 
most likely does not change the stability of p53 or Mdm2, but slightly increases the levels 
of p21 mRNA and protein.
Since overexpressed IRF2BP2 had an influence on the cell cycle, we also examined the ef­
fect of IRF2BP2 knockdown followed by stress treatment on the cells. Using BrdU staining 
we wanted to detect differences in the cell cycle between control and IRFBP2 knockdown 
cells, but we could not observe any significant changes in the distribution of cells in G1- 
/S- or G2-phase (data not shown). Very interestingly we found again significant differences 
in the induction of apoptosis (Fig. 5C). Control and IRF2BP2 knockdown cells were treated 
either with 5 nM Act.D or with 1 nM Doxorubicin for the indicated time points, before 
the activation of Caspase 3 was analyzed. After both treatments the cells containing the 
IRF2BP2 knockdown show higher levels of active Caspase 3 already after 24 hr. To quantify 
this effect we measured the Sub-G1 population by FACS after propidium iodide staining. 
Under unstressed conditions the IRF2BP2 knockdown and the control siRNA transfection 
show similar levels of spontaneous apoptosis (Fig. 5D). After the induction of a stress re­
sponse, mediated through 5 nM Act.D, the knockdown of IRF2BP2 leads to a slight accu­
mulation of apoptotic cells after 24 hr, this population increases after 48 hr in total almost 
fourfold compared to the untreated cells. The respective increase of the apoptotic popu­
lation in the control cells is significantly smaller upon Act.D treatment. When treated with
1 nM Doxorubicin for 24 hr IRF2BP2 knockdown cells already display twice the amount 
of apoptotic cells compared to the control (Fig. 5E). After 48 hr of treatment with Do­
xorubicin the control and the knockdown cells accumulate high levels of apoptotic cells, 
with the amount of apoptotic cells being 10% higher in the IRF2BP2 knockdown cells. Our 
interesting observation that the IRF2BP2 knockdown cells are more sensitive to chemo­
therapeutic treatment and undergo apoptosis more rapidly hints at a role of endogenous 
IRF2BP2 in the inhibition of cell death.
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In this study we identified the transcriptional coregulator IRF2BP2 as a new, direct target 
gene of p53. The binding site we found was bound in vivo and in v itro by p53 and it had 
transactivating potential. We showed that IRF2BP2 participates in the genotoxic response 
mediated by p53, influencing the stress-response pathways of the cells. We observed an 
upregulation of IRF2BP2 mRNA after treatment with Act.D in different cell systems contai­
ning functional p53, but not in cells without functional p53.
Analyzing the function of IRF2BP2 after its overexpression as well as its knockdown, we 
found that it influences the cellular response after genotoxic insults. Its overexpression 
without stress treatment seems to slightly increase the population of cells in S-phase. This 
might be due to an IRF2BP2-mediated stabilization of IRF2 containing complexes at pro­
moters like the one for the histone H4-gene (Vaughan et al. 1995). This gene is regulated 
during cell cycle with a peak in transcription during early S-phase (Vaughan et al. 1995; 
Vaughan et al. 1998). When U2OS cells are exposed to Doxorubicin, the overexpression 
of IRF2BP2 seems to delay the induction of apoptosis. On the other hand cells overex­
pressing IRF2BP2 display an reduced S-phase population after low doses of Act.D. In line 
with this, the knockdown of IRF2BP2 leads to increasing amounts of apoptotic cells after 
Doxorubicin treatment and also after treatment with Act.D, which normally causes rather 
growth arrest. This points towards an important function of IRF2BP2 in the decision bet­
ween cellular survival and programmed cell death. From this data the question rises for 
which purpose p53 induces IRF2BP2, a factor that appears to delay or diminish apoptosis. 
Here we suggest a role for IRF2BP2 in maintaining a cell growth arrest state, which might 
allow the cells to repair damaged DNA.
After the identification of IRF2BP2 as an interaction partner of IRF2, it had been specula­
ted that they act together to inhibit the tumor suppressor function of IRF1 by impeding 
on the IRF1 mediated induction of p21 (Coccia et al. 1999). Our IRF2PB2 knockdown data 
seem to support this model: We observe a slight upregulation of p21 expression and more 
apoptosis after chemotherapeutic treatments in IRF2BP2 knockdown cells. These obser­
vations are very similar to the effect of the IRF2 knockdown cells in which the p21 expres­
sion is also upregulated and more spontaneous apoptosis is found (Wang et al. 2007). 
Thus, while physiological levels of IRF2 can upregulate the anti-apoptotic Bcl-2 (Wang et 
al. 2007), the knockdowns of IRF2 as well as the knockdown of IRF2BP2 seem to have a 
pro-apoptotic effect.
According to a current model of the p53-response, low doses of cellular stress that occur 
more frequently do not lead to apoptosis although they activate p53. Higher doses of
4.4. Discussion
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stress can damage the cell irreversibly, leading to apoptotic cell death (Vousden and Lu 
2002). Both pathways seem to be influenced by groups of cofactors, driving the cellular 
outcome towards one or the other decision depending on the kind and extent of geno- 
toxic stress. The induction of growth arrest requires other cofactors than the apoptotic 
pathway, and some of them are transcriptional targets of p53, thereby forming feedback 
loops and regulating the outcome of p53-activation. An important factor is the zinc-finger 
containing protein Hzf, which is found in a transcriptional complex with p53 and can tar­
get this complex preferentially to promoters of genes involved in growth arrest, but not in 
apoptosis (Das et al. 2007). Since the induction of growth arrest should allow DNA-repair 
and eventually cell survival, it also requires a temporary inhibition of apoptotic induction. 
Thus, notably, other target genes of p53 are involved in the inhibition of apoptosis, like 
the transcriptional repressor SLUG that can repress the expression of puma, a BH3-only 
protein, which is a key mediator of apoptosis in hematopoietic progenitor cells (Wu et al. 
2005).
We found here that IRF2BP2 might function in a comparable way, since it was able to inhi­
bit p53-mediated p21- and Bax-luc transactivation, but this inhibition of Bax-luc transac­
tivation could be overcome if higher levels of p53 were present. A similar mechanism has 
also been described for Hzf, where after prolonged p53-activation, Hzf is degraded and 
p53-activity is rendered towards pro-apoptotic genes (Das et al. 2007). This could happen 
for example upon higher doses of stress leading to an accumulation of p53, thereby pas­
sing a certain apoptotic threshold followed by the induction of programmed cell death 
(Vousden 2006).
Since we could not detect a direct interaction between p53 and IRF2BP2 (data not shown) 
it is possible that the regulation of p53 target genes by IRF2BP2 is mediated through IRF2 
to which the transcriptional factor IRF2BP2 binds. We observed a downregulation of IRF2 
around twofold after 6 hr of Act.D treatment. IRF2 is an antagonist of the growth sup­
pressor IRF1, which is involved in the induction of p21 (Tanaka et al. 1996) and the ratio 
of IRF2:IRF1 is believed to be an important determinant in the regulation of cell growth 
(Harada et al. 1998). Besides the activation of H4-transcription (Vaughan et al. 1995), IRF2 
is able to stimulate the transcription of different regulatory subunits of checkpoint kina­
ses, like cyclin D1 or cyclin B1 and it was also shown to upregulate the anti-apoptotic 
Bcl-2 protein, displaying features of a proto-oncogene (Xie et al. 2002; Wang et al. 2007). 
Furthermore high levels of IRF2 keep IRF1 from entering the nucleus (Wang et al. 2007). 
The concerted regulation of IRF2 and IRF2BP2 might display a mode of dual action of p53 
through the upregulation of IRF2BP2 on the one hand and the downregulation of IRF2 on 
the other hand. Thereby the balance between growth stimulating and inhibiting activities
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of the IRF1:IRF2-ratio could be rendered (Harada et al. 1993) and growth arrest pathways 
could be positively influenced.
It has been reported, that both IRF1 and IRF2 directly activate or repress target genes. 
The binding element both proteins compete for is known as PRDI/CCE (Vaughan et al. 
1995; Huang et al. 2007) or ISRE (Childs and Goodbourn 2003) and this element has been 
implicated to have activating as well as repressing functions. We found several copies of 
it in the here used luciferase constructs by Match-analysis using the Transfac-database 
(Transfac professional 11.1). Furthermore, Coccia et al. verified one out of five putative 
ISRE-elements 1.2 kb upstream of the p21 transcriptional start site as a true binding site 
for IRF1/2 (Coccia et al. 1999). Surprisingly the motif in the p21 promoter found by Coccia 
et al. (Coccia et al. 1999) seems to be dispensable for the IRF1 mediated enhancement 
of p21 activation by p53, since this enhancement was shown to be the result of an inter­
action of IRF1 with p300 leading to increased p53 acetylation and higher transcriptional 
activity towards p21 (Dornan et al. 2004). Interestingly the domain of p300 interacting 
with IRF1 maps in the same region as the interacting domains of JMY and p300, may­
be leading to an mutual exclusive activation of either pro-apoptotic or pro-growth arrest 
target genes (Shikama et al. 1999; Dornan et al. 2004). A further possible mechanism of 
repression of p53-target genes might involve the PU.1 protein. This transcriptional cofac­
tor reduces the transcriptional activity of p53 and it directly interacts with IRF2 (Huang 
et al. 2007; Tschan et al. 2008). Besides a high degree of homology in their DNA binding 
domain, the C-terminus of IRF2 is unique compared to IRF1 and it can recruit IRF2BP2 to 
DNA, thereby mediating transcriptional repression towards artificial promoter constructs 
(Childs and Goodbourn 2003). Nonetheless, the exact circumstances leading to activation 
or repression through IRF1 or IRF2 are still unclear. Thus, the IRF2BP2-induction by p53 
could be the direct link between the p53 pathways upon cellular stress and the for the cell 
cycle progression so important balance between the IRF1- and IRF2-activities.
Thus, the here observed induction of IRF2BP2 expression after p53-activation appears to 
play an interesting role to influence the cellular stress response. As a possible mechanism 
we propose that IRF2BP2 modulates p53 transcriptional activity, by decreasing the p53- 
mediated p21- and Bax-transactivation until the p53-levels increase and the IRF2BP2-me- 
diated repression is reversed. Our findings suggests that IRF2BP2 might be part of a new 
feedback-loop for the cells after p53-activation, increasing the threshold for induction of 
apoptosis, but also inhibiting the progression of cell cycle, possibly to allow repair of da­
maged DNA.
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4.5.1. Cell culture conditions
The human osteosarcoma cell line U2OS expressing wild-type p53, the human osteosar­
coma Saos-2 cell lines, the human embryonic kidney cell line HEK 293T, the synovial sar­
coma Syo-1, the lung adeno-carcinoma NCI-H460 and the breast carcinoma MDA-MB231 
cells were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal 
calf serum at 37°C. The Tet-on inducible expression system (BD Biosciences) was used to 
generate a cell line that conditionally express TAp73a in Saos-2 cells as described previ­
ously (Smeenk et al. 2008). To generate p53 knockdown cells following oligos were cloned 
into a pSuper-vector, which was transfected into U2OS cells: pSuperp53-s 5'-gatccccgactc- 
cagtggtaatctacttcaagagagtagattaccactggagtctttttggaaa-3' and pSuperp53-as 5'-agcttttc- 
caaaaagactccagtggtaatctactctcttgaagtagattaccactggagtcggg-3'. Transfections were 
performed using the calcium phosphate precipitation method (BES). Stable clones were 
selected with 1 ^g/ml puromycin (Sigma).
The U2OS cells were treated for ChIP-experiments and expression-analysis, the Syo-1, NCI- 
H460 and MDA-MB231 cells for expression analysis with 5 nM Act.D (Sigma) for 24 hours. 
For FACS-analysis U2OS cells were treated either with 2.5 nM Act.D for 12 hours, or with 1 
nM Doxorubicin (Sigma) for 18 or 24 hours. IRF2BP2 knockdown cells were treated for 24 
or 48 hours either with 5 nM Act.D or with 1 nM, Doxorubicin, respectively. The inducible 
Saos-2 cell line was first induced with doxycyclin (Sigma) for 24 hours and then additio­
nally also treated with 5 nM Act.D for another 24 hours.
4.5.2. Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) was basically done as described by Denissov 
et al. (Denissov et al. 2007). Briefly, cells were crosslinked for 30 minutes in 1% formal­
dehyde at room temperature. Crosslinking was stopped by adding 125 mM glycine. The 
cells were washed three times, resuspended in lysis buffer and sonicated using a Biorup- 
tor sonicator (Diagenode) for 15 minutes at high power, 30 seconds ON, 30 seconds OFF. 
Antibody incubation of chromatin was performed overnight at 4°C in incubation buffer 
supplemented with 0.1% BSA with protein A/G-Sepharose beads (Santa Cruz) and 1 ^g of 
antibody. For U2OS cells, DO1 antibody (BD PharMingen) was used to immunoprecipitate 
p53. For ChIP experiments in the Saos-2 inducible cell line, BL906 (Abcam) was used for 
p73a, respectively. Beads were washed sequentially with four different washbuffers at 4°C. 
Precipitated chromatin was eluted from the beads in 1% SDS and 0.1 M NaHCO3 at room 
temperature for 20 minutes. Protein-DNA crosslinks were reversed at 65°C for 4 hours in 
the presence of 0.2 M NaCl, after which DNA was isolated by phenol-chloroform extrac­
tion and ethanol precipitated with 10 ^g of glycogen. Real-time PCR was performed using
4.5. Material and methods
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the SYBR Green mix (Biorad) with the MyIQ machine (Biorad). Primers used for real-time 
PCR are available upon request. Enrichment of the chromatin-immunoprecipitated mate­
rial was calculated as recovery over an unspecific control (myoglobin exon 2).
4.5.3. Electrophoretic Mobility Shift Assay (EMSA)
TnT T7 Quick Coupled Transcription/ Translation System (Promega) was used for in vitro ex­
pression of p53 starting with 500 ng of pcDNA3-p53. 3 ng of radioactively labeled oligonuc­
leotides derived from the motifs 1-4 or the p53-binding motif of the p21-promoter were in­
cubated with IVT p53 and 1 nL of p53 antibody (pAb421; CalBiochem). 150 ng of unlabeled 
wildtype or mutant p21-oligonucleotid was used as competitor where indicated.
4.5.4. RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini Kit according to protocol (Qiagen). For cDNA 
synthesis retrotranscription was performed using 1 ng of RNA with oligo dT anchor primers, 
dNTPS, DTT, buffer and Superscript Retrotranscriptase (Invitrogen). The cDNA was analyzed 
by real-time PCR using a MyIQ machine (Biorad). Primers used for real-time PCR are available 
upon request. After quantitative PCR the obtained values were normalized to GAPDH and 
induction of target genes was calculated against the untreated control cells.
4.5.5. Construction and transfections of plasmids
Full length cDNA of IRF2BP2A was subcloned from pEF.IRF-2BP2A, a kind gift of S. Good- 
bourn into pcDNA3.1-FLAG using BamHI and XhoI.
The IRF2BP2-luciferase construct was made by PCR amplification of a 500 bp region out of 
genomic DNA from U2OS cells using the primers 5'-ggagtcaccgtatactttacttttca-3'and 5'- ttt- 
tgaagcctctgacttcg-3' linked to attachment sites of the Gateway Clonase system (Promega). 
The binding site was subcloned into a promoter-containing pGL3-vector by using Gateway 
clonase. The mutation of the central p53-binding motif was introduced into the Gateway 
entry clone using the Quickchange Kit (Stratagene).
U2OS and Saos cells were transiently transfected using the calcium phosphate precipitation 
method (BES).
4.5.6. Transactivation assays
Saos and U2OS cells were transiently cotransfected with 500 ng p53-responsive luciferase 
reporter constructs containing either a sequence derived from the identified p53-binding
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site upstream of the IRF2BP2 gene, a p21- (a gift of Y. Tu) or a Bax-promoter (a gift of M. 
Oren), 50 ng pRL-TK Renilla reporter (Promega), 2 ng pcDNA3.1FLAG-IRF2BP2, 200 ng 
pcDNA3.1FLAG-p53 (a gift of K.Vousden) by calcium phosphate transfection. Empty pcD- 
NA6 was used to equalize the amount of transfected cDNA. Cells were lysed and luciferase 
activity was measured using the Dual-Luciferase Reporter Assay System (Promega) accor­
ding to protocol.
4.5.7. Cell cycle analysis and quantification of apoptosis
Transfected and non-transfected cells treated as described above were prepared for ana­
lysis as follows: cells were grown in 10 nM BrdU for 1 hr, before fixation in ethanol. Cells 
were then stained with anti-BrdU-antibody (Dako) and propidium iodide (Sigma) for 30 
min at room temperature. DNA content was analyzed by flow cytometry (Becton Dickinson 
FACScan). The data was analyzed using CellQuest Pro software.
4.5.8. RNAi mediated knockdown of IRF2BP2
Stable knockdown of IRF2BP2 was mediated by lentiviral infection of the following oligos 
targeting mRNA sequences of IRF2BP2, which were cloned into the pLKO-vector, contai­
ning a puromycin resistance gene flanked by LTR's used for genomic integration: IRF2BP2 
si1- 5'-caacggcttctccaagctaga-3'; IRF2BP2 si2- 5'-gcagttgcaagaacagcaagg-3'; IRF2BP2 si3- 
5'-aactgcttgaattgtatatat-3'. pLKO-Luciferase si 5'-cgtacgcggaatacttcga-3' served as control.
1.8 ng of the single pLKO-si constructs, 1.8 ng packaging vector R8.91 and 300 ng VSV-G were 
transfected into HEK 293T cells to produce viral particles using Lipofectamin2000 (Invitro- 
gen). After 24 hours the supernatant was filtrated and then used to transduce target U2OS 
cells. The transduction was repeated after 24 hours. On day three the selection was started 
with 1 ng/ml puromycin (Sigma). Transient knockdown of IRF2BP2 was achieved by using 
Dharmacon ON-TARGETplus siRNAs, according to manufacturer's manual.
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4.8. Supplemental Material
TH E N O V E L P53 TA R G E T G E N E  IR F2B P 2 PARTIC IPATES IN C E LL S U R V IV A L D U R  
IN G  TH E  P53 S T R E S S  R E S P O N S E
p53 ChIP
motif 4 0-0,5 kb 0,5-1kb 1-1,5kb 1,5-2kb 2-2,5 kb 2,5-3kb 3-3,5 kb 3,5-4kb 4-4,5 kb 4,5-5 kl
Fig. S1
F igure  S1:
U 2 0 S  ce lls  w e re  trea ted  w ith  5 nM  A c t.D  fo r  24  h r p rio r to  ch rom atin  iso la tion  and C hIP  
aga ins t p53. Q uan tita tive  PC R  w a s  perfo rm ed w ith  p rim e rs  scann ing  a 5 k b  region 
upstream  o f th e  IR F2B P 2 gene. The m o tif 4 w a s  used as  a positive  con tro l. S D  resu lts  
from  tw o  in depend en t expe rim en ts
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5. The F-box protein Fbxo22 is a 
new p53 target gene that 
influences the Mdm2-p53 
feedback-loop
Max Koeppel, Kim-Vy Nguyen-Ngoc, Simon J. van Heeringen, Anna C. Navis, Leonie Sme- 
enk, Leonie Harwig and Marion Lohrum. Submitted.
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The p53 tumor suppressor is one of the crucial factors in maintaining genomic stability 
and preventing malignant transformation of eukaryotic cells and its deregulation is fre­
quently found in human cancers. Besides mutations in the p53 gene, p53-deregulation 
can also be due to malfunction of its antagonists, like the Mdm2 ubiquitin-ligase that tar­
gets p53 for proteasomal degradation. Mdm2 is transcriptionally induced by p53 forming 
a negative feedback-loop with p53. Here we describe another, new target gene of p53, 
Fbxo22, which we found to influence the p53-Mdm2 feedback-loop. Fbxo22 is an F-box 
protein and can be a component of the SCF multisubunit ubiquitin-ligase complex. We 
show that Fbxo22 expression can influence the levels of p53 and Mdm2 and that this func­
tion is independent of its F-box domain and therefore it might be also independent of the 
SCF complex. Since Fbxo22 can directly interact with Mdm2 and also renders its cellular 
localization, we suggest that Fbxo22 exerts its effect on p53 via a modulation of the Mdm2 
activity.
5.1. Abstract
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The tumor suppressor p53 is one of the main guards against cancer (Vousden and Lu 
2002). The precise regulation of p53 is crucial for cell survival and cellular growth. Many of 
its regulators are induced directly by p53 itself in negative feedback-loops, thereby decre­
asing its stability, inhibiting its transcriptional activity and rendering its subcellular locali­
zation. The main p53-regulator is the E3-ubiquitin ligase Mdm2 (Brooks and Gu 2006), but 
increasing groups of E3-ligases have been identified, modifying p53 function not only via 
ubiquitination, but also via sumoylation and neddylation (Hoeller et al. 2006).
The F-box proteins comprise a large protein family in plants and animals and are involved 
in non-proteolytic as well as proteolytic processes, the latter especially as part of the SCF 
(Skp-Cul-F-box) complex. SCF is one of the seven cullin-based E3-ubiquitin ligases that 
are a subfamily of RING-finger-type E3 ubiquitin ligases (Ho et al. 2008). The SCF complex 
is an E3-ubiquitin ligase complex essential for regulating the ordered progression and 
unidirectionality of the cell cycle by proteasomal processes in eukaryotic cells. The F-box 
proteins are responsible for recognizing the different substrates. In principle, the F-box 
proteins are divided into 3 categories based on their domain structure: F-box proteins a) 
with WD40 repeats (FBXW), b) with leucine-rich repeats (FBXL) or c) with other domains 
(FBXO) (Nakayama and Nakayama 2006).
Several F-box proteins are crucial for the control of proper cell proliferation, e.g. Skp2, 
Fbw7 and P-Trcp (Ho et al. 2006). Skp2 degrades the cyclin dependent kinase inhibitor 
protein p27, which is essential for the S-phase entry (Carrano et al. 1999; Sutterluty et al. 
1999; Tsvetkov et al. 1999). Through the degradation of p27 its binding partner CyclinE- 
Cdk2 becomes free and active. In addition, Skp2 can also degrade p21, p57 and p130 
(Nakayama and Nakayama 2006) and it also appears to be involved in the onset of mitosis, 
via Cdk1 (Nakayama et al. 2004). The F-box protein Fbw7, a direct transcriptional target of 
p53 (Kimura et al. 2003; Mao et al. 2004) plays also a crucial role in the regulation of the 
cell cycle at the G1-S phase transition. Fbw7 has been shown to degrade CyclinE, thereby 
preventing activation of the cyclin dependent kinase Cdk2 and negatively regulating cell 
growth (Koepp et al. 2001; Strohmaier et al. 2001). Skp2 and Fbw7 regulate the growth 
factor c-Myc. While Skp2 appears to stimulate the transactivation activity of c-Myc (Kim 
et al. 2003; von der Lehr et al. 2003), Fbw7 seems to mainly promote its degradation (Wel- 
cker et al. 2004; Yada et al. 2004). Another F-box protein, of which the precise regulation is 
important for proper development, is P-Trcp. Its deregulation, independent whether a full 
length or a truncated dominant negative form is overexpressed, induces cancer in mice
5.2. Introduction
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(Belaidouni et al. 2005).
SCF complexes do not only lead to the degradation of target proteins, they have also been 
reported to regulate their neddylation. The F-box protein Fbxo11 promotes the neddyla- 
tion of p53 at two lysine residues within its nuclear localization domain and thereby it 
inhibits the transactivation function of p53 (Abida et al. 2007). A similar inhibition of the 
function of p53 is mediated by the Cullin7 scaffold protein (Andrews et al. 2006; Jung et 
al. 2007), but no degradation of p53 was observed. Also some viral proteins use a cullin- 
containing complex to diminish p53-activity (Querido et al. 2001).
In a previous study we identified target genes of p53 in the human genome (Smeenk et 
al. 2008). Since we were interested in unraveling new regulatory feedback-loops of p53 
we focused here on genes, which we could link to processes involved in ubiquitination. 
We describe now the characterization of Fbxo22, a so far unknown component of the SCF 
complex. We verify that it is induced in a treatment- and p53-specific manner in several 
human cell lines. Expression of Fbxo22 influences the stability of p53 and through direct 
interaction with Mdm2 it leads to a relocalization of Mdm2 into the cytoplasm. We show 
that these functions of Fbxo22 do not depend on its F-box domain and that knockdown 
of Fbxo22 increases the levels of p53 and Mdm2.
5.3. Results
5.3.1. Verification of ubiquitin related target genes
In a previous study we identified target genes of p53 and p73a on a genome wide scale by 
chromatin-immunoprecipitation coupled to microarray analysis (ChIP-on-chip) (Smeenk 
et al. 2008). Since p53 is regulated through ubiquitination by negative feedback-loops, 
we analyzed all potential target genes for a link to ubiquitin processes, using the GO- 
annotation. We derived a group of 24 genes, which were shown to be bound in one or 
more ChIP-on-chip experiments and contained a p53 and/or a p73a-binding site within 
5 kb of the gene (Table 1). Four of these genes had a preferential binding site for p53; five 
other genes had one for p73a. The remaining 15 genes had a common binding site for 
both proteins. To verify binding of p53 and/or p73a respectively, we performed targeted 
ChIP analysis either in Act.D treated U2OS cells or in stably transfected Saos-2 cell lines 
expressing either p53 or p73a under the control of an inducible promoter (Figure 1A-C). 
In U2OS cells we can verify the binding of p53 to 10 genes with a 5-15 fold enrichment, 
whereas the supposedly p73a specific target genes are indeed not bound by p53 with an 
occupancy higher than 3 (Figure 1A). In the p53-inducible Saos-2 cell line 8 binding sites 
are bound by p53 with an occupancy higher than 3 (Figure 1B). Interestingly, RNF182 and 
RNF185, which were selected as target genes specifically for p73a and for p53 in U2OS
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cells, are not bound in the Saos-2 p53 cell line. Furthermore, p53 binding to preferential 
p73a binding sites does not occur. By far the strongest p53 binding in Saos-2 p53 cells is 
detected in the promoter region of the F-box gene Fbxo22 (Figure 1B). All the by ChIP-on- 
chip determined p73a specific binding sites are confirmed by targeted ChIP (Figure 1C), 
except the RNF165 binding site. Interestingly, p73a can also weakly bind to 2 sites prefe-
Table 1: Putative target genes related to ubiquitination
Gene Bound in ChIP-on-chip by Verified in targeted ChIP
1 MEX3B p53 and p73a yes
2 MID1 p53 and p73a no
3 ZNRF3 p53 and p73a yes
4 FBXW7 p53 and p73a yes
5 UCHL3 p53 and p73a no
6 UBE2G2 p53 and p73a yes
7 RNF185 p53 and p73a yes
8 RNF216 p53 and p73a no
9 ATG4A p53 and p73a no
10 PARK2 p53 and p73a no
11 IBRDC1/AL713649 p53 and p73a no
12 RNF182 p53 and p73a yes
13 TRIM36 p53 and p73a no
14 UBE2E2 p53 and p73a no
15 USP46 p53 and p73a no
16 MARCH10 p53 yes
17 MAT1 p53 yes
18 ATG10 p53 yes
19 Fbxo22 p53 yes
20 RNF220/PRNPIP p73a yes
21 UBE2U p73a yes
22 RFPL4B p73a yes
23 ZNRF1 p73a yes
24 RNF165 p73a no
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rentially bound by p53 in our ChIP-on-chip analysis, MARCH10 and Fbxo22.
Fbxo22 is a so far uncharacterized F-box protein and since it is highly bound by p53, 
transcriptional regulation of the Fbxo22 gene by p53 might occur. The ChIP-on-chip data 
showed several p53 binding sites and we validated binding to all sites in targeted ChIP 
(Overview in Figure 1D; left). The enrichment is highest in the binding site close to the 
promoter, comparable to the binding of p53 to the Mdm2 promoter (Figure 1D; right).
Thus, we can verify with targeted ChIP-experiments several new potential target genes 
for p53 and p73a, which might be involved in ubiquitination pathways and we show that 
some target genes are cell type specific.
5.3.2. p53 induces the expression of Fbxo22
In a next step we analyzed the functional consequences of p53 activation on mRNA ex­
pression of Fbxo22. Since an alternative transcriptional start site in exon 3 has been re­
ported (Strausberg et al. 2002), different Fbxo22-isoforms can exist, including one lacking 
the F-box domain (Figure 2A). Therefore we designed primers to test for the expression 
of different isoforms (Fbxo22F and Fbxo22A, respectively). After treatment of U2OS cells 
with Act.D we observe an increase of Fbxo22 mRNA levels (all putative isoforms, Fbxo22A)
Fig. 1.: Verification of ubiquitin related p53-target genes
A. Binding sites w ith in 5 kb o f 15 genes from U2OS, Saos-2 p53 and Saos-2 p73a cells identified by ChIP-on-chip 
(Smeenk et al. 2008) were selected for validation and grouped in to  3 binding categories: bound by p53 and 
p73a; p53 only; p73a only
B. U2OS cells were treated for 24 hr w ith 5 nM ActinomycinD (Act.D) prio r to isolation o f  chromatin. Complexes o f 
p53 and chromatin were precipitated w ith an anti-p53 antibody and qPCR analysis was performed with primers 
fo r the putative binding sites and enrichment is shown in fo ld over an unspecific control (myoglobin). Error bars 
are derived from a t least 2 independent experiments.
C. Saos-2 p53 inducible cells were induced for 24 hr to express p53, before chromatin was isolated. ChIP analysis 
was done as in A.
D. Saos-2 cells w ith inducible p73a were induced for 24 h r to express p73a, before chromatin was isolated. ChIP 
analysis was done as in A using an anti-p73 antibody.
E. A schematic overview o f  the Fbxo22-gene is shown on the left. The upper panel displays the whole gene; the 
lower track shows an enlarged region a t the 5'-end o f  the gene. The locations o f  the primers used in the ChIP 
experiments are indicated. Shown are targeted ChIP results from U2OS cells treated as in A. A fter p53 ChIP, 
binding was analyzed with primers for Mdm2 and the three regions o f the Fbxo22 gene. Enrichment was 
calculated as in A, error bars are derived from 3 biological replicas.
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to similar relative levels as Mdm2 (Figure 2B). On protein level we see an increase of the 
Fbxo22 protein levels upon Act.D and Etoposide (Eto.) treatment (Figure 2B; right), whe­
reas treatment with Doxorubicin (DoxR.) does not increase Fbxo22 protein levels in U2OS 
cells.
To show that the changes in mRNA and protein level of Fbxo22 are due to p53 activation, 
we used the isogenic HCT116 cell line, either as wildtype or as a p53 knockout offspring. 
Upon treatment with Act.D we observe an increase in the mRNA of Mdm2 and Fbxo22 
only in HCT116 wildtype cells, but not in the p53 knockout HCT116 cells (Figure 2C). On 
protein level, basal amounts of Fbxo22 are present in both cell lines as well as basal levels 
of the Mdm2-protein, but after treatment with Act.D a clear upregulation of both prote­
ins is seen only if p53 is present (Figure 2D, right). Therefore, we conclude that Fbxo22 is 
transcriptionally upregulated by p53.
5.3.3. Induction of Fbxo22 by p53 occurs in a time- and stress dependent manner
Furthermore, we set out to evaluate the kinetics and cell type specificity of Fbxo22 in­
duction. We treated U2OS and SYO-1 cells, both containing wild type p53, with Act.D or 
Etoposide (Eto.) and isolated RNA and proteins after several intervals between 0 and 24 hr. 
We analyzed the mRNA-induction of all putative Fbxo22-isoforms (Fbxo22A) as well as of 
a potential long isoform of Fbxo22 containing the F-box motif (Fbxo22F) and compared it 
to the induction of three other, known p53 target genes, p21, Mdm2 and Bax (Figure 3). In 
U2OS cells treated with Act.D we observe a rapid and strong induction of Mdm2 and p21, 
starting after 3 hr of treatment and steadily increasing to 24 hr (Figure 3A). Changes in the
Fig. 2.: Changes of Fbxo22 expression are dependent on p53 activation
A. A schematic overview o f  the putative gene organization o f the Fbxo22 gene locus, including the putative protein 
isoforms. Indicated are putative start codons and the primers used for expression analysis.
B. U2OS cells were treated for 24 hr w ith 5 nM Act.D prio r to RNA extraction. After cDNA synthesis qPCR was 
performed w ith primers for the last exon o f Fbxo22 (Fbxo22A) and results were normalized against 
GAPDH expression. SD was calculated from three independent experiments. For protein analysis U2OS cells 
were treated for 24 hr either w ith 5 nM Act.D, 10 pM  Etoposide (Eto.) or 2 nM Doxorubicin (DoxR.). Whole 
cell extracts were analyzed by western blot. Tubulin was used as a loading control.
C. HCT116 wildtype or HCT116 p53 knockout cells were treated for 24 hr w ith 5 nM Act.D or le ft untreated prio r to 
RNA extraction. Analysis o f mRNA expression was performed as in B.
D. HCT116 wildtype or HCT116 p53 knockout cells were treated w ith Act.D or Eto. as in B to  detect changes in the 
protein levels o f  Fbxo22, p53 and Mdm2.
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mRNA of Bax and Fbxo22 occur later (after 12 hr) and increase to a similar level over 24 
hr. On protein level a stabilization of p53 is observed 3 hr after treatment and Mdm2 and 
p21 accumulate rapidly. The Fbxo22 protein accumulates after 18 hr and increases slightly 
after 24 hr. The treatment with Eto. induces also a stabilization of p53 and an accumulation 
of Mdm2 and p21 mRNA and protein, although the levels of Mdm2 are lower compared to 
the Act.D-treatment (Figure 3B). Interestingly, the mRNA-levels of Bax and Fbxo22 incre­
ase somewhat earlier upon Eto.-treatment although the total induction is around 2-fold. 
Also the protein level of Fbxo22 increases like the mRNA and this increase occurs earlier 
compared to Act.D-treatment, after 6-12 hr.
Also in wild type p53-containing SYO-1 cells the Act.D-treatment leads to a stabilization 
of p53 as in U2OS cells and subsequently to an accumulation of mRNA and protein of 
p53-target genes (Figure 3C). Strikingly, p21-mRNA expression is highly upregulated and 
also Mdm2-mRNA increases. In these cells the levels of Bax- and Fbxo22-mRNA increase 
continuously over the whole 24 hr time interval. The mRNA of the full-length Fbxo22- 
isoform displays a 3-4-fold induction. Mdm2 and p21 begin to accumulate after 3-6 hr 
and this accumulation continues up to 24 hr whereas Fbxo22-protein accumulates only 
after 18 hr. Interestingly, the treatment of SYO-1 cell with Eto. shows some differences to 
Act.D treatment and to U2OS cells (Figure 3D). Although mRNA of Mdm2 and p21 incre­
ases after 3-12 hr, this effect is reversed again at later time points. The same is observed 
for the mRNA expression of Bax and the full-length isoform of Fbxo22, both peaking at 
12 hr and decreasing again afterwards. On protein level p53 and at the same time Mdm2 
are stabilized and similarly p21 starts to accumulate. After 12 hr of treatment also Fbxo22 
becomes detectable. The stabilization of p53 decreases again from 18 hr of treatment on 
and so does the Fbxo22-protein.
Fig. 3.: Fbxo22 expression is upregulated in a cell type and treatment specific manner
A. U2OS cells were treated w ith 5 nM Act.D for the indicated time points prio r to RNA extraction or protein iso 
lation. A fter cDNA synthesis qPCR was performed w ith the indicated primers and results were normalized 
against GAPDH. Fold induction was calculated by comparing the relative expression a t each time po in t 
with the relative expression a t the 0 h r time point. SD was derived from tw o independent experiments. Whole 
cell extracts were analyzed by western b lo t using antibodies against the indicated proteins.
B. U2OS cells were treated w ith 10 pM Eto. A fter the indicated time points the same analysis as in A was performed.
C. SYO-1 cells were treated with 5 nM Act.D for the indicated time points. Analysis was performed as in A.
D. SYO-1 cells were treated for the indicated time points w ith 10 pM Eto. Analysis was performed as in A.
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Furthermore, we analyzed the mRNA and protein expression of Fbxo22 after treatment 
in additional cell lines (Supplemental Figure 1). We observe an increase of Fbxo22-mRNA 
only in cells containing wild type p53, and not in MDA-MB231 cells, which harbor a non­
functional p53. On protein level we detect an induction of Fbxo22, which seems to de­
pend on the treatment, since in NCI-H460 cells treatment with DoxR. was able to increase 
the Fbxo22-protein, but not Eto.-treatment.
Thus, we show here for the Fbxo22-induction kinetic as well as quantitative differences 
between treatments and cell lines.
5.3.4. Specific activation of p53 with Nutlin3 induces Fbxo22
Because chemotherapeutic treatments may induce several parallel pathways, besides the 
p53-pathway, we wondered whether a specific activation of p53 also induces Fbxo22. To 
disrupt the feedback-loop of Mdm2 and p53 we used Nutlin3 to specifically inhibit Mdm2- 
mediated degradation of p53. After Nutlin3-treatment of U2OS or SYO-1 cells we moni­
tored the accumulation of the respective proteins (Figure 4). The application of Nutlin3 in 
U2OS cells leads to a stabilization of p53 and subsequently to a strong increase of Mdm2 
and p21 already after 6 hr (Figure 4A). Accumulation of Fbxo22, on the other hand, is pre­
sent only after 24 hr. In SYO-1 cells the stabilization of p53 by Nutlin3 and the induction 
of Mdm2 and p21 is weaker, but also occurs after 6 hr of treatment (Figure 4B). Fbxo22 is 
detectable at all time points in SYO-1 cells, but clearly accumulates only after 24 hr.
The induction of Fbxo22 after Nutlin3-treatment in two different cell lines further sup­
ports our findings that Fbxo22 is a direct target gene of p53.
5.3.5. Fbxo22 influences protein levels of p53 and Mdm2
Since F-box proteins in general are linked to ubiquitination pathways we wondered about 
the effect of Fbxo22 on p53. To this end we constructed Flag-tagged expression plasmids 
for the full-length Fbxo22 (Fbxo22F) and for the isoform lacking the first two exons (Fb- 
xo22S), which we transfected into U2OS cells. After transfection the cells were treated 
with Act.D or left untreated. The treatment induces stabilization of the p53 protein and 
a subsequent increase in Mdm2 levels. Interestingly, cells transfected with either of the 
Fbxo22 isoforms show lower levels of endogenous p53 protein compared to cells trans­
fected with an empty vector (Figure 5A). To quantify the effect that Fbxo22 has on p53 
we transfected U2OS cells with expression vectors for p53 and both isoforms of Fbxo22 
and measured the levels of p53 after normalization relative to co-transfected GFP. In com-
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Figure 4
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Fig. 4.: Specific inhibition o f Mdm 2 by Nutlin3 induces Fbxo22
p53
Fbxo22
p21
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24
A. The induction o f p53-target proteins after the application o f 10 pM Nutlin3 to U2OS cells for the indicated time 
points was followed by western blot.
B. SYO-1 cells were treated and analyzed as in A.
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parison to transfection of p53 alone, a significant decrease of p53 is observed upon co­
transfection with the full-length Fbxo22 (Figure 5B). After transfection of Fbxo22 and p53 
followed by treatment with Act.D the level of p53 decreases in the Fbxo22 co-transfected 
cells as well. We also treated transfected cells with the proteasome inhibitor MG132 to 
evaluate whether the effect of Fbxo22 on p53 involves proteasomal degradation. A slight 
stabilization of the p53-protein levels was observed upon MG132 treatment, arguing that 
the proteasome inhibitor can inhibit the effect Fbxo22 has on p53 (data not shown). To 
analyze whether the decrease of p53 protein depends on the amount of Fbxo22 present 
in the cells, we transfected increasing amounts of the shorter isoform of Fbxo22 into U2OS 
cells, which we treated again with Act.D. Already small amounts of transfected Fbxo22 
are sufficient to decrease the amount of p53 (Figure 5C). Nevertheless, an increase in the 
amount of Fbxo22 does not lead to a further decrease of the p53 protein level, arguing 
for the requirement of additional cellular components limiting the function of transfected 
Fbxo22.
We further tested whether the knockdown of Fbxo22 would lead to higher p53 levels. 
Therefore we transfected a pool of short interfering RNAs against Fbxo22 into U2OS cells 
and treated them with Act.D or left them untreated. The control knockdown cells, trans­
fected with a pool of non-targeting siRNAs, express Fbxo22-protein (Figure 5D). In the 
Fbxo22 knockdown cells Fbxo22 cannot be detected anymore, neither in untreated nor 
in Act.D treated cells. In the untreated Fbxo22 knockdown cells higher levels of Mdm2 
are present, compared to the cells transfected with the control siRNAs. Very interestingly, 
in the cells treated with Act.D, p53 and Mdm2 accumulate stronger in the Fbxo22 siRNA 
cells compared to the control. Quantification of the amounts of p53 and Mdm2 reveals an 
increase of Mdm2 and p53 of around 50% compared to the non-targeting siRNAs after 
treatment and interestingly for Mdm2 also in untreated cells.
Thus, Fbxo22 seems to influence the steady-state levels of Mdm2 as well as the p53 and 
Mdm2 protein levels upon stress treatment of the cells.
5.3.6. Characterization of Fbxo22 interactions
Since we observed an effect of Fbxo22 on the protein stability of p53 and Mdm2, it was 
likely that Fbxo22 could interact with p53 and/or Mdm2. Because we could not detect a 
direct interaction between Fbxo22 and p53 (data not shown), we performed co-purifica­
tion experiments between Mdm2 and Fbxo22. In U2OS cells, which were transfected with 
expression plasmids for Mdm2 and both Fbxo22 isoforms (Figure 6A), Mdm2 is co-preci­
pitated with Fbxo22F as well as with Fbxo22S (Figure 6A; lanes 5, 6). To examine whether
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Fbxo22 can also interact with endogenous Mdm2 we transfected Fbxo22S into U2OS cells 
(Figure 6B). To increase the levels of Mdm2 and to detect possible changes in the interac­
tion between Mdm2 and Fbxo22 upon treatment, we treated the cells with Act.D. Fbxo22S 
can co-precipitate a certain portion of endogenous Mdm2 (Figure 6B; lanes 4-6), although 
it cannot deplete Mdm2 completely from the supernatant. Interestingly, after treatment 
of Fbxo22S transfected cells with Act.D the proportion of Mdm2 in the IP fraction does not 
increase (Figure 6B; lanes 7-9). In a next step we evaluated the possibility of endogenous 
Fbxo22 interacting with endogenous Mdm2. Therefore we treated SYO-1 cells with Act.D 
and performed immunoprecipitations of Mdm2 or Fbxo22 (Figure 6C). The precipitation 
of endogenous Mdm2 clearly co-purified endogenous Fbxo22 and vice versa. To obtain 
more insight into the interaction between Mdm2 and Fbxo22 we analyzed their cellu­
lar distribution before and after co-expression. U2OS cells were either transfected with 
Mdm2 alone or with Mdm2 together with one of the Fbxo22-isoforms and the cytoplas­
mic fraction was separated from the nuclear compartments (Figure 6D). The majority of 
Mdm2 was found in the nucleus when Mdm2 was transfected alone. Upon co-transfection 
with Fbxo22 its subcellular localization changes and more Mdm2 protein is found in the 
cytoplasm. Thus, we showed that exogenous and endogenous Mdm2 and Fbxo22 could 
interact with each other and that for this interaction the F-box motif of Fbxo22 is not re­
quired.
Since the F-box motif had been described to interact with the SCF-component SKP1, we 
evaluated whether Fbxo22 was part of an SCF complex. Interestingly, the shorter isoform 
of Fbxo22 analyzed here, lacks the N-terminus, which harbors the predicted F-box motif. 
To test for possible protein-protein interactions, we co-transfected the different Fbxo22- 
isoforms with or without an expression construct for the myc-tagged SCF-component 
SKP1 and performed co-immunoprecipitations. Figure 6E shows the immunoprecipita­
tions of either SKP1, on the left, or Fbxo22 on the right. A specific co-precipitation to­
gether with SKP1 occurs only if Fbxo22F is co-transfected, while Fbxo22S did not show 
this interaction (Figure 6E; left side; lanes 4-6). On the other hand SKP1 is also only co­
purified together with Fbxo22F, but not with the isoform lacking the F-box motif (Figure 
6E; right side; lanes 4-6).
Because Fbxo22 can interact with Mdm2 and Fbxo22F also with SKP1, it was of interest 
to determine whether an interaction between Mdm2 and SKP1 could be detected, which 
was not the case after transfections and immunoprecipitation of SKP1 and Mdm2 (Sup­
plemental Figure 2).
Thus, as predicted, the Fbxo22-isoform containing the F-box (Fbxo22F) was shown to in­
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teract with Skp1, whereas Fbxo22S did not show this interaction. Since on the other hand 
both isoforms directly interact with Mdm2, it seems likely that the effect that Fbxo22 has 
on Mdm2 and p53 is not mediated through the SCF complex, but through a new, yet to 
be discovered mechanism.
5.4. Discussion
Here we report the identification of several genes linked to ubiquitin pathways, which are 
putative new target genes of the p53 family. We identified the F-box protein Fbxo22 as a 
p53 responsive gene in several cell lines. The stabilization of p53 induces the expression 
of Fbxo22-mRNA and -protein in a treatment and cell type specific manner. When over­
expressed, Fbxo22 significantly decreases the amount of transfected p53. It also appears 
to decrease the levels of endogenous p53 after Act.D treatment in U2OS cells. The knock­
down of Fbxo22 mediates the opposite effect and also increases the levels of Mdm2 in 
untreated as well as treated cells. While endogenous Fbxo22 can directly interact with 
Mdm2, we used overexpression constructs to show that the F-box motif is not responsible 
for this interaction, but for the association of full-length Fbxo22 with Skp1. Fbxo22 does 
not interact with p53 and the interaction with Mdm2 is not further enhanced through 
Act.D treatment. Finally, it appears that Fbxo22 can induce the translocation of Mdm2 into
Fig. 5.: Fbxo22 renders the protein level of p53
A. U2OS cells were transfected with the full-length (Fbxo22F) or the short isoform (Fbxo22S) o f Flag-Fbxo22, befo 
re they were treated w ith 5 nM Act.D for 24 hr (lanes 4-6) or le ft untreated (lanes 1-3). GFP was used as a 
control for transfection efficiency. Whole cell lysate was analyzed by western blot.
B. Quantification o f  changes in the p53 protein level. Flag-p53 was transfected alone or w ith one o f  the indicated 
Fbxo22-isoforms. Afterwards cells were treated w ith 5 nM Act.D or le ft untreated for 24 hr, prio r to harvest o f  
whole cell lysate and western b lo t analysis. For quantification the am ount o f Flag-p53 was normalized against 
the GFP-levels using the Odyssey-system. SD was derived from three independent experiments and statistical 
significance was determined by student's T-test.
C. Transfection o f  U2OS cells w ith increasing amounts o f  the short Fbxo22-isoform (0-4,5 pg) and GFP. Cells were 
treated for 24 hr w ith 5 nM Act.D. Analysis o f proteins as in A.
D. Knockdown o f Fbxo22 in U2OS cells was done by repeated transfection o f  a pool o f siRNAs directed against 
Fbxo22. A fter the second transfection cells were treated w ith 5 nM Act.D or le ft untreated for another 24 hr, 
before cell extract was prepared and analyzed by western blot. Quantification was performed after normalize 
tion o f protein levels against TBP. SD derived from tw o independent experiments.
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the cytoplasm.
The here observed effect of an F-box protein on p53 is not the only functional interaction 
between p53 and a F-box protein described so far, although it is one of the first ones that 
describes an influence on the stability of p53. F-box proteins have been reported to exert 
complex roles at different phases of the cell cycle, including growth promoting as well as 
growth inhibiting functions by different mechanisms (Ho et al. 2008), like Skp2 and Fbw7. 
Recently, the Kelch-domain containing F-box protein JFK was shown to directly media­
te the proteasomal turnover of p53, via an SCF complex (Sun et al. 2009). The function 
of Fbxo22 seems to involve a different pathway, since the reduction of p53-levels upon 
Fbxo22-overexpression does not rely on the presence of the F-box domain and it seems 
to involve Mdm2. Similar findings have been reported for other F-box proteins, which 
can indirectly render the function of p53 by interacting with p53-regulating factors. Besi­
des its function as a promoter of the cell cycle progression, Skp2 was shown to suppress 
apoptosis by forming a complex with p300 and inhibiting p300-mediated acetylation of 
p53 by antagonizing its binding to p300 (Kitagawa et al. 2008). For this function the F- 
box domain of Skp2 seems to be dispensable. Also another F-box protein, Fbxo11, can 
inhibit the transcriptional activity of p53 by conjugating NEDD8 to it (Abida et al. 2007). 
In this publication, the authors suggested that F-box proteins of SCF-complexes can exert 
other functions besides degradation, but they did not test whether the observed effect of 
Fbxo11 also occurs with a AF-box-mutant.
Fig. 6.: Characterization of Fbxo22 interactions
A. To detect direct interactions between Fbxo22 and Mdm 2 U2OS cells were transfected w ith M dm2 and 
Flag-Fbxo22F or Flag-Fbxo22S or an em pty vector. 36 hr after transfection, cells were lysed and immunoprecipi 
tated w ith anti-Flag antibody, followed by western b lo t analysis o f  the inpu t (Inp.) and the immunoprecipitation  
(IP).
B. Endogenous Mdm2 was co-purified with transfected Fbxo22S. U2OS cells were transfected w ith Flag-Fbxo22S 
and treated for 24 hr w ith 5 nM Act.D, where indicated. IP was done with an anti-Flag antibody.
C. Endogenous Fbxo22 interacts w ith endogenous Mdm2. SYO-1 cells were treated for 24 hr w ith 5 nM Act.D, prior 
to  isolation o f proteins and im munoprecipitation either w ith an Mdm2- or Fbxo22-antibody.
D. Overexpression o f  Fbxo22 leads to an increase in cytoplasmic M dm 2.36 hr after transfection o f Mdm2 with 
Fbxo22F or Fbxo22S into U2OS cells, cellular fractionation was performed and cytoplasmic and nuclear extracts 
were separated and analyzed by western b lo t against Mdm2. Tubulin or TBP served as loading controls.
E. Fbxo22F interacts w ith Skp1 through the F-box motif. Flag-Fbxo22F was transfected alone, or w ith Skp1 con 
ta in ing a myc-tag, Flag-Fbxo22S together with Skp1 into U2OS cells and IP was performed with an anti-myc 
antibody, 36 hr after transfection (left panel). U2OS cells were transfected w ith Skp1 alone or w ith Flag-Fbxo22F/ 
Fbxo22S, followed by an IP with anti-FLAG antibody (right panel). Western b lo t was performed against
the indicated proteins (* indicates an unspecific band).
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Also other components of SCF complexes have been reported to inhibit p53 activity, like 
the Cullin7 protein (Jung et al. 2007). Cullin7 was shown to relocalize small proportions of 
p53 into the cytoplasm (Kasper et al. 2006), further supporting the notion, that compo­
nents of the SCF-complex are not only involved in processes of proteasomal degradation, 
but also in other regulation mechanisms such as cellular localization and thereby maybe 
influence the function of target proteins. There is the possibility that Fbxo22 also influen­
ces the stress-response regulation of cells via its influence on Mdm2. In that respect it is 
very interesting that Fbxo22 seems to change the cellular localization of Mdm2 as well. We 
observed an increased cytoplasmic fraction of Mdm2 upon Fbxo22 overexpression. Fur­
thermore, we detected an increase of a putative cleavage product of Mdm2, when over­
expressed together with Fbxo22 (our unpublished observation). It is feasible that Fbxo22 
enhances the nuclear export of Mdm2, thereby maybe influencing Mdm2's cleavage and 
this might be part of the mechanism of Fbxo22 to render the function of Mdm2 and sub­
sequently that of p53. The exact mechanisms and protein domains of Fbxo22 mediating 
the observed effects need to be further characterized. Searching for other conserved do­
mains in Fbxo22 results in the identification of a domain suggested to be involved in sig­
nal transduction pathways, the FIST-domain (Borziak and Zhulin 2007). This domain could 
connect p53 via Fbxo22 to another, so far unidentified signaling pathway.
Thus, we have identified in our study a new p53-target gene, Fbxo22. It appears, that it is 
involved in a new regulatory feedback-loop of p53 probably by influencing the function 
of the main p53-regulator Mdm2.
5.5. Material and Methods
5.5.1. Cell culture conditions
The human osteosarcoma cell lines U2OS and Saos-2 inducible for p53 or p73a, the colon 
carcinoma line HCT116, the synovial sarcoma Syo-1, the lung adeno carcinoma NCI-H460 
and the breast carcinoma cell lines MCF-7 and MDA-MB231 as well as non-transformed 
RPE cells were maintained in Dulbecco modified Eagle medium supplemented with 10% 
fetal calf serum at 37°C. Transfections were performed using the calcium phosphate pre­
cipitation method (BES). Transient knockdown of Fbxo22 was achieved by using Dharma- 
con ON-TARGETplus siRNAs, according to manufacturer's manual.
5.5.2. Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) was basically done as described by Denissov
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et al. (Denissov et al. 2007). To immunoprecipitate p53 DO1 antibody (BD PharMingen) 
was used and BL906 (Abcam) was used for p73a. Real-time qPCR was performed using 
the SYBR Green mix (Biorad) with the MyIQ machine (Biorad). Primers are available upon 
request.
5.5.3. RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini Kit according to protocol (Qiagen). For 
cDNA synthesis reverse transcription was performed using 1 ng of RNA with oligo dT 
anchor primers, dNTPs, DTT, buffer and Superscript Retrotranscriptase (Invitrogen). The 
cDNA was analyzed by real-time qPCR using a MyIQ machine (Biorad). Primers are availa­
ble upon request.
5.5.4. Plasmid construction
Full length cDNA of Fbxo22 was PCR amplified from a cDNA clone purchased from ImaGe­
nes. The amplified fragment was cloned in frame behind a Flag-tag containing pcDNA3 
vector. The shorter isoform was amplified by PCR from the same cDNA clone with a 5'-pri- 
mer skipping the first two exons.
5.5.6. Protein-quantification
After separation of whole cell extract by SDS-PAGE, quantification of proteins was done 
with the infrared western detection system Odyssey (Li-Cor).
5.5.7. Co-immunoprecipitations
After transfection cells were grown for 36 hr, plates were washed once with cold 1x PBS 
and proteins were isolated by incubation with NP-40 lysis buffer (50 mM Tris-HCl, pH: 8.0;
150 mM NaCl; 1% NP-40; 1 mM EDTA) + 10 nL of protease inhibitor cocktail (Roche) at 4°C 
for 30 min. Samples were collected and after centrifugation (13.000 rpm; 4°C; 10 min) the 
aqueous fraction was incubated either with 5 ng of Flag-antibody (M2, Sigma), 1 ng of 
Fbxo22-antibody (ProteinTech Group) or 1 ng of Mdm2-antibody (2A10, Abcam) , and 30 
nL of protein-A sepharose (GE Healthcare) overnight at 4°C. Samples were washed twice 
with 200 nL NP-40 buffer, prior to preparation for western blot.
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5.5.8 Cellular fractionation
The cells were collected 36 hr after transfection and the cell pellet was resuspended in two 
volumes of hypotonic buffer (10 mM NaCl; 5 mM MgCl2; 20 mM Hepes, pH: 7.9; 0,1% Tri­
ton; 10% protease inhibitor cocktail; 1 mM PMSF and p-mercaptoethanol 0.36 nl/mL) and 
incubated on ice for 10 min. The cytosolic fraction was yielded after centrifugation (10.000 
rpm; 4°C; 10 min). The remaining pellet was resuspended in one volume of hypertonic 
buffer (420 mM NaCl; 20% glycerol; 20 mM Hepes, pH: 7.9; 5 mM MgCl2; 0.2 mM EDTA; 
0,1% Triton, 10% protease inhibitor cocktail; 1 mM PMSF and p-mercaptoethanol 0.36 nl/ 
mL) and subjected to three rounds of freeze/thawing in liquid nitrogen. Afterwards the 
samples were incubated on ice for 1 hr, before centrifugation (13.000 rpm; 4°C; 1 hr).
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5.7. Supplemental Material
Supplemental Figure 1 
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Fbxo22 expression is upregulated in several cell lines upon stress treatment.
A) MCF-7, NCI-H460, RPE and MDA-MB231 cells were treated for 24 hr with 5 nM Act.D or left
untreated prior to RNA extraction. After cDNA synthesis qPCR was performed with the indicated primers and 
results were normalized against GAPDH. SD was calculated from two independent experiments.
B) MCF-7 cells were treated for 24 hr with 5 nM Act.D or left untreated, NCI-H460 cells either with 5 nM Act.D, 
10 pM Eto. or 2 nM DoxR before whole cell extract was analysed by western blot.
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Supplemental Figure 2
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Skp1 does not in teract w ith  Mdm2.
U2O S cells w e re  tran s fec ted  w ith  m yc-Skp1 o r M dm 2 o r both vectors and 36h r post trans fec tion  IP w as perform ed 
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6.1. Summary of results
In the previous chapters different aspects of the function and regulation of members of the 
p53 tumor suppressor family have been described. The first and second chapter evaluated 
the important function of target gene selection of p53 and p73 proteins, either upon activa­
tion of an endogenous stress response pathway or in an exogenous system to allow compa­
rison of family member functions in a similar cellular background. All tested family members 
were able to bind and regulate their own specific subset of target genes, besides a rather big 
set of common or overlapping target genes. Interestingly, we found differences between 
family members in binding motifs and probable co-factor recruitment, possibly explaining 
the different physiological responses.
Chapters four and five exemplified how target genes of p53 can regulate the p53-function. 
The levels on which this regulation occurs are diverse and we showed that they could either 
render the transcriptional program mediated by p53, as described for IRF2BP2 in chapter 
four, or influence the stability of the p53-protein, like Fbxo22 does (chapter five). In both ex­
amples regulation seems to be independent of direct protein-protein interactions between 
p53 and the described factors. It rather seems to be mediated by other factors, in the case of 
IRF2BP2 it could be through modulation of transcription factors of the family of interferon 
response factors, while Fbxo22 appears to regulate the activity of Mdm2.
6.2. Genome-wide DNA-binding of the p53-family members
The identification of genome wide binding sites for members of the p53-family showed that 
between 11% (TAp73) and 28% (p53) of all bindings sites could be annotated to regions 
known as transcriptional start sites (TSS). This is comparable to binding site distributions of 
other transcription factors (Hearnes et al. 2005; Nielsen et al. 2008; Welboren et al. 2009). The 
question remains why the majority of binding sites is localized somewhere else. Others and 
we have shown that in some cases these sites serve either as enhancers of transcription or 
give rise to so far unidentified transcripts (Wei et al. 2006; Smeenk et al. 2008), while intronic 
binding sites could also be used as alternative promoters. Furthermore, binding sites away 
from TSS have been suggested to direct transcription of non-coding RNAs with regulatory 
functions (Kapranov et al. 2002; Cawley et al. 2004), although our experimental approach 
did not allow the detection of these transcripts. It has been reported that p53 recruits, be­
sides components of the basal transcriptional machinery (Espinosa et al. 2003), chromatin 
remodeling factors like hCas (Tanaka et al. 2007). Thus, additional binding sites might also 
allow long range regulatory chromatin interactions by bending chromatin and bridging si-
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tes, to establish a local environment for the efficient cycling of present transcription fac­
tors (West and Fraser 2005; Li et al. 2006; Fullwood et al. 2009). Future research will have to 
evaluate whether higher orders of target gene regulation exist and to which extend genes 
in a common biological pathway are regulated together. If so, what might be the content 
of such gene clusters and under which circumstances can a specific cluster be regulated? 
To what extent are additional mechanisms involved in the regulation? Exploiting the fast 
development of deep-sequencing techniques will make it possible to distinguish between 
full-length coding transcripts and putative regulatory anti-sense counterparts. Furthermore, 
increasing bioinformatical tools will allow the identification of co-regulatory networks and 
also their interconnectivity.
6.3. Motif variations and additional transcription factor binding sites
In a first attempt to predict the DNA-binding site motif of p53 Hoh and colleagues used a 
set of published binding sites to develop p53MH, a motif prediction algorithm (Hoh et al. 
2002). Having derived a positional weight matrix (PWM) from around 40 known p53 binding 
sites, they applied this PWM in a subsequent step to find p53-motifs in a set of roughly 2500 
binding sites. After recent publications of global DNA-binding data, other prediction algo­
rithms were established or existing ones improved, allowing the unbiased de-novo search 
for motifs using larger data-sets (Wei et al. 2006; Smeenk et al. 2008). This results in the pre­
diction of binding motifs with higher specificity and lower false positive rate, therefore more 
confident binding sites can be identified. Although the comparison of motifs from different 
experimental set-ups needs to be done carefully, specific motifs could be identified for the 
different p53-family members (Ortt and Sinha 2006; Yang et al. 2006); Koeppel at al. submit­
ted). Besides a certain overlapping set of target sites that all family-members seem to be able 
to bind to, several specific binding sites could be observed, which are bound preferentially 
by only a subset or only one of the family-members. The composition of the binding motif 
may partly reflect this specificity. Binding sites for p63 and p73 show a more degenerate 
motif, so besides the core-nucleotides more variation occurs compared to binding sites of 
p53. Interestingly, the presence of this motif varies in subsets of binding sites, in general it is 
present more often (> 60%) at sites to which TAp73p is bound, while it is present in fewer si­
tes to which p53 and TAp73a are bound. Furthermore, some peculiar p53 binding sites have 
been identified in which no p53-like motif could be detected (Wei et al. 2006; Smeenk et al. 
2008; Koeppel et al. in Press). The reason for binding of p53 to these sites remains unclear, 
although it is possible that indirect binding occurs in which additional transcription factors 
or DNA-binding proteins recruit p53 to DNA. It also remains to be elucidated why TAp73a- 
and TAp73p-specific DNA-binding sites exist, since they appear to have the same p73-motif.
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The interaction with varying transcription factors and co-regulators may also contribute 
to the distinct repertoire of target genes of the respective p53-family member. In distinct 
groups of binding sites binding motifs for different additional transcription factors are pre­
sent, like NF-1- and c-ETS-1-motifs for p63, motifs for KLF or Sp1 close to p53 binding sites or 
API - and Runx-motifs for p73a (Yang et al. 2006; Smeenk et al. 2008). In some cases additio­
nal factors known to bind these motifs have been suggested or proven necessary to activate 
certain target genes, like Sp1 for p53 mediated p21- and Bax-activation or c-Jun for induction 
of p73a target genes (Koutsodontis et al. 2001; Thornborrow and Manfredi 2001; Koeppel et 
al. in Press). Since in some cases, e.g. as for Slug, IRF2BP2 or Zbtb4 a direct interaction of the 
different family member and its transcriptional co-regulator does not occur, these co-regu­
lators might bind to distinct binding sites in the respective target genes, thereby increasing 
the selectivity of target gene regulation of the p53-family (Wu et al. 2005; Weber et al. 2008; 
Koeppel et al. 2009). Also in the case of p73 and c-Jun no direct interaction takes place (Toh 
et al. 2004), while p63-isoforms containing the complete C-terminus associate with c-Jun and 
these isoforms have been shown to exert a crucial function in embryonic development of 
skin and limb (Fei et al. 2006; Wolff et al. 2009). Several co-factors have important roles in the 
function of p53-famliy members but it remains to be elucidated which factors co-regulate 
which subset of target genes. Therefore not only the analysis of the binding site regions of 
the p53-family with respect to additional transcription factor binding motifs will be useful, 
but also the purification of chromatin bound complexes might obtain valuable information 
about the interaction with co-factors at specific loci as it has been shown for the function of 
hCas (Tanaka et al. 2007).
6.4. Biological impact of p53-family members
For the identification of family-member and isoform specific functions the groups of bin­
dings sites preferential for single family-members are very interesting, since preferential tar­
get gene activation and clear differences in growth suppression mediated by the different 
isoforms have been reported (De Laurenzi et al. 1998; Davison et al. 1999; De Laurenzi et al. 
2000; Koeppel et al. in Press). These isoform-specific functions probably cause the varying 
biological consequences of their activity. The differentially spliced C-terminus of the p73- 
isoforms most likely allows interactions with varying co-factors and thereby distinct target 
gene selection. An example for this differential interaction is the co-activator YAP1, which en­
hances binding of p73 to pro-apoptotic promoters (Strano et al. 2005). However, the interac- 
ting-domain of YAP1 binds an amino-acid sequence present in TAp73a and TAp73p, but not 
in TAp73y and TAp735 (Strano 2001). The analysis of family-member- and isoform-specific 
functions is complicated by the lack of systems expressing enough endogenous protein in
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a similar cellular background, but the comparison o f exogenous TAp73a and TAp73p shows 
specific binding sites and differential biological pathways of the target genes after functional 
annotation (Koeppel et al. submitted).
The interactions between the different family members become more important in the con­
text of growth control and tumorigenesis. Both, p63- and p73-isoforms have the capacity 
to form homo- or hetero-dimers w ith each other, but not with wild-type p53 (Davison et al.
1999). Nevertheless, mutated p53 can interact w ith and inhibit the function of p63 and p73, 
thereby promoting cancer progression (Li and Prives 2007). Mutant p53 interferes with the 
DNA-binding and transactivation function of p73 (Marin et al. 2000; Strano et al. 2000) and 
it also increases the rate of metastasis, as it has been reported for an in vivo murine model 
(Lang et al. 2004). The basis for increased invasiveness of tumors harboring p53 mutations 
seems to be at least in part due to  an inhibition of p63, followed by enhanced integrin-recy- 
cling (Muller et al. 2009). Thus, the interconnectivity between the p53-family members has a 
profound impact on the cellular fate and severe implications for cancer research. It will be of 
interest to determine whether all p63- or p73-isoforms show the same degree of inhibition 
mediated by mutant p53 towards all their target genes. Additionally, it might be useful for 
cancer therapy to target the interaction between mutant p53 and p63/p73 e.g. by confor­
mation-specific antibodies against mutant p53 in an attempt restore p63- or p73-function. 
Another way to disrupt interactions between inhibitors and p63 or p73 might also be the use 
of minimal p53-derived apoptotic peptide as it has been recently reported (Bell et al. 2007).
6.5. Regulating the regulators
Since long it has been known, that p53 induces the expression o f proteins, which in turn 
regulate p53's activity. Besides Mdm2, the most prominent feedback regulator of p53, a gro­
wing set of newly identified target genes influences the outcome of p53-activity. They can 
either interact directly w ith p53, regulating its stability, activity or localization or they in­
fluence the expression of other p53 target genes (Vousden and Lu 2002; Harris and Levine 
2005; Hoeller et al. 2006). Some o f the genes regulating p53 can influence each other to keep 
the balance between survival and apoptosis. One o f the important regulators of Mdm2 and 
p53 is the tumor suppressor p14ARF, since it inhibits the ubiquitin-ligase activity of Mdm2 to ­
wards p53, but probably it also influences the activities of ARF-BP1, another ubiquitin-ligase 
crucial for p53-turnover (Pomerantz et al. 1998; Zhang et al. 1998; Honda and Yasuda 1999; 
Chen et al. 2005). Interfering w ith ubiquitination-activities of Mdm2 is HAUSP, a de-ubiquiti- 
nating enzym involved in the stabilization not only of p53 but also of MdmX (Li et al. 2002; 
Meulmeester et al. 2005). Additional regulation of Mdm2 occurs during the response to sur­
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vival signals, like IGF1 or Erbb2. Mediated by the Akt/PIK3 pathway these signals inhibit p53 
transcriptional activity and apoptotic induction (Yamaguchi et al. 2001; Zhou et al. 2001). Akt 
can directly phosphorylate Mdm2, leading to its re-localization to the nucleus and enhan­
ced p53-degradation (Mayo and Donner 2001). Conversely, we found that Fbxo22 directly 
interacts with and re-localizes Mdm2 into the cytoplasm, thereby reducing the amount of 
p53-protein by a so far unknown mechanism (Koeppel et al. submitted). Furthermore, Mdm2 
degrades other regulators of p53, like HIPK2 or Tip60, inhibiting pro-apoptotic modification 
of p53 by HIPK2 or Tip60 (Legube et al. 2002; Tang et al. 2006; Rinaldo et al. 2007). This net­
work o f interactions and cross-talks complicates the analysis of the p53-response, but careful 
examination o f all involved factors may allow highly specific interventions to drive the p53- 
response into a desirable direction.
6.6. Fine-tuning of the p53-response
Modulating the activity of p53 is a crucial event during the response upon genotoxic insults 
to ensure the most suited response for certain cellular conditions (Vousden and Lu 2002). To 
adapt the response to a changing environment p53 can regulate target genes that in turn 
modify its activity to provide regulatory feedback mechanisms keeping p53 under appropri­
ate control. Modifications of p53 can be regulated by some of its target genes, like p53DINP1 
which phosphorylates Ser46 of p53 to allow apoptotic induction, while another target gene, 
the phosphatase WIP1, reverses this specifc PTM (Takekawa et al. 2000; Okamura et al. 2001), 
showing the complexity of p53-regulation. Other target genes regulate the selection of tar­
get genes further downstream of p53, such as HZF or Slug (Wu et al. 2005; Das et al. 2007). 
IRF2BP2, like Slug, has a repressive effect on some p53-target genes, impeding on apoptosis 
induction, but enhancing growth arrest upon certain stress treatments (Act.D), thereby shif­
ting the cellular response into the direction of cellular survival (Koeppel et al. 2009). Recently 
an effect of a p53-induced gene on the stability o f p53-mRNA has been described. Wig-1 
impedes on de-adenylation, thereby stabilizing p53-transcripts (Vilborg et al. 2009). These 
examples of target genes having a profound impact on the cellular outcome of p53-activa- 
tion illustrate how diverse the p53-regulation is, which most likely is further complicated by 
tissue-specific effects. Therefore continuous analysis of the function of other target genes 
and the circumstances of their expression is required, to unravel additional mechanisms of 
p53-regulation and their impact in specific tissues or during development.
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During the last decade it became more and more obvious that p53 connects and intertw i­
nes many pathways o f different cellular functions. During growth- and apoptosis-control 
p53 is regulated by and regulates itself several different signal-cascades (Vousden and 
Prives 2009). The response to interferon increases the expression o f p53 (Takaoka et al. 
2003) and conversely p53-activation induces the expression o f the IRF2BP2 protein (Ko­
eppel et al. 2009), linking upstream signaling to downstream events. Further connections 
between the immune response and p53 result from  an interaction o f IRF1 w ith p300 to 
induce p53-mediated transactivation o f p21 (Tanaka et al. 1996; Dornan et al. 2004). Cel­
lular metabolism is influenced by p53 in many ways to adapt cells to different growth 
conditions. As a consequence o f starvation p53 inhibits protein-synthesis by negatively 
regulating mTor and promoting autophagy by induction o f DRAM (Crighton et al. 2006; 
Mathew et al. 2007). The induction o f TIGAR inhibits glycolysis, linking p53 to another me­
tabolic pathway (Bensaad et al. 2006). Since this happens together w ith a reduction of 
reactive-oxygene-species and impaired apoptosis, p53 seems to support cellular survival 
under specific circumstances. Recently the effect o f p53 on the induction o f pluripotent 
cells was described, showing an im portant role for p53 in the inhibition o f this process as 
well, maybe as a barrier against inappropriate cell renewal (Hong et al. 2009; Kawamura et 
al. 2009; Marion et al. 2009). The function o f p53 in this pathway has several implications 
for stem cell research as well as for putative therapeutic applications. The efficiency of 
reprogramming can be greatly enhanced through silencing or deletion o f p53. Since p53 
prevents stem cells generation in the presence o f DNA damage, even its transient silenci­
ng during reprogramming m ight increase the number o f mutation in iPS-cells, leading to 
early malignant transformation.
The different p73-isoforms (like the isoforms o f p63) are most likely involved in a similar 
network o f different pathways regulating various functions. Their roles in development 
have been partly defined through knock-out mice models highlighting the importance 
o f TA-isoforms in tum or protection (Tomasini et al. 2008) and the function o f the AN- 
isoforms in the protection o f neuronal cells against apoptosis (Wilhelm et al.; Yang et al.
2000). Furthermore, the AN-isoforms have been shown to disrupt the DNA-damage-si- 
gnaling network, an event co-occurring w ith elevated levels o f these isoforms in some 
cancers (Wilhelm et al.; Zaika et al. 2002; Concin et al. 2004).
Nevertheless, all p53-family members are probably able to regulate a comparable amount 
o f target genes involved in many different pathways and most likely even in an isoform- 
dependent manner. Thus, for the future it w ill be a major task to define the pathways eve­
ry member o f the p53-family is involved in and also the degree o f participation, to allow 
specific adjustments o f the p53-response to cancer or developmental defects.
6.7. Future perspectives:
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Summary:
In multicellular organisms the proper control o f cellular growth is essential for tissue 
homeostasis. If the regulation o f growth is disturbed developmental defects may occur or 
malignant growth events may lead to cancer. Cancer is a multi-factorial disease that can 
be caused by various external as well as internal signals and the failure o f cellular safety 
mechanisms. Inappropriate growth signals can result from genomic mutations leading to 
constitutively active signal cascades, while the failure o f safety mechanisms m ight also re­
sult from  inactivating mutations o f crucial growth control genes. At the hub o f these safe­
ty mechanisms the transcription factor p53 links several pathways sensing DNA-damage 
and additional harmful conditions and directs the cellular response. Due to the variety of 
possible stressful conditions, the resulting response pathways and the existence o f the 
p53-homologs p63 and p73, the p53-network is very complex to adapt the cell in an ap­
propriate way to the respective conditions.
The first chapter o f this thesis provides a general overview about the p53-family about the 
known modes o f their regulation, their interactions and the consequences o f their activa­
tion upon various events. The second chapter focuses on the characterization o f genome- 
wide binding patterns o f p53 upon genotoxic stress. We show that p53 is not only recrui­
ted to promoters o f target genes but also binds to intergenic regions which m ight serve as 
enhancer region or from which unknown transcripts m ight be regulated. The analysis of 
target gene choice continues in the th ird chapter, in which we identify target genes o f two 
p73-isoforms. Besides a set o f overlapping genes, TAp73a and TAp73p can bind and regu­
late d istinct subsets o f target genes which are also differentially bound by an additional 
transcription factor, c-Jun. We show that this differential regulation o f target genes m ight 
be the cause for the much stronger apoptotic induction mediated by TAp73p.
The feedback-loops o f certain p53-target genes on p53-function are examined in the 
chapters four and five. In chapter four we describe how the transcriptional co-repressor 
IRF2BP2 influences the transcriptional activity o f p53 in a feedback-loop, interfering with 
the transcriptional activation mediated by p53, thereby increasing the threshold for in­
duction o f apoptosis. Fbxo22, another newly identified target gene o f p53, influences the 
stability o f the p53-protein probably by rendering the function o f p53's main antagonist, 
Mdm2. This function o f Fbxo22 seems to be independent o f the previously described F- 
Box-SCF-complex and involves possibly a relocalization o f Mdm2.
The chapter six finally summarizes the previous findings and highlights the new insight 
into the selection o f target genes o f the p53-family as well as some o f the target gene 
functions as newly described p53 feedback-regulators.
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Samenvatting:
Een goede controle van celgroei is essentieel voor weefsel homeostase in meercellige or­
ganismen. Als deze groeiregulatie verstoord w ordt kunnen ontwikkelingsdefecten on t­
staan o f kan het optreden van maligne groei to t kanker leiden. Kanker is een multifacto- 
riële ziekte die veroorzaakt kan worden door verschillende externe en interne signalen 
in combinatie met het falen van cellulaire veiligheidsmechanismen. Verkeerde groeisig- 
nalen kunnen het gevolg zijn van genomische mutaties die leiden toe constitutief actie­
ve signaal cascades. Ook het falen van veiligheidsmechanismen kan veroorzaakt worden 
door inactiverende mutaties van cruciale genen verantwoordelijk voor de groeicontrole. 
Centraal in het geheel van deze veiligheidsmechanismen bevindt zich de transcriptiefac- 
to r p53, die verscheidene mogelijkheden heeft om DNA schade te detecteren en de cellu­
laire respons regelt. De grote verscheidenheid aan mogelijke stresscondities, de cellulaire 
reacties die hierop volgen en het bestaan van de p53-homologen p63 en p73, zorgen 
ervoor dat het p53-netwerk erg complex is. Dit maakt het mogelijk voor de cel om op een 
passende manier te reageren op uiteenlopende verschillende condities.
Het eerste hoofdstuk van d it proefschrift geeft een algemeen overzicht van de p53-familie 
en komen de bekende manieren van hun regulatie, hun interacties en de gevolgen van 
hun activatie als reactie op verschillende gebeurtenissen aan bod. Het tweede hoofdstuk 
legt de focus op de karakterisatie van genoombrede bindingspatronen van p53 als ge­
volg van genotoxische stress. We laten zien dat p53 niet alleen gerekruteerd wordt naar 
promotors van doelgenen, maar ook bindt in intergenische regio's, die kunnen fungeren 
als een enhancer o f de locatie zijn van regulatie van onbekende transcripten. We gaan 
verder met de analyse van de keuze van doelgenen in het derde hoofdstuk, waarin we 
doelgenen van twee p73-isoformen identificeren. Naast een set van overlappende genen, 
kunnen TAp73a en TAp73p ook distincte subsets van doelgenen binden en reguleren, en 
worden die genen ook differentieel gebonden door een additionele transcriptiefactor, c- 
Jun. We laten zien dat deze differentiële regulatie van doelgenen de oorzaak zou kunnen 
zijn van de veel sterkere apoptose-inductie die door TAp73p in gang gezet wordt.
De feedback loop van specifieke p53 doelgenen die effect hebben op de functie van p53 
worden bekeken in de hoofdstukken vier en vijf. In hoofdstuk vier beschrijven we hoe 
de transcriptionele co-repressor IRF2BP2 de transcriptionele activiteit van p53 in een 
feedback loop beïnvloedt, door de transcriptionele activatie door p53 te verstoren, en 
daarmee de grens voor de inductie van apoptose verhoogt. Fbxo22, een ander nieuw geï­
dentificeerd doelgen van p53, beïnvloedt de stabiliteit van het p53-eiwit, waarschijnlijk 
door de functie van Mdm2, de belangrijkste antagonist van p53, te remmen. Deze functie 
van Fbxo22 lijkt onafhankelijk te zijn van het eerder beschreven F-Box-SCF-complex en
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behelst mogelijk een relocalisatie van Mdm2.
Hoofdstuk zes ten slotte vat de hiervoor beschreven bevindingen samen en belicht de 
nieuwe inzichten in de selectie van doelgenen van de p53-familie, evenals de functie van 
sommige van de doelgenen als nieuw beschreven regulatoren van p53 feedback.
Zusammenfassung:
Die exakte Kontrolle zellulären Wachstums ist essentiell für die Erhaltung der Gewebe­
integrität in vielzelligen Organismen. Falls die zelluläre Wachstumsregulation gestört ist, 
können Entwicklungsdefekte auftreten oder wucherndes Wachstum kann zur Entstehung 
von Krebs führen. Krebs ist Erkrankung, die durch eine Vielzahl von extrinsischen oder 
intrinsischen Faktoren und den Ausfall zellulärer Sicherungen ausgelöst werden kann. 
Genomische Mutationen können zu konstitutiv aktiven Signalkaskaden führen, die un­
kontrollierte Wachstumssignale zur Folge haben, oder durch inaktivierende Mutationen 
die zellulären Sicherungssysteme außer Kraft setzen. Im M ittelpunkt vieler dieser Siche­
rungssysteme verbindet der Transkriptionsfaktor p53 die Sensoren, welche Schäden der 
DNA und andere Stressfaktoren registrieren, und steuert die zelluläre Antwort. Durch die 
Vielzahl verschiedener schädlicher Bedingungen und die zusätzlichen p53-Homolge p63 
und p73 sind die aus einer Aktivierung der p53-Signalwege resultierenden Antworten 
vielschichtig um dem p53-Netzwerk die Adaption der Zelle an bestimmte Konditionen 
zu ermöglichen.
Im ersten Kapitel dieser Arbeit wird eine grundlegende Übersicht über die p53-Familie 
dargestellt, es werden sowohl bekannte Arten ihrer Regulation, ihre Interaktionen als 
auch die Konsequenzen ihrer Aktivierung durch verschiedene Stimuli erörtert. Das zwei­
te Kapitel befasst sich m it der Charakterisierung genomischer Bindungsmuster von p53 
nach genotoxischem Insult. Wir zeigen, dass p53 nicht nur zu Promotoren seiner Zielgene 
rekrutiert wird, sondern auch Regionen zwischen Genen bindet, die entweder als Verstär­
ker zur Genaktivierung beitragen können oder von denen bislang unbekannte Transkrip- 
te reguliert werden können. Die Analyse der Zielgen-Selektion wird im Kapitel drei fo rtge­
setzt, in dem w ir Zielgene für zwei p73-Isoformen identifizieren. Neben einer Gruppe von 
gemeinsamen Genen können TAp73a und TAp73ß auch unterschiedliche Gruppen von 
Zielgenen binden und deren Expression regulieren. Diese Zielgene unterscheiden sich 
auch durch die Bindung von c-Jun, einem weiteren Transkriptionsfaktor, der nur einzelne 
Gruppen von p73-Zielgenen bindet. Wir zeigen, dass diese unterschiedliche Regulation 
einer der Gründe für ausgeprägteren induzierten Zelltod verursacht durch TAp73ß ein 
kann.
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Die Rückkopplungsmechanismen, m it denen einige der p53-Zielgene die Funktion von 
p53 regulieren werden in den Kapiteln vier und fün f untersucht. In Kapitel vier beschrei­
ben wir, wie der transkriptionelle Corepressor IRF2BP2 die transkriptionelle Aktivität von 
p53 in solch einer Rückkopplung beeinflusst und dabei die Schwelle zur Einleitung von 
Apoptose erhöht. Fbxo22, ein weiteres neu identifiziertes Zielgen von p53, kann die Stabi­
lität von p53 vermutlich über die Interaktion m it Mdm2, dem wichtigsten p53-Gegenspie- 
lers, beeinflussen. Dies geschieht möglicherweise unabhängig von der bislang bekannten 
Funktion von F-box Proteinen als Teil des SCF-Komplexes, und beinhaltet vermutlich eine 
Relokalisierung von Mdm2.
Schließlich fasst das Kapitel sechs die vorherigen Ergebnisse zusammen und zeigt die 
neuen Aspekte sowohl der Auswahl von Zielgenen als auch der Funktionsweise neu iden­
tifizierter p53-Regulatoren auf.
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